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ABSTRACT 
As sequencing and genotyping technologies are advancing, larger and more 
complex sets of biological data are being produced. Databases can be used to 
efficiently store and manage the data. Typically, publicly available datasets are 
accessed through web browsers that offer a user-friendly interface to a 
database, making complex queries simple to execute. However, research project-
specific data are not commonly stored in this way. In this research, a database 
(designed in MySQL) and accompanying interface (developed using PHP, HTML 
and CSS) has been designed for the storage and querying of the quality 
controlled data from the current project using Metabochip-genotyped Birth to 
Twenty (Bt20) cohort participants and their female caregivers. Users can easily 
access the data to generate summary statistics on the phenotype data and 
download phenotype, single nucleotide polymorphism (SNP) annotation and 
association analysis data that match user-supplied criteria.  
Some of the data from the database was used to investigate the genetics of 
blood pressure (BP) in black South African individuals. Hypertension is a major 
risk factor for cardiovascular diseases (CVDs). BP variation is known to have a 
genetic component, but genetic studies in indigenous Africans have been limited. 
Association analysis, carried out in a merged sample of caregivers and 
participants, pointed to novel regions of interest in the NOS1AP (DBP and SBP), 
MYRF (SBP) and POC1B (SBP) genes and two intergenic regions 
(DACH1|LOC440145 (DBP and SBP) and INTS10|LPL (SBP)). Two SNPs in the 
MYRF gene met the calculated “array-wide” significance threshold (p<6.7x10-7 
for the merged dataset) for multiple testing.  
Genotype imputation is a useful addition to association studies to increase the 
SNP panel for association testing. An investigation into the efficiency of 
imputation in this dataset using a mixed population reference panel was carried 
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out. Imputation was achieved with high confidence in all genes, but a more 
detailed view of the region was only seen in NOS1AP (DBP and SBP in both the 
merged and female caregiver datasets) and POC1B (Bt20 participant dataset 
only).  
Overall, the research contributed a useful tool for the efficient management of 
project-specific biological data. The analysis and genotype imputation, which is a 
promising tool in future studies in this or other African datasets, also provided 
some insight into the genetics of blood pressure in black South Africans with 
further functional and replication studies in larger samples required to confirm 
and explain the findings.  
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PREFACE 
The current study and its significance 
The current study forms part of a larger project focused on investigating the 
genomic and environmental risk factors for cardiometabolic disease (CMD) in 
Africans (Lombard et al., 2012; Pillay et al., 2015; Ramsay et al., 2016). The huge 
burden of chronic non-communicable diseases (NCDs) and specifically 
cardiometabolic or cardiovascular diseases (CVDs) in black or African individuals 
provides motivation for these investigations. The study makes use of a dataset 
consisting of individuals from the Birth to Twenty (Bt20) cohort genotyped using 
the Metabochip.  
The Bt20 cohort forms the basis of the largest longitudinal study on child and 
adolescent health and development in Africa. The cohort initially enrolled 3273 
babies born as single births to women residing in Soweto, Johannesburg during a 
7-week enrolment period between April and June 1990 (Richter et al., 2007). The 
race groups represented in the cohort are an approximate representation of the 
South African population (78% African, 6% White, 12% Coloured and 4% Indian) 
(Richter et al., 2007), although only individuals of African ancestry are included in 
this study. Data, including body composition and cardiometabolic data, have 
been collected regularly at various stages since then, with a decrease in 
individuals from the initial number largely due to migration and resultant loss of 
follow up (Richter et al., 2007).  
The Metabochip is a custom genotyping array that allows for the genotyping of 
almost 200,000 single nucleotide polymorphisms (SNPs) known to influence 
cardiometabolic traits. The chip was designed using contributions from several 
large consortia and contains SNPs specific to various traits of primary interest 
including type 2 diabetes (T2D), fasting glucose, coronary artery disease and 
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myocardial infarction (CAD/MI), low density lipoprotein (LDL) cholesterol, high 
density lipoprotein (HDL) cholesterol, triglycerides, body mass index (BMI), 
systolic blood pressure (SBP) and diastolic blood pressure (DBP), QT interval, and 
waist-to-hip ratio (WHR) adjusted for BMI. Also contained on the chip are SNPs 
specific to traits of  secondary interest, namely fasting insulin, 2-hour glucose, 
glycated hemoglobin, T2D age of diagnosis, early onset T2D, waist circumference 
(WC) adjusted for BMI, height, body fat percentage, total cholesterol, platelet 
count, mean platelet volume, and white blood cell count. The SNPs on the chip 
are mostly replication (to follow up top independent association signals for each 
of the traits) and fine-mapping SNPs (to fine-map 257 loci associated at genome-
wide significance SNPs in preliminary analyses for one or more of the traits). 
(Voight et al., 2012)  
The data being used and produced in this project includes Bt20 phenotype (from 
multiple data collection time points), Metabochip SNP annotation and resulting 
association analysis outputs. This constitutes a significant volume and has, up 
until now, been stored in basic Excel spreadsheets.  This data needs to be 
organised in a more user-friendly format that is easily accessible and usable by 
relevant individuals, and also queryable for useful information. Relational 
databases are one such tool that can be used to achieve this. Publically available 
data is usually accessed via a web interface linked to a database, but project-
specific data is not often stored in this way.  A major part of the current study 
therefore involved the development of a queryable cardiometabolic database, 
and accompanying user interface, which stores the longitudinal phenotype, SNP 
annotation and association analysis data. Having the data organised in a 
database will facilitate access to the data and extraction of specific data and 
useful information/summary statistics by individuals within the research group. 
The stored association analysis data will also be a useful reference to inform 
future studies. In addition, the database will provide a model/framework for the 
development of other similar databases. 
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This study also involved an investigation into one aspect of CMD risk using the 
data stored in the database, namely the genetics of blood pressure (BP) or 
hypertension. Important advances are being made in genomic research to 
discover the genetics of BP/hypertension, but the studies have largely been 
conducted in non-African populations. This is, in fact, the case in most genetic 
association studies. African populations are genetically more diverse than non-
African populations and tend to have a greater SNP density and lower linkage 
disequilibrium (LD) between SNPs (Remm & Metspalu, 2002; Tishkoff & Verrelli, 
2003). The level of genetic diversity is also known to be greatly decreased as one 
moves further away from Africa (Tishkoff et al., 2009). Genetic association 
studies involve the identification of either a SNP that has a direct association 
with the phenotype in question (i.e. it is the causal variant) or a SNP that has an 
indirect association and is in LD with the causal variant (Lewis & Knight, 2012). 
Due to the differences in LD structure between African and other populations 
and the fact that different SNPs may be in LD with the causal SNP in the different 
populations, markers identified in other populations as being associated with 
disease susceptibility may in fact have no significant association in an African 
population. Indeed, in the few studies on various diseases that have been 
conducted in Africans, the associated SNPs are often different to those reported 
in other populations. Despite this, the African population still remains largely 
under-represented in genetic association studies. Some studies on blood 
pressure and hypertension have been reported in individuals of “African 
ancestry”, but have mainly been conducted in African-Americans. African-
Americans are, however, also genetically very different to native Africans, due to 
the European admixture, and therefore cannot be accurately used as a reference 
for what is found in “true African” individuals (i.e. those individuals of pure 
African ancestry who have not undergone migration and been influenced 
genetically by non-African populations). Studies have also suggested that there is 
great genetic diversity between subgroups within the African population itself 
(Tishkoff et al., 2009), highlighting the importance of not only conducting genetic 
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association studies in separate populations, but in distinct subgroups too. This 
study will hopefully provide some insight into the genetics of BP/hypertension in 
a black population of “true African” ancestry in South Africa. 
The Metabochip was developed from data obtained from studies in European 
populations. The set of SNPs available for testing therefore might not be ideal or 
adequate for use in an African population and associations or exact causal 
variants may be undetectable with the dataset as it is. Genotype imputation has 
become a useful addition to genetic association studies to recover some of the 
missing or ungenotyped data. African populations can be challenging to impute 
due to their genetic diversity and lower levels of LD (Howie et al., 2011; Huang et 
al., 2011). An investigation was therefore deemed necessary in this study to 
assess the effectiveness of genotype imputation in this African dataset. This 
serves as an extension to the investigation into the genetics of BP/hypertension 
in our black South African population. Successful imputation in identified regions 
of interest may help to identify actual causal variants. In addition, imputation in 
the rest of the dataset, including regions where no signals are initially identified, 
may allow for identification of additional signals associated with the phenotype 
under investigation.  
Aims and objectives 
Minor aim: 
(1) Perform quality control on the raw genotype and associated phenotype 
data for use in each subsequent step. 
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Major aims: 
(1) Develop a queryable cardiometabolic database using the current project-
specific data.  
- Arrange the data into structured tables in MySQL. 
- Design a web interface for users to access and query the data. 
- Set up a model/framework for use by other researchers to 
develop other similar databases. 
 
(2) Use the data stored in the database to identify genetic markers for SBP 
and DBP in black South African individuals and record the findings in the 
developed database. 
 
(3) Investigate the effectiveness of genotype imputation in this black South 
African dataset and possibly provide a more detailed view of identified 
association signals.  
Outline of the thesis 
Chapter 1 of this thesis gives an overall background to and literature review of 
the three main parts of the study, namely the generation of “big data”, data 
management and databases in the biological field; CVD and hypertension 
prevalence and the non-genetic and genetic risk factors of BP/hypertension; and 
various aspects of genotype imputation. A description of the participants, the 
associated data and the quality control of the data used in all aspects of the 
research is presented in Chapter 2. The three major aims of the study are dealt 
with separately in Chapters 3 (Database), 4 (BP genetics) and 5 (genotype 
imputation). General conclusions pertaining to all areas of the research are 
presented in Chapter 6. 
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All program commands/scripts used throughout the thesis are recorded in 
Appendix C, unless otherwise stated. Due to the length of the PHP/HTML/CSS 
code used for the web interface described in Chapter 3, it is accessible in a 
separate file (Web_interface.pdf) along with the general database model code 
(General_database_model.pdf) at https://github.com/LieslH/Liesl-Hendry-PhD-
Code. 
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Chapter 1: INTRODUCTION 
1.1 The “omics” and “big data” 
Researchers in biology are constantly striving to characterise biological molecules 
and translate the information into the structure, function and dynamics of 
organisms. High-throughput experiments and multi-disciplinary research have 
contributed to this endeavour and have resulted in a huge growth in the amount 
and diversity of biological data being generated in recent years (Hirschman et al., 
2012). The broad field of biology dedicated to collectively exploring and 
analysing large amounts of data representing an entire set of some kind is 
referred to as the “omics”. Genomics specifically involves research into 
deoxyribonucleic acid (DNA) and its structure and function. It is through the field 
of genomics and advancements in DNA technologies that have helped 
researchers to understand the underlying genetic basis of various traits and to 
better characterise the relationship between a particular phenotype and the 
genomic pattern for possible prediction of disease risk in high-risk individuals 
(Merelli et al., 2010).     
1.1.1 Advancements in DNA sequencing and chip technologies 
To date, great advancements have been made in DNA sequencing technologies 
resulting in vast amounts of sequencing data being produced. Common 
techniques build on the Sanger process that was developed in the 1970’s 
(Adams, 2008) and which lead to the success of the Human Genome Project. 
Over the years, sequencing has been improved by developing much faster and 
more automated technologies which has allowed for a subsequent decrease in 
the cost associated with sequencing (Adams, 2008). Next generation sequencing 
has also become a popular sequencing technology. This technique parallelises 
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sequencing, thus increasing the number of sequence reads per run and in turn 
lowering costs even further (Buermans & den Dunnen, 2014).  
Advancements have also been made in the various genotyping arrays (also 
known as chips) that have already been produced and continue to be produced. 
These arrays have allowed for the analysis of millions of SNPs per individual in a 
relatively simple, cost-effective manner. Advancement has been seen in genome-
wide association study (GWAS) arrays, as well as arrays for higher resolution SNP 
genotyping, comprising dense SNP representation at specific loci already 
identified to be associated with specific trait(s) of interest (Voight et al., 2012). 
One such chip that has been developed is the Metabochip. 
1.2 Data management: benefits and challenges 
The volume and complexity of the biological data being produced, together with 
the pace at which it is being produced, poses many challenges to researchers 
who need to analyse the data efficiently (Topaloglou, 2004). In order to do this, 
researchers need to find efficient ways to store and manage the data and make it 
more accessible. This will allow researchers to process large amounts of data 
quickly and design experiments with more insight (Howe et al., 2008). 
Several challenges have arisen, however, when dealing with the management of 
biological data. As biological data are broad, diverse and forever evolving, 
existing data management technology has often not been adequate or suitable 
(Topaloglou, 2004). Another barrier has been the cost associated with 
implementing some data management systems or paying data managers 
(Anderson et al., 2007) and, very often, little funding is set aside for this (Gross, 
2011). The limited extra time available for researchers to implement their own 
data management systems and change their current practices into more efficient 
ones has also been a challenge (Anderson et al., 2007). 
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Many researchers generally use some form of electronic organisation, but 
instead of using specialised applications suited for their data, they have in the 
past, and still to this day, used general-purpose applications like spreadsheets. 
Spreadsheets have become a common tool for storing data, but are limited by 
processing power, the complexity of queries that can be run and in the size of 
data that can be stored. As data becomes more complex and increases in size, 
spreadsheets become a less feasible option for storage. Spreadsheets, however, 
remain a popular choice due to their ease of use, simplicity, familiarity and little 
or no cost associated with using them. (Anderson et al., 2007) 
1.3 Databases 
The challenges associated with data management and some past and current 
practices has lead to the need to develop formal databases to efficiently store 
and manage data (Larranaga et al., 2006). The organisation of relevant data into 
databases aims to make the data more accessible and in such a format that 
allows for easy extraction of useful information from the data (Larranaga et al., 
2006). Central to database development is biocuration. Biocuration can be 
defined as “the activity of organising, representing and making biological 
information accessible to both humans and computers” (Howe et al., 2008).  
Although biocuration is considered to be a vital “tool” in making data accessible, 
it tends to lag behind data generation in terms of available funding and the 
development and recognition of the tool as an important step in biological 
research (Howe et al., 2008).  
1.3.1 Online databases 
Online databases, which are those accessible via the internet as opposed to 
being stored locally, have become popular tools for publishing biological data 
(Howe et al., 2008), with the number of databases increasing every year 
(Hirschman et al., 2012). The Nucleic Acids Research online Molecular Biology 
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Database Collection currently lists 1685 available databases (Rigden et al., 2016). 
These databases make up a selection of resources provided by three major 
bioinformatics centres: the United States National Centre for Biotechnology 
Information (NCBI), the European Bioinformatics Institute (EMBL-EBI) and the 
Swiss Institute for Bioinformatics (SIB) (Rigden et al., 2016).  
Many of the new and updated databases for 2016 are dedicated to the genetics 
of disease and drug research (Rigden et al., 2016). The existing databases fall into 
several categories with some being specific to certain populations, 
diseases/traits or genetic loci. Some are also more general. Examples of some of 
these general databases related to human genes and diseases and which are 
relevant to our area of research are listed in Table 1.1. 
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Table 1.1 A selection of useful internet accessed databases related to human 
genes and diseases 
Database Brief description URL 
ClinVar 
Groups information about 
genomic variation and its 
relationship to human 
health. 
www.ncbi.nlm.nih.gov/clinvar/ 
dbGaP 
Database of genotypes and 
phenotypes. Archives and 
distributes the data and 
results from studies 
investigating the interaction 
of genotypes and 
phenotypes in humans. 
www.ncbi.nlm.nih.gov/gap 
dbSNP and dbSNP-Q 
Database of SNPs and 
multiple small-scale 
variations including 
insertions/deletions, 
microsatellites, and non-
polymorphic variants. 
dbSNP-Q is a web 
application for querying 
dbSNP. 
www.ncbi.nlm.nih.gov/projects/SNP/ 
cgsmd.isi.edu/dbsnpq/ 
DECIPHER (DatabasE 
of genomiC varIation 
and Phenotype in 
Humans using Ensembl 
Resources) 
Incorporates a suite of tools 
designed to aid the 
interpretation of genomic 
variants. 
decipher.sanger.ac.uk/ 
F-SNP 
Provides integrated 
information about the 
functional effects of SNPs 
obtained from 16 
bioinformatics tools and 
databases. 
compbio.cs.queensu.ca/F-SNP/ 
GenAtlas 
Provides information on the 
structure, expression and 
function of genes, gene 
mutations and their 
consequences on diseases. 
genatlas.medecine.univ-paris5.fr/ 
GWAS Catalog 
A curated collection of all 
published genome-wide 
association studies. 
www.ebi.ac.uk/gwas/ 
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Table 1.1 (continued) 
Database Brief description URL 
GWAS Central 
Provides a centralized 
compilation of summary 
level findings from genetic 
association studies, both 
large and small. 
www.gwascentral.org/ 
GWASdb 
Human genetic variants 
identified by genome wide 
association studies. 
jjwanglab.org/gwasdb/ 
PhenomicDB 
Integrates public 
genotype/phenotype data 
from a wide range of model 
organisms and humans. 
www.phenomicdb.de/ 
SNPedia 
Wiki on SNPs and genome 
annotation. 
snpedia.com/ 
SNPlogic 
Provides a comprehensive 
interactive SNP annotation, 
selection and prioritization 
system for focused 
genotyping projects and/or 
analysis and interpretation 
of SNP data. 
www.snplogic.org/ 
VarySysDB 
Contains various types of 
human gene polymorphisms. 
h-invitational.jp/varygene/home.htm 
VaDE (VarySysDB 
Disease Edition) 
Provides genomic 
polymorphisms associated to 
diseases, traits, and 
pharmacogenomics. 
bmi-tokai.jp/VaDE/ 
 
The multitude of online databases contain publicly available data for use by 
multiple researchers to obtain important information relevant to their studies. 
Biological research can be further advanced by moving project-specific data from 
basic spreadsheets into databases and making the data available to and 
queryable by all members of a research group via web interfaces similar to those 
that exist for the public databases. 
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1.4 Biological focus: Cardiovascular diseases and hypertension 
CVDs are the leading cause of NCD deaths globally ahead of cancers, respiratory 
diseases and diabetes (World Health Organization, 2014b). Research on 
communicable or infectious diseases has gained much of the focus until now, 
particularly in Africa where they are a main cause of morbidity and mortality. 
Chronic NCDs are, however, gaining increasing interest due to their burden 
becoming as significant.  In the latest global status report on NCDs, it was 
reported that in 2012 approximately 38 million (63%) deaths globally were due 
to NCDs (World Health Organization, 2014a). It is projected that NCD deaths will 
increase to 52 million by 2030 (Mathers & Loncar, 2006). Low- and middle-
income countries (LMIC) are the most affected, with about 28 million of the NCD 
deaths occurring in these countries and the NCD death rate being 625 and 673 
per 100 000 in low-income and lower-middle-income countries, respectively, 
compared to 397 per 100 000 in high-income countries (World Health 
Organization, 2014b). In addition, 82% of premature deaths (deaths before the 
age of 70) occur in LMIC. 
CVDs were responsible for approximately 17.5 million (46%) NCD deaths in 2012, 
with more than 80% occurring in LMIC (Abegunde et al., 2007). This figure is 
expected to increase to about 22.2 million in 2030, with approximately 85% 
occurring in LMIC (World Health Organization, 2014b; Mathers & Loncar, 2006). 
In LMIC, serious and fatal CVD-related events usually occur in females, and 
commonly those that are pregnant, and younger individuals (Sliwa et al., 2014).  
 A major risk factor contributing to CVDs, and the leading cause of morbidity and 
mortality worldwide (Guwatudde et al., 2015), is hypertension or raised BP. In 
2014 the global prevalence of raised BP was approximately 22% in adults aged 18 
years and older, with the highest prevalence reported in Africa at 30% for all 
adults combined (World Health Organization, 2014b). In 2010, raised BP was 
estimated to have caused 9.4 million deaths globally (World Health Organization, 
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2014b). Hypertension itself is considered a major risk factor for strokes, MI, 
cardiac failure, dementia, renal failure and blindness. Specifically, hypertension is 
responsible for about 45% and 51% of deaths due to heart disease and stroke, 
respectively (Singh et al., 2016). 
Two main forms of hypertension exist: primary (or essential) hypertension, which 
is the most prevalent form and has no single known cause, and secondary 
hypertension, which results from some or other underlying condition and include 
the monogenic forms of hypertension. The focus of this research and the main 
subject for the remainder of this chapter is primary hypertension. SBP and DBP 
(both continuous traits) are common measurements of hypertension (a 
dichotomised disease category), which is characterised by sustained high BP, 
with average SBP and DBP readings in adults of 140mmHg and 90mmHg or 
greater, respectively (Rosamond et al., 2007). This is in contrast to the normal or 
accepted values of less than 120mmHg and 80mmHg for SBP and DBP, 
respectively. 
1.4.1 Ethnic differences in hypertension prevalence 
There is a difference in the prevalence and clinical presentation of hypertension 
among individuals of different ethnicity, with African or black individuals in many 
cases fairing much worse (Cooper & Rotimi, 1994, 1997; Takeuchi et al., 2010; 
Egan et al., 2010). Hypertension in black Africans usually presents more 
frequently, is more severe (Salako et al., 2007) and is more resistant to 
treatment (Addo et al., 2007). The 2005-2006 National Health and Nutrition 
Examination Survey reported that 27% of African American adults suffer from 
hypertension compared to only 17% of Caucasians (Redmond et al., 2011). A 
similar trend was seen in a study in an adult urban population in Durban, South 
Africa with the prevalence in black, white and Indian individuals being 25%, 
17.2% and 14.2%, respectively (Seedat, 1999).  
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The increased prevalence of and predisposition to hypertension in black 
individuals may be due to differences in the handling of potassium by the kidney, 
with black individuals usually having a lower urinary excretion of potassium (Aviv 
et al., 2004). In addition, they have increased sodium reabsorption by the 
kidneys leading to a more expanded plasma volume (Tu & Pratt, 2013). As a 
result, black individuals usually develop salt-sensitive hypertension (Weinberger 
et al., 1986).  
The total number of individuals with hypertension in developing countries, and 
particularly in Africa, is high. A major contributing factor to this is the inability of 
these individuals to afford treatment, compared to those in developed countries 
(Nissinen et al., 1988), or the lack of treatment facilities (Opie & Seedat, 2005). 
Poor education and a low understanding of the severity of hypertension also play 
a role in inadequate control of BP (Opie & Seedat, 2005). There has also been a 
reported difference in prevalence in rural compared to urban areas, with 
individuals in urban areas being at a higher risk than those in rural areas (Opie & 
Seedat, 2005), mainly due to dietary differences. This difference becomes less 
apparent, however, following urban exposure in rural areas. 
Hypertension was once considered rare in sub-Saharan Africa (SSA), but has 
become more prevalent in recent years, mainly due to migration of people from 
rural to urban areas and subsequent changes in lifestyle (Ogah & Rayner, 2013). 
In 2008, the prevalence of hypertension in SSA was 16.2%, with approximately 
74.7 million affected individuals. This figure is expected to increase to about 
125.5 million by 2025 (Ogah & Rayner, 2013). A recent study also reported an 
increased severity in South African blacks compared to African Americans where 
SBP was 9.7mmHg higher in South African blacks (Cooper et al., 2015). As with 
the rest of Africa, the awareness, treatment and control of hypertension are 
generally low in SSA (Ogah & Rayner, 2013).  
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1.4.2 Non-genetic risk factors 
Several studies have reported obesity, or an increased BMI, and salt intake as 
two of the main risk factors associated with raised BP and hypertension 
(Forrester, 2004; Yang et al., 2012). A study conducted in individuals of African 
ancestry from West Africa, the Caribbean and North America showed that these 
two risk factors accounted for about 70% of the prevalence differences across 
these populations. In addition, they are risk factors common to populations 
worldwide (Forrester, 2004). Approximately 1.7 million CVD-related deaths 
globally are due to excessive sodium intake (World Health Organization, 2014b).   
Age and sex are also known risk factors for BP and hypertension. For example, 
men have a higher SBP and DBP than women at a younger age (Roger et al., 
2012), but, following menopause, women have higher BP than men (Reckelhoff, 
2001). An early study in South African men and women revealed that women 
aged between 35 to 40 are at a greater risk for hypertension than men (Seedat, 
1983).  Additionally, an assessment of hypertension in four countries in SSA 
(Burkina Faso, Ghana, Kenya and South Africa) showed that the prevalence of 
hypertension was significantly higher in women than in men and increased with 
age in males and females separately and combined  (Gómez-Olivé et al., under 
review). 
Other risk factors include insulin resistance (Banerjee, 2013), physical inactivity 
(Council on High Blood Pressure Research, 2003), alcohol (Council on High Blood 
Pressure Research, 2003) and coffee (Chalmers et al., 1999) intake, psychosocial 
stress (Council on High Blood Pressure Research, 2003), consumption of high-fat 
foods (Douglas et al., 2003; Boutin-Foster et al., 2007), smoking (Chalmers et al., 
1999), dyslipidemia (Tchelougou et al., 2015) and HIV infection (Bärnighausen et 
al., 2007). 
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1.4.3 Genetic risk factors 
Primary hypertension is a multifactorial disorder with genetics playing a role in 
its aetiology in addition to the various environmental or non-genetic risk factors. 
Familial studies have shown that BP/hypertension is roughly 30-50% heritable 
(Munroe et al., 2013). It has also been suggested that differences in prevalence 
of the disorder among various ethnic groups is due to the underlying genetics of 
the individuals (Grim & Robinson, 1996). Although much has been elucidated 
about the rare monogenic forms of hypertension, the underlying genetic basis of 
primary hypertension remains poorly understood, with small contributions from 
multiple genes believed to affect the aetiology of the disorder (Doris, 2002). This 
makes identifying loci/variants associated with BP/hypertension quite 
challenging.  
Attempts to identify the genetic determinants of BP/hypertension have been 
made by conducting genome-wide linkage analyses, candidate gene studies and, 
more recently, GWAS. Probable candidate genes for investigation were first 
chosen based on their known biochemical or physiological function and link to BP 
regulation.  
As the kidney plays a role in the long-term regulation of BP, genes influencing 
renal salt handling were of particular interest (Singh et al., 2016). Mutations in 
genes involved in BP control by the kidneys have already been identified for the 
monogenic forms of hypertension (Lifton, 2004).   It has been hypothesised that 
causes of hypertension include low plasma renin levels, sodium sensitivity and 
cellular abnormalities, epithelial sodium channel (ENaC) changes, altered genes 
regulating the renin-angiotensin-aldosterone system (RAAS) or increased 
peripheral vascular resistance (Opie & Seedat, 2005). Some of the first genes 
studied for primary hypertension were those involved in the RAAS including, 
among others, the angiotensin-converting enzyme (ACE) and angiotensinogen 
(AGT) genes (Norton et al., 2010). As reviewed by Norton and colleagues (2010), 
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despite the role of the protein products of ACE and AGT in BP regulation, studies 
have generally been inconclusive about the impact of variants in these genes on 
BP, with studies both supporting and refuting an association. In black South 
Africans, an association was found between a polymorphism in the promoter 
region of AGT and a greater than expected increase in SBP (Tiago et al., 2002). In 
a study in Burkina Faso, West Africa, an association was found between the DD 
genotype of the ACE gene and hypertension susceptibility (Tchelougou et al., 
2015). Another association was found between the aldosterone synthase gene 
(CYP11B2) and higher initial SBP in previously untreated black South Africans 
(Tiago et al., 2003).  
Other candidate genes of interest are those encoding the subunits of the ENaC. It 
is a plausible candidate for salt sensitivity as it is the final regulator of sodium 
balance in the kidney (Jones et al., 2012). The first report of SNPs in ENaC genes 
associated with hypertension in blacks was in a set of individuals from London 
where an association was found with the T594M SNP of the β-chain (Baker et al., 
1998). This finding could not, however, be replicated in African Americans or 
South African blacks (Nkeh et al., 2003; Hollier et al., 2006). A novel mutation 
was, however, found between R563Q and low-renin, low-aldosterone 
hypertension in black and mixed ancestry South Africans (Rayner et al., 2003). 
The G protein-coupled receptor kinase 4 (GRK4) gene has also been suggested as 
a possible candidate for hypertension. Variants in GRK4, especially Ala142Val, 
could account for the low-renin, low-aldosterone phenotype seen in black 
individuals (Rayner & Spence, 2017).  
Early studies were relatively unsuccessful and produced inconsistent findings 
(Zhao et al., 2013) and replication in linkage analyses and candidate gene studies 
has proven to be challenging (Zheng et al., 2015b). Introduction of SNP 
genotyping arrays for large numbers of variants and the formation of large BP 
consortia has advanced the discovery of BP/hypertension variants to a certain 
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extent (Zhao et al., 2013; Padmanabhan et al., 2015). In many cases, however, 
although multiple BP/hypertension loci have been found, few reach genome-
wide significance (p<5x10-8), raising concern about the effectiveness of GWAS in 
studying BP/hypertension (Levy et al., 2009; Takeuchi et al., 2010). In addition, 
the identified variants/loci are very often not the causal variants/loci, but rather 
tag the causal variants, making fine-mapping studies a necessity (Wang et al., 
2011). Nevertheless, GWAS, and meta-analysis across many studies, have shed 
some light on possible genetic variants or loci linked to BP for further study.  
To date, however, most of the large scale studies that have been published have 
been carried out in individuals of European Ancestry, with fewer conducted in 
individuals of Asian or African ancestry. Significant findings from some of the 
main studies conducted in non-African individuals are summarised in Table 1.2. 
In addition, several associations not at genome-wide significance were reported 
in smaller studies in Europeans, with some of these findings then confirmed in 
the larger studies or following replication. The identified loci included STK39 (SBP 
and DBP) (Wang et al., 2009), upstream of CDH13 (DBP and hypertension) (Org et 
al., 2009) and NPPA/NPPB (SBP, DBP and hypertension) (Newton-Cheh et al., 
2009b). 
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Table 1.2 Findings from some of the main BP/hypertension genetic studies in non-Africans 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
Europeans [Global BP 
Genetics (GBPGEN) 
consortium] 
GWAS meta-analysis Yes 
Variants in/near: 
CYP17A1 (SBP) 
CYP1A2 (DBP) 
FGF5 (DBP) 
SH2B3 (DBP) 
MTHFR (SBP) 
C10orf107 (DBP) 
ZNF652 (DBP) 
PLCD3 (SBP) 
2009 
(Newton-Cheh et al., 
2009a) 
Europeans [Cohorts for 
Heart and Aging Research in 
Genomic Epidemiology 
(CHARGE) consortium] 
GWAS meta-analysis Yes 
Variants in/near: 
ATP2B1 (SBP, DBP, hypertension) 
C18orf1 (SBP) 
CASZ1 (SBP) 
SH2B3 (DBP) 
ATXN2 (DBP) 
TRAFD1 (DBP) 
TBX3/TBX5 (DBP) 
PLEKHA7 (DBP) 
 
In silico comparison with GBPGEN: 
ATP2B1 (SBP, DBP and hypertension) 
SH2B3 (DBP) 
TBX3/TBX5 (DBP)  
 
Joint meta-analysis of CHARGE and  GBPGEN: 
CYP17A1 (SBP) 
PLEKHA7 (SBP) 
ATP2B1 (SBP, DBP, hypertension) 
SH2B3 (SBP, DBP) 
2009 (Levy et al., 2009) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
   
ULK4 (DBP) 
CACNB2 (DBP) 
TBX3/TBX5 (DBP) 
Locus adjacent to CSK/ULK3 (DBP) 
  
Japanese 
Multistage replication 
study (of European 
signals) 
No 
Variants in/near: 
CASZ1 (SBP, DBP, hypertension) 
MTHFR(SBP) 
ITGA9 (hypertension) 
FGF5 (SBP, DBP, hypertension) 
CYP17A1/CNNM2 (SBP, DBP, hypertension) 
ATP2B1 (SBP, DBP, hypertension) 
CSK/ULK3 (DBP, hypertension) 
2010 (Takeuchi et al., 2010) 
Europeans GWAS Yes Variant upstream of UMOD (hypertension) 2010 
(Padmanabhan et al., 
2010) 
East Asians [Asian Genetic 
Epidemiology Network 
Blood Pressure (AGEN-BP) 
consortium] 
GWAS meta-analysis (3-
stage including 
replication) 
Yes 
Novel loci: 
ST7L-CAPZA1 (DBP) 
FIGN-GRB14 (SBP) 
ENPEP (DBP) 
NPR3 (SBP) 
 
Novel association near known locus (TBX3) 
 
East Asian specific association at ALDH2 
 
Previous European loci replicated in East Asians: 
CASZ1 (DBP) 
FGF5 (SBP, DBP) 
CYP17A1 (SBP, DBP) 
ATP2B1 (SBP, DBP) 
2011 (Kato et al., 2011) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
Europeans [International 
Consortium for BP-GWAS 
(ICBP-GWAS)] 
GWAS meta-analysis 
(including discovery and 
follow-up data) 
Yes 
Novel loci: 
MOV10 (SBP, DBP) 
SCL4A7 (DBP) 
MECOM (SBP, DBP) 
SLC39A8 (SBP, DBP) 
GUCY1A3-GUCY1B3 (DBP) 
NPR3-C5orf23 (SBP, DBP, hypertension) 
EBF1 (SBP, DBP) 
HFE (SBP, DBP, hypertension) 
BAT2-BAT5 (SBP, DBP, hypertension) 
CACNB2(5’) (SBP, DBP) 
PLCE1 (SBP, hypertension) 
ADM (SBP) 
FLJ32810-TMEM133 (SBP, DBP, hypertension) 
FURIN-FES (SBP, DBP) 
GOSR2 (SBP) 
JAG1 (SBP, DBP) 
GNAS-EDN3 (SBP, DBP, hypertension) 
 
Confirmed loci: 
MTHFR-NPPB (SBP, DBP, hypertension) 
ULK4 (DBP) 
FGF5 (SBP, DBP) 
CACNB2(3’) (SBP, DBP, hypertension) 
C10orf107 (SBP, DBP, hypertension) 
CYP17A1-NT5C2 (SBP, DBP) 
PLEKHA7 (SBP, DBP) 
ATP2B1 (SBP, DBP, hypertension) 
SH2B3 (SBP, DBP) 
2011 (Ehret et al., 2011) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
   
TBX5-TBX3 (DBP) 
CYP1A1-ULK3 (SBP, DBP, hypertension) 
ZNF652 (SBP, DBP) 
 
9 loci replicated in East Asians and 6 in South 
Asians 
  
Europeans (multiple 
cohorts) 
Meta-analysis using a 
gene-centric array 
(HumanCVD BeadChip 
from Illumina) 
Yes 
Novel loci: 
LSP1/TNNT3 (mean arterial pressure (MAP)) 
MTHFR-NPPB (DBP) 
 
Confirmed loci: 
ATP2B1 (hypertension) 
AGT (hypertension) 
 
Combined discovery and follow-up data: 
MTHFR-NPPB (DBP) 
AGT (hypertension) 
NPR3 (SBP) 
HFE (DBP) 
NOS3 (DBP) 
LSP1/TNNT3 (MAP) 
SOX6 (MAP) 
ATP2B1 (hypertension) 
2011 (Johnson et al., 2011) 
Europeans [HYPERGENES 
project part of the 
European Network for 
Genetic-Epidemiological 
Studies] 
GWAS meta-analysis (of 
discovery and validation 
phase) 
Yes 
Novel  locus: 
NOS3 (hypertension) 
2012 (Salvi et al., 2012) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
Europeans (multiple 
cohorts) 
Meta-analysis using a 
gene-centric array 
(HumanCVD BeadChip 
from Illumina) 
Yes 
Novel loci: 
HRH1 (SBP) 
SOX6 (SBP) [previously MAP] 
MDM4 (DBP) 
 
Confirmed loci: 
ADRB1 (MAP) 
ATP2B1 (SBP, MAP) 
SH2B3/ATXN2 (SBP, DBP, MAP) 
CSK (SBP, DBP, MAP) 
CYP17A1 (SBP, pulse pressure (PP)) 
FURIN (SBP, DBP, MAP) 
HFE (DBP) 
LSP1 (SBP) 
MTHFR (SBP, DBP, MAP) 
2013 (Ganesh et al., 2013) 
Europeans (multiple 
cohorts) 
Meta-analysis using a 
gene-centric array 
(HumanCVD BeadChip 
from Illumina) 
Yes 
Novel loci: 
PDE1A (DBP, MAP)  
HLA-DQB1 (DBP) 
VCL (DBP, MAP) 
PRKAG2 (SBP) 
H19 (SBP, MAP) 
NUCB2 (SBP, MAP, PP) 
SIPA1 (SBP) 
HOXC complex (SBP) 
RELA (MAP) 
CDK6 (PP) 
FBN1 (PP) 
NFAT5 (PP) 
Confirmed 27 previous loci 
2014 (Tragante et al., 2014) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
Chinese GWAS meta-analysis Yes 
Novel loci: 
CACNA1D (DBP) 
CYP21A2 (SBP, DBP, hypertension) 
MED13L (SBP, DBP) 
 
Confirmed loci: 
CASZ1 (SBP, hypertension) 
MOV10 (SBP, hypertension) 
FGF5 (SBP, DBP, hypertension) 
CYP17A1 (SBP, DBP, hypertension) 
SOX6 (SBP, DBP) 
ATP2B1 (SBP, DBP, hypertension) 
ALDH2 (DBP) 
JAG1 (SBP, DBP) 
SLC4A7 (new variant; SBP) 
2015 (Lu et al., 2015) 
Trans-ethnic (East Asian, 
South Asian, European) 
GWAS meta-analysis Yes 
Novel loci: 
IGFBP3 (PP) 
KCNK3 (MAP) 
PDE3A (DBP) 
PRDM6 (SBP) 
ARHGAP24 (SBP) 
OSR1 (PP) 
SLC22A7/TTBK1/ZNF318 (SBP) 
TBX2/c17orf82 (MAP)  
ABLIM3/SH3TC2 (DBP) 
HDAC9 (PP) 
LRRC10B/SYT7 (MAP) 
AMH/DOT1L/PLEKHJ1/SF3A2 (PP) 
2015 (Kato et al., 2015) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
Various populations (East 
Asian, African, Caucasian) 
Meta-analysis of case-
control studies 
No 
Variants in: 
GRK4 (hypertension in Caucasians) 
DRD1 (hypertension in East Asians) 
2015 (Zhang et al., 2015) 
Europeans [Early Genetics 
and Lifecourse 
Epidemiology (EAGLE) 
consortium] 
GWAS meta-analysis Yes 
Novel loci: 
ITGA11 (pre-puberty SBP) 
rs872256 in unknown locus (puberty SBP) 
 
2016 (Parmar et al., 2016) 
Europeans [BELHYPGEN 
cohort] 
Snapshot genotyping of 
a few SNPs 
No 
Confirmed loci: 
STK39 (SBP, hypertension) 
WNK1 (SPB, hypertension) 
2016 (Persu et al., 2016) 
Europeans (multiple 
studies) 
Meta-analysis using the 
Metabochip 
Yes 
Novel loci: 
HIVEP3 (SBP) 
PNPT1 (DBP) 
FGD5 (SBP, DBP) 
ADAMTS9 (DBP) 
TBC1D1–FLJ13197 (SBP, DBP) 
TRIM36 (SBP, DBP) 
CSNK1G3 (DBP) 
CHST12–LFNG (SBP, DBP) 
ZC3HC1 (SBP, DBP) 
PSMD5 (SBP) 
DBH (SBP, DBP) 
RAPSN/PSMC3/SLC39A13 (SBP, DBP) 
LRRC10B (SBP, DBP) 
SETBP1 (SBP, DBP) 
INSR (SBP, DBP) 
ELAVL3 (DBP) 
CRYAA–SIK1 (SBP, DBP) 
 
2016 (Ehret et al., 2016) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
   
Confirmed loci: 
CASZ1 (SBP, DBP) 
MTHFR–NPPB (SBP, DBP) 
ST7L–CAPZA1–MOV10 (SBP, DBP) 
MDM4 (DBP) 
AGT (SBP, DBP) 
KCNK3 (SBP, DBP) 
NCAPH (DBP) 
FIGN–GRB14 (SBP, DBP) 
HRH1–ATG7 (SBP) 
SLC4A7 (SBP) 
ULK4 (DBP) 
MAP4 (SBP, DBP) 
MECOM (SBP, DBP) 
FGF5 (SBP, DBP) 
ARHGAP24 (SBP) 
SLC39A8 (SBP, DBP) 
GUCY1A3–GUCY1B3 (SBP) 
NPR3–C5orf23 (SBP, DBP) 
EBF1 (SBP, DBP) 
HFE (SBP, DBP) 
BAT2–BAT5 (DBP) 
ZNF318–ABCC10 (SBP) 
RSPO3 (SBP, DBP) 
PLEKHG1 (DBP) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
   
HOTTIP–EVX (SBP, DBP) 
PIK3CG (SBP) 
BLK–GATA4 (SBP) 
CACNB2 (SBP, DBP) 
C10orf107 (SBP, DBP) 
SYNPO2L (SBP) 
PLCE1 (SBP, DBP) 
CYP17A1–NT5C2 (SBP, DBP) 
ADRB1 (SBP, DBP) 
LSP1–TNNT3 (SBP, DBP) 
ADM (SBP, DBP) 
PLEKHA7 (SBP, DBP) 
SIPA1 (SBP) 
FLJ32810–TMEM133 (SBP, DBP) 
PDE3A (DBP) 
ATP2B1 (SBP, DBP) 
SH2B3 (SBP, DBP) 
TBX5–TBX3 (DBP) 
CYP1A1–ULK3 (SBP, DBP) 
FURIN–FES (SBP, DBP) 
PLCD3 (SBP) 
GOSR2 (SBP) 
ZNF652 (DBP) 
JAG1 (SBP, DBP) 
GNAS–EDN3 (SBP, DBP) 
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Table 1.2 (continued) 
Population 
[Cohort/Consortium] 
Type of study 
Replication/follow-up 
performed? 
Genes/Variants (Association) 
(At genome-wide, array-wide, replication or 
study significance level) 
Year Reference 
Hispanic and trans-ethnic 
(Hispanics and African 
Americans) [Population 
Architecture using 
Genomics and 
Epidemiology (PAGE) 
consortium] 
Meta-analysis using the 
Metabochip 
Yes 
Hispanics – known loci: 
KCNK3 (DBP) 
FGF5 (SBP, DBP) 
ATXN2-SH2B3 (DBP) 
 
Trans-ethnic – novel variants in known loci: 
ULK4 (DBP) 
FGF5 (DBP) 
HOXA-EVX1 (SBP) 
2016 
(Franceschini et al., 
2016) 
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BP genetics in African individuals 
The first BP GWAS to be carried out in individuals of African ancestry focused on 
an African-American population (Adeyemo et al., 2009). SNPs in or near six loci 
(PMS1, SLC24A4, YWHA7, IPO7, CACNA1H and AL365365.23 (a pseudogene)) 
associated with SBP at a genome-wide significance level, but no SNPs met 
genome-wide significance for association with DBP or hypertension. Of the 17 
SNPs taken through for replication in a West African population, three were 
associated with either SBP, DBP or hypertension. A combined meta-analysis of 
the African American and West African individuals revealed a significant 
association with five of the SNPs, including rs11160059 in SLC24A4 (Adeyemo et 
al., 2009). A later evaluation of 16 top associated SNPs from this study in a 
different sample of African Americans showed no replication (Kidambi et al., 
2012).  
In a second GWAS in African-Americans, and the largest to date, two novel loci 
(rs2258119 in C21orf91 - SBP and rs10474346 intergenic to GPR98 and ARRDC3 - 
DBP) reached genome-wide significance, but could not be replicated in 
independent African American cohorts (Fox et al., 2011). In addition, three loci 
previously reported in Americans of European ancestry (SH2B3, TBX3-TBX5 and 
CSK-ULK3) were replicated in the African-Americans in this study.  
A GWAS meta-analysis of 19 African American and one Yoruban sample from the 
Continental Origins and Genetic Epidemiology Network (COGENT) revealed an 
association between a SNP in CYB5R2 (rs11041530) and SBP. A trans-ethnic 
meta-analysis of the discovery samples and additional African, European and 
East Asian samples failed to replicate this association, but identified three novel 
loci (EVX1-HOXA, RSPO3, PLEKHG1) and one novel association in a known locus 
(SOX6) and managed to fine map four previously identified loci (EBF1, ATP2B1, 
NT5C2, ULK4) (Franceschini et al., 2013). A further study in the same set of 
individuals integrated association evidence from summary statistics of multiple 
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traits and found genome-wide significant associations with CHIC2, HOXA-EVX1, 
IGFBP1/IGFBP3 and CDH17 (Zhu et al., 2015). 
Several smaller scale studies have also identified BP or hypertension associated 
loci in African-Americans. For example, a SNP in VNN1 (rs2272996) is associated 
with increased risk for hypertension (Zhu & Cooper, 2007); rs7726475, a SNP 
located between SUB1 and NPR3, is associated with SBP and DBP (Zhu et al., 
2011) and rs437470 in CXADR is associated with SBP and DBP (Shetty et al., 
2012). In another study in African-Americans, suggestive associations were found 
between polymorphisms in RGS5 and hypertension, SBP and DBP; 
polymorphisms in the SELE gene and SBP and BDP; and polymorphisms in 
ATP1B1 and SBP (Faruque et al., 2011). These three genes had all previously 
been shown to be associated with hypertension in Americans of European 
ancestry and also replicated some of the findings from previous investigations in 
African-Americans (Chang et al., 2007).  
Genetic association studies conducted in individuals of African ancestry other 
than African-Americans have been limited. An association was found between a 
SNP in SLC4A5 (rs8179526) and SBP in West African women (Taylor et al., 2011). 
Some very small scale studies have been conducted in South African individuals. 
In addition to the aforementioned associations reported in ENaC subunit genes, 
AGT and CYP11B2, studies conducted in individuals from Johannesburg have 
shown associations between the 460-Trp variant in the α-adducin gene and 
hypertension (Barlassina et al., 2000) and an intron 2 polymorphism in the atrial 
natriuretic peptide (ANP) gene and the absence of hypertension (Nkeh et al., 
2002). On the other hand, associations could not be found between a β2 
adrenoreceptor polymorphism (Candy et al., 2000) and hypertension.   
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1.5 Genotype imputation 
GWAS have become a powerful alternative to family-based linkage studies 
(Marchini et al., 2007) and are a useful tool in genetics to discover variants 
associated with specific traits of interest. The chips or arrays used in GWAS, 
however, only contain a fraction of the SNPs that exist (Pei et al., 2008) and the 
findings from GWAS only explain a small proportion of the heritability of many 
phenotypes leading to what has become known as “missing heritability” 
(Manolio et al., 2009). In the case of BP/hypertension, the identified loci and 
variants to date explain less than 2.5% of the phenotypic variance for SBP and 
DBP (Ehret et al., 2011). A potential source of much of this “missing heritability” 
are rare variants (minor allele frequency (MAF) < 1%) (Dickson et al., 2010; Frazer 
et al., 2009), which are not generally included on the genotyping arrays or are 
removed during QC. Missing genotype information also results from removal of 
SNPs due to low call rates and deviations from Hardy-Weinberg equilibrium 
(HWE) (Pei et al., 2008) or variations in the depth and scope of assessment across 
different genotyping platforms (Zhang et al., 2011). Having more complete 
information can significantly enhance the power to detect causal variant(s) for a 
trait of interest (Zhang et al., 2011). 
Genotype imputation, which involves the inference of genotype information at 
SNPs not initially genotyped, has become a useful addition to many GWAS to 
recover some of the missing or ungenotyped data and has become possible due 
to an increased understanding of the genome structure, substructure and 
population admixture (Zhang et al., 2011). The aim of imputation is to predict or 
impute the missing or ungenotyped data into the dataset based on the observed 
or genotyped data and information about the LD within the region from a chosen 
reference panel (Marchini et al., 2007; Biernacka et al., 2009). Imputation also 
relies on the fact that individuals with a common ancestor share extended 
haplotypes over short regions (Scheet & Stephens, 2006; Browning & Browning, 
2007).  
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1.5.1 Benefits of imputation 
The result of imputation is a larger and denser set of SNPs to test for association 
with the trait/phenotype under investigation and a much more detailed view of 
the associated region (Marchini et al., 2007), thus increasing the power of GWAS. 
Imputation can allow researchers to use  genotyping arrays with slightly lower 
coverage and genotype more individuals rather than additional SNPs (Anderson 
et al., 2008). It has also increased the potential to identify increasingly subtle 
signals from large and complex datasets (Howie et al., 2009).  
Imputation can help in the fine-mapping of a region of association through 
testing of a larger number of SNPs, with some imputed SNPs being more strongly 
associated with the trait of interest than genotyped SNPs (Li et al., 2009). This 
helps researchers to potentially pinpoint the associated regions more precisely 
(Nho et al., 2011) and has huge implications for follow-up studies where these 
imputed SNP signals can be studied in more detail (Ellinghaus et al., 2009). In 
addition, SNPs identified in pathway analyses, but that are not genotyped, can be 
imputed into the dataset for further analysis (Nho et al., 2011).   
Many disease variants have small effects and are often undetected in individual 
studies. Meta-analyses, conducted by combining data across several studies, can 
facilitate detection of these variants (Marchini et al., 2007; Li et al., 2012) and 
identification of novel variants/loci (de Bakker et al., 2008). Different studies, 
however, often use different genotyping platforms or analyse a different set of 
SNPs. Imputation is useful in this case as it allows for a successful combination of 
different datasets and imputation of missing SNPs across studies to produce one 
common set of SNPs for analysis. Despite the possible benefit, however, Li et al 
(2012) suggested that the power of analysis of individual studies may still be 
higher than that of a meta-analysis with imputation, due to the genotype 
uncertainty that may be introduced with imputation being higher than the 
gained power from increasing the sample size. They suggested that the results 
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from the largest study be studied first as it may provide more power (Li et al., 
2012). In addition, it has been found that imputation-induced bias can be 
introduced when combining all genotyped SNPs across arrays, even if very similar 
(Johnson et al., 2013). A more favourable option is to only combine those SNPs 
available on all arrays and then impute up to a common set of reference panel 
SNPs (Johnson et al., 2013).  
In addition to increasing the power of GWAS and its usefulness in fine-mapping 
and meta-analysis, imputation can also help in QC steps by highlighting possible 
genotype errors and may help in the reconstruction of missing genotype data in 
ungenotyped family members in the context of pedigree data (Ellinghaus et al., 
2009). 
Central to imputation is the use of an appropriate software package with 
underlying imputation algorithm and a reference panel, which provides the 
necessary information to infer ungenotyped SNPs. Several imputation tools have 
been developed in recent years as the need for efficient imputation has 
increased (Zhang et al., 2011) and IMPUTE (initially version 1 and later version 2) 
is one such commonly used tool (Marchini et al., 2007; Howie et al., 2009). 
1.5.2 IMPUTE and IMPUTE2 
To infer missing genotypes, IMPUTE uses a set of known haplotypes from 
publically available data (reference panel) and the information from all markers 
in LD with the SNPs to be imputed (Zhao et al., 2008). The algorithm underlying 
the tool is based on a hidden Markov model (HMM). The set of haplotypes from 
the reference panel make up the pool of “hidden states” of the Markov chain 
and haplotypes and missing genotypes are inferred in the study samples 
according to these “hidden states”. It compares the potential haplotype for each 
individual with all other observed haplotypes, rather than using a representative 
set of haplotypes (Li et al., 2009). The computation time of the program 
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increases linearly with the number of markers and quadratically (or less) with the 
number of “states” at each marker (Browning, 2008) making the process 
computationally quite intensive at times. IMPUTE imputes the missing genotypes 
without any reference to the phenotype data (Marchini & Howie, 2008) and 
generates an ‘info’ metric for each SNP which gives an indication of the certainty 
with which the SNP is imputed.  
An update to the first version of IMPUTE (IMPUTE2) was developed to address 
the challenges faced by newer, more complex datasets and to improve 
imputation accuracy of ungenotyped SNPs by improving the accuracy of 
haplotype estimation (phasing) at genotyped SNPs (Howie et al., 2009). The 
newer generation of datasets may be larger, contain unphased and incomplete 
genotypes and offer additional reference data, even in the form of multiple 
reference panels with different SNP sets (Howie et al., 2009). IMPUTE2 uses a 
Markov chain Monte Carlo (MCMC) framework and separates the phasing and 
imputation stages into two steps by alternatively estimating haplotypes at SNPs 
genotyped in both the study sample and reference panel and imputing 
genotypes at SNPs genotyped in only the reference panel (Howie et al., 2009). In 
the phasing step information from both the reference panel and the study 
sample is used – more information than is used by most other imputation 
methods. This increases overall accuracy, but due to the multiple iterations, 
IMPUTE2 is generally slower than IMPUTE version 1 (Howie et al., 2009). 
IMPUTE (1 and 2) shows generally favourable performance compared to other 
commonly used imputation tools. IMPUTE and MaCH (Li et al., 2010) 
outperformed fastPHASE (Scheet & Stephens, 2006), PLINK (Purcell et al., 2007; 
Purcell & Chang, 2014) and Beagle (Browning & Browning, 2007) in a comparison 
by Pei et al (2008) due to the fact that neither used haplotype clustering 
strategies (Pei et al., 2008). IMPUTE and MaCH again outperformed fastPHASE 
and PLINK in a comparison by Biernacka et al (2009), with both generating lower 
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imputation error rates and more reliable association test results. In another 
comparison with MaCH and Beagle, IMPUTE required less processing time than 
MaCH, but more than Beagle, and required less memory if imputation was 
carried out in smaller chromosomal subgroups (Ellinghaus et al., 2009). A pre-
compiled version of IMPUTE is available for all major platforms and pre-prepared 
reference panels are also available. The produced output file is small in size and 
can be used immediately in association testing (Ellinghaus et al., 2009).    
IMPUTE2 also outperforms other methods. It is able to use a larger reference 
panel and has higher specificity and sensitivity to detect copies of the minor 
allele at rare SNPs and is therefore efficient in imputation of rare variants (Howie 
et al., 2009). Compared to Beagle, one of its closest competitors, IMPUTE2 
showed a haplotype best guess error rate 15-20% lower (Howie et al., 2009). 
Although IMPUTE2 is comparable to MaCH in terms of general performance, 
MaCH performed better than IMPUTE2 when using a HapMap reference panel 
and IMPUTE2 performed better than MaCH when using a 1000 Genomes or 
combined 1000 Genomes and HapMap reference panel (Nho et al., 2011). 
IMPUTE2 also required less time and memory than Beagle when considering the 
type of imputation datasets that are starting to emerge in the field (Howie et al., 
2011). Another comparison of imputation performance in African Americans by 
Chanda et al (2012) showed that IMPUTE2 and MaCH outperformed Beagle and 
that IMPUTE2 was faster than MaCH. In yet another study comparing IMPUTE2, 
Beagle, MaCH and MaCH-Admix, MaCH and IMPUTE2 were computationally 
efficient and showed the highest accuracy (as measured by genotype 
concordance when masking and re-imputing genotyped SNPs). In addition, 
IMPUTE2 showed the highest accuracy (as measured by imputation quality score) 
when taking MAF into account and the highest quality (as measured by average 
r2hat), regardless of the reference panel used (Hancock et al., 2012). One study 
has reported that MaCH performed slightly better than IMPUTE2 in most 
scenarios. This was, however, at the cost of increased computation time 
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(Roshyara et al., 2014). Another study, comparing IMPUTE2, minimac 
(Fuchsberger et al., 2015) and Beagle showed that IMPUTE2 and minimac 
outperformed Beagle (Liu et al., 2014).   
1.5.3 Reference panel 
One challenge of imputation is deciding on which reference panel to use. Early 
imputation methods required that a reference panel closely matching the 
ethnicity of the study sample was chosen (Hoffmann & Witte, 2015). Imputation 
uses the LD structure from the reference panel to infer the genotypes of 
ungenotyped SNPs (Pasaniuc et al., 2010). In theory, one would assume that an 
exact ethnic match would be best. Reference panels closely matching the study 
sample can indeed increase imputation accuracy but can also mean a decrease in 
diversity and therefore result in more missing genotype calls (Huang & Tseng, 
2014). Choosing a reference panel is particularly challenging for populations with 
no available matching reference panel. 
Mixed/”cosmopolitan” reference panels 
More recent imputation methods are able to use a “cosmopolitan” reference 
panel which contains all available haplotypes from individuals of multiple 
ethnicities. Whether or not this is the most suitable reference panel to use in all 
scenarios is still debatable. It has given accurate results in a variety of 
populations (Huang et al., 2009; Howie et al., 2011) and could improve 
imputation in admixed populations (Chanda et al., 2012; Huang & Tseng, 2014), 
of rare variants (Howie et al., 2009; Liu et al., 2014; Howie et al., 2011) and in 
cases where no clear reference panel matches exist (Roshyara et al., 2016). It is 
reported to be advantageous to use “ancestrally inclusive” reference panels and 
that using a “cosmopolitan” reference panel might allow unexpected allele 
sharing between different populations to be captured (Howie et al., 2011).  
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Inclusion of more distantly related reference samples may or may not have an 
adverse effect on imputation. In a study in African Americans, inclusion of 
reference populations unrelated to African Americans didn’t adversely affect 
imputation (Chanda et al., 2012). On the other hand, Hancock et al (2012) noted 
a reduction in imputation quality after addition of more distantly related 
reference panels, due to the introduction of low frequency SNPs which are 
monomorphic in some populations. They also noted that imputation of low 
frequency SNPs was of the highest quality when using a closely related reference 
panel and for other frequency SNPs was of the highest quality when using a more 
diverse reference panel (Hancock et al., 2012). 
IMPUTE2 is able to handle these “cosmopolitan” reference panels. It uses local 
sequence similarity to select a custom reference panel from all available 
reference haplotypes for each study haplotype in each genomic region (Howie et 
al., 2011). In the process, it is able to ignore any unhelpful reference haplotypes 
(Howie et al., 2011) and is able to use the extra information more effectively 
than other imputation methods (Howie et al., 2009). 
HapMap reference panels 
In earlier studies, researchers used a HapMap (The International HapMap 
Consortium, 2003) reference panel for imputation. HapMap Phase 1 to 3 of the 
HapMap data consists of 4.1 million directly genotype SNPs in 1486 individuals 
from 11 locations and has facilitated imputation of about 2.5 million SNPs (Wood 
et al., 2013). Phase 2 data is limited in that it only covers a few ethnicities and 
the sample size within each ethnicity is low (Browning, 2008). Imputation with 
the Phase 2 reference panel produced the highest imputation accuracy in 
Europeans and the lowest in Africans when a single HapMap panel was used, 
with an improvement in accuracy when a mixed panel was used (Huang et al., 
2009).  
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1000 Genomes reference panels 
Reference panels from the 1000 Genomes Project (The 1000 Genomes Project 
Consortium, 2015) are being used more frequently than HapMap reference 
panels due to their denser SNP coverage and more diverse selection of reference 
populations (Hancock et al., 2012). Generation of Phase 1 1000 Genomes data 
involved whole-genome sequencing of 1094 individuals from a range of ethnic 
groups and covers more than 37 million variants, including low frequency and 
rare variants (Wood et al., 2013). Phase 3 1000 Genomes data was an 
improvement on Phase 1 in that it contained information for over 88 million 
variants (84.7 million SNPs, 3.6 million short insertions/deletions (indels) and 
60 000 structural variants) from 2504 individuals from 26 populations (The 1000 
Genomes Project Consortium, 2015). This has allowed for many more SNPs to be 
imputed. In a study in Europeans, although accuracy was the same for both 
HapMap and 1000 Genomes reference panels, 1000 Genomes Phase 1 
imputation resulted in more than twice as many successfully imputed SNPs than 
HapMap imputation, with twice as many common SNPs, four times as many low 
frequency SNPs and eight times as many rare SNPs (Sung et al., 2012b). This 
shows that the 1000 Genomes reference panels can be useful across a range of 
MAFs, with particular interest in discovering rare variants (Sung et al., 2012b, 
2012a). Another study using a 1000 Genomes reference panel allowed for 
stronger signals of association at known loci as well as the discovery of novel 
associations (Wood et al., 2013). Using a 1000 Genomes Phase 3 reference panel 
is thought to significantly increase the number of imputed variants even more 
compared to using HapMap or other 1000 Genomes reference panels (Zheng-
Bradley & Flicek, 2016) and is therefore an appropriate choice in any current or 
future studies.         
There is some concern that the quality of 1000 Genomes data is lower than that 
of HapMap data due to the depths of sequencing reads being low. Low quality 
SNPs are usually removed, but due to the significantly higher number of SNPs to 
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start with, the number remaining is still higher than if a HapMap reference panel 
is used (Sung et al., 2012b). 
1.5.4 Factors affecting imputation performance and accuracy 
In addition to the composition of the reference panel, several other factors 
influence imputation accuracy. These include the size of the reference panel, 
study sample size and SNP density of the region to be imputed, LD and MAF of 
the SNPs to be imputed.  
Reference panel size 
Although the running time and computational burden is increased, the larger the 
reference panel (in terms of number of samples and SNPs) or the more 
haplotypes in the reference panel, the higher the accuracy (Pei et al., 2008; Nho 
et al., 2011; Howie et al., 2011; Huang & Tseng, 2014). This is because a larger 
reference panel brings an increase in length of the haplotype stretches shared 
between study samples and reference panel samples and are easier to identify 
unambiguously with a larger reference panel (Li et al., 2009). Zhang et al (2011) 
recommended a reference sample size of more than 100 for homogenous 
populations and more than 200 for admixed populations. The improved accuracy 
with larger reference panels is specifically evident for less common variants (Liu 
et al., 2012; Roshyara & Scholz, 2015; Zheng et al., 2015a; Howie et al., 2011), 
although very rare variants remain difficult to impute. A study in African 
Americans showed that the addition of more distantly related populations to 
increase reference sample size improved imputation quality, but this was mostly 
for SNPs present in populations more closely related to African Americans 
(Hancock et al., 2012). 
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Study sample size and SNP density 
The study sample size seems to have little effect on imputation accuracy (Zhao et 
al., 2008; Zhang et al., 2011). It does, however, influence the accuracy of 
haplotype estimation during phasing as, especially with IMPUTE2, phasing 
information is gained from all other individuals in the dataset, so having a larger 
sample increases haplotype estimation accuracy (Howie et al., 2009). SNP density 
in the study sample also influences imputation, with a higher SNP density in the 
region to be imputed leading to better imputation quality due to there being 
more neighbouring SNPs and therefore a higher LD (Zhang et al., 2011; Wang et 
al., 2012; Howie et al., 2012). This is particularly evident with low frequency and 
rare variants (Zheng et al., 2015a; Spencer et al., 2009). The quality of imputation 
of a region with less than 100 SNPs is likely not very stable and a window size of 
more than 500 SNPs or one SNP every 2 kilobases is recommended (Zhang et al., 
2011). In addition, larger chromosomes are easier to impute due to lower 
recombination rates and subsequent higher levels of LD (The International 
HapMap Consortium, 2005) and an ungenotyped rate of less than 50% is 
favourable for good imputation (Zhang et al., 2011). It is also thought that the 
imputation quality depends more on the number of SNPs in the study sample 
rather than their quality (Roshyara et al., 2014). 
LD and MAF 
LD between genotyped and ungenotyped SNPs and the MAF of ungenotyped 
SNPs also influence imputation accuracy, with MAF having a weaker effect on 
accuracy than LD (Nho et al., 2011). Several studies have shown that stronger LD 
and lower MAF of ungenotyped SNPs together result in improved imputation 
accuracy (Pei et al., 2008; Biernacka et al., 2009; Huang et al., 2009; Nho et al., 
2011). The influence of MAF seems to be lower for high LD regions and higher for 
low LD regions (Pei et al., 2008). One study found an increase in power with 
higher MAF under medium to high LD levels (Pei et al., 2010). The difference in 
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imputation accuracy between lower and higher MAF markers was shown to be 
highly variable in African populations (Huang et al., 2009). 
Lower frequency or rare SNPs are, in general, more difficult to impute due to 
lower coverage in study samples, lower degrees of LD and more challenging 
haplotype reconstruction (Liu et al., 2012; Sung et al., 2012a; Chanda et al., 2012; 
Band et al., 2013; Zheng et al., 2015a). Inclusion of rare SNPs may affect the 
phasing step and lead to a lower imputation quality. On the other hand, including 
rare SNPs in the reference panel may also improve imputation quality of rarer 
SNPs (Liu et al., 2012). Rare indels can be more accurately imputed than rare 
SNPs (and vice versa for common variants) (Liu et al., 2014).  
Other factors 
Another factor which may influence imputation is the filtering or removal of 
SNPs during QC. Little or no SNP filtering seems to be favourable for imputing 
small to moderately sized datasets to keep the LD structure between SNPs intact 
(Roshyara et al., 2014). Other factors causing low imputation accuracy include 
low variant heterozygosity, high sequence similarity to other genomic regions, 
high GC content and segmental duplication (Liu et al., 2014). In addition, some 
regions such as GWAS loci for haematological measurements and immune 
system diseases are enriched with low imputability regions (Liu et al., 2014).  
1.5.5 Imputation in African populations 
Imputation accuracy across different populations varies, with the highest 
accuracy generally seen in European populations and the lowest seen in Africans 
(Zhao et al., 2008; Huang et al., 2009). Most of the studies involving imputation 
in populations of African ancestry have been carried out in African Americans, 
which are an admixed population and therefore don’t give a true indication of 
imputation performance in all Africans.  
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Imputation in Africans, in general, is more challenging due to their high genetic 
diversity and lower levels of LD, which leads to more difficult haplotype 
estimation and a reduced imputation accuracy (Howie et al., 2011; Huang et al., 
2011). This increases the required sample size to maintain power in imputation 
based GWAS in Africans (Huang et al., 2011). Early reference panels added to the 
challenge in that African populations were poorly captured (Huang et al., 2011), 
but imputation was improved with availability of more populations of African 
ancestry (Huang et al., 2011). In a recent study in three African populations 
(Kenya, Malawi and Gambia) imputation was able to capture most common 
variants in the three populations, but the accuracy and calibration of confidence 
(measured by the info score) was still lower than in European populations (Band 
et al., 2013). 
One advantage of the greater genetic diversity in Africans is the improved 
accuracy of imputing rare variants in African ancestry populations compared to 
other populations. This is due to the larger number of haplotypes resulting from 
the diversity and the subsequent improved chance that a rare variant is tagged 
by one of the haplotypes (The 1000 Genomes Project Consortium, 2015). 
In addition to the shorter LD blocks seen with all individuals of African ancestry, 
African Americans have proven challenging to use in imputation due to their high 
levels of admixture. There is no ideal single population reference panel to use for 
admixed populations (Sung et al., 2012a). Ideally for admixed populations, the 
reference panel should include samples from all the ancestral populations 
making up the admixed population under investigation (Zhang et al., 2011). In 
this respect, mixed or “cosmopolitan” reference panels have improved 
imputation performance in African Americans (Hao et al., 2009; Hancock et al., 
2012).    
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1.5.6 Pre-phasing 
Pre-phasing has become a popular option as it ultimately speeds up imputation 
as haplotypes can first be statistically estimated and missing genotypes then 
imputed directly into the inferred haplotypes (Howie et al., 2011, 2012). Pre-
phasing significantly reduces the computational burden of imputation as a study 
sample only needs to be phased once and can therefore undergo multiple runs 
of imputation quickly with, for example, each new reference panel update, 
without re-phasing. In addition, it is faster to match phased study haplotypes to a 
single reference panel haplotype than to match unphased study haplotypes to 
more than one reference haplotype (Howie et al., 2012). Despite imputation of 
low frequency SNPs being generally less accurate, pre-phasing tends to achieve 
competitive accuracy at these variants (Howie et al., 2012). A tool called SHAPEIT 
has been developed to carry out the haplotype estimation/phasing step and can 
be used successfully in conjunction with IMPUTE2.   
  
  
39 
 
Chapter 2: STUDY PARTICIPANTS AND DATA QUALITY 
CONTROL 
2.1 Study participants 
This study used DNA samples and data from a mixed-sex subset of Bt20 
participants and their female caregivers, with phenotype data taken from the 
year 17/18 (i.e. the year that the participants turned 17/18) and year 13 (i.e. the 
year that the participants turned 13) collection time points, respectively. The 
female caregivers are the female relatives who care for the Bt20 participants and 
include mothers, grandmothers, aunts and sisters.  
Written informed assent was obtained from the participants in conjunction with 
written informed consent from the caregivers prior to each blood sample 
collection. Individuals also re-consented to the collection of data at each data 
collection session. Ethical clearance was previously obtained from the University 
of the Witwatersrand Human Research Ethics Committee (Medical) for collection 
of DNA samples and phenotype data from this cohort (M010556). Further ethical 
clearance was obtained to use the samples to identify genetic risks associated 
with obesity (M120647) and blood pressure (M1411116) in a black South African 
population. Ethics certificates, other relevant agreements/letters and the most 
recent consent forms are in Appendix A. 
2.2 Phenotyping 
Weight was measured to the nearest 0.1 kg using a digital scale with participants 
wearing light clothes and no shoes. Standing height was measured to the nearest 
0.1 cm using a wall-mounted stadiometer (Holtain, Crosswell, UK). BMI was 
calculated as weight (kg) divided by height squared (m2) (Kagura et al., 2015).  
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BP readings were taken using an Omron 6 automated machine (Kyoto, Japan). 
Measurements were taken with participants in a seated position. After five 
minutes of sitting in a resting position, three measurements were taken at 
intervals of two minutes. The first reading was discarded, in case of possible 
“white coat syndrome”, and an average of the second and third measurements 
was calculated and used in all analyses (Kagura et al., 2015). 
WC was measured at the level of the widest girth above the navel and hip 
circumference (HC) was measured as the widest part of the buttocks. Both were 
measured using a soft measuring tape to the nearest 0.5 cm with the participants 
in a standing position. WHR was calculated as WC divided by HC. 
Body fat (g) and lean mass (g) were measured using dual-energy X-ray 
absorptiometry (DXA) (Hologic, Malborough, MA, USA) as per the guidelines 
recommended by the International Society of Clinical Densitometry (Gordon et 
al., 2008). Measurements were taken with participants wearing light clothes and 
with all jewellery or other metal objects removed. Percentage body fat was 
calculated as fat mass divided by total body mass (g).  
2.3 DNA sample preparation and genotyping 
DNA sample normalization and genotyping was carried out as part of another 
PhD study (Sahibdeen, 2016). Samples were extracted using the salting out 
method (Miller et al., 1988). They were then normalized to a concentration of 
50ng.µl-1 following quantification using either a Tecan Infinite® 200 PRO 
NanoQuant or PicoGreen® dsDNA Quantitation Reagent. DNA is currently stored 
in the Division of Human Genetics at the National Health Laboratory Service 
(NHLS), Braamfontein, South Africa. Genotyping was conducted at the UC Davis 
Genome Center (California, USA) using the Metabochip (Illumina, San Diego, CA, 
USA) (Voight et al., 2012) [See Preface]. Samples were sent for genotyping in two 
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phases (the female caregiver samples were genotyped in May 2013 and the Bt20 
participants were genotyped in November 2013). A few duplicate samples from 
both datasets were sent with the unique samples to make sure that there 
weren't "chip effects” from one chip to another and also to ensure that samples 
were genotyped consistently. Genotypes were called using GenomeStudio 
Software for Illumina (v2011.1) and a custom DNAtech cluster file and output 
was provided as final reports in the forward strand orientation. 
2.4 Data quality control 
2.4.1 Genotype data quality control 
Prior to analysis of the genotype data, a QC process was carried out separately 
for the two datasets to convert the data into a usable format and to remove any 
SNPs or samples that may have affected downstream use of the data. The steps 
involved in the QC process and the number of SNPs and samples removed in 
each step are outlined in Figure 2.1 and detailed below. Most of the steps were 
performed using PLINK (v1.9) (Purcell et al., 2007; Purcell & Chang, 2014), unless 
otherwise stated.  
Before QC, the Bt20 participant dataset comprised data from 1248 samples 
(1240 unique samples and 8 duplicates) and the female caregiver dataset 
consisted of data from 1034 samples (1033 unique samples and 1 duplicate). Of 
the 2273 unique samples, there were 975 caregiver-participant pairs. Both 
datasets initially contained genotype data for 196725 SNPs.  
Initial QC steps 
Raw genotype data from GenomeStudio forward report files was converted into 
transposed PLINK files (.tped/.tfam) using a Python script written by Dr Tom 
Gaunt (University of Bristol, UK) (Appendix B). These files were then converted 
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into binary PLINK files (.bed/.bim/.fam) prior to initial removal of SNPs with 100% 
missing genotype data and samples with more than 20% missing genotype data.  
SNP QC 
SNPs with high missingness, low MAF and those failing HWE were then removed. 
Based on plots of maximum missing rate versus number of SNPs remaining in the 
study, SNPs with more than 2% missing data were removed. Default values of 
0.01 for MAF (i.e. SNPs with MAF less than 0.01 were removed) and 0.00001 
(1x10-5) for HWE (i.e. SNPs with a HWE p-value of less than 1x10-5 were removed) 
were selected for both datasets  (Anderson et al., 2010). In both datasets, the 
high number of SNPs removed due to low MAF was due to many of the SNPs 
being monomorphic in our black South African population. In both cases, some 
SNPs failed more than one of the SNP QC criteria.  
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1. Conversion of final 
report files into  PLINK files. 
2. Removal of SNPs with 
complete missing data. 
 
Both datasets: n = 21 
3. Initial removal of poorly 
genotyped samples. 
 
Female caregivers: n = 3 
Bt20 participants: n = 100 
4. Removal of SNPs with 
high missingness rate. 
 
Female caregivers: n = 4127 
Bt20 participants: n = 19658 
5. Removal of SNPs with 
low minor allele frequency 
(MAF). 
 
Female caregivers: n = 52603 
Bt20 participants: n = 51819 
6. Removal of SNPs failing 
Hardy-Weinberg 
equilibrium (HWE). 
 
Female caregivers: n = 2517 
Bt20 participants: n = 2623 
 
7. Removal of samples with 
high missingness rate. 
 
Female caregivers: n = 7 
Bt20 participants: n = 63 
 
8. Sex check and removal 
of samples with discordant 
sex. 
 
Female caregivers: n = 24 (25) 
Bt20 participants: n = 26 (96) 
9. Removal of related 
samples.  
 
Female caregivers: n = 16 
Bt20 participants: n = 57 
10. Removal of duplicates 
11. Removal of samples 
based on extreme 
heterozygosity. 
 
Female caregivers: n = 1 (8) 
Bt20 participants: n = 0 (52) 
12. Principal component 
analysis (PCA) and removal 
of population outliers. 
 
Female caregivers: n = 9 
Bt20 participants: n = 4 
 
 
 
 
 
Figure 2.1 The steps involved in the genotype data QC process. The process was 
divided into initial QC steps, SNP QC and sample QC. In some sample QC steps, 
samples had already been removed in a previous step. If this was the case the 
number of samples actually removed in the step is given with the total number 
of “problem” samples identified in the steps shown in brackets. 
 
SNP QC 
SAMPLE 
QC 
INITIAL 
QC STEPS 
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Sample QC 
A second step to remove individuals with a high missingness rate was 
performed. Based on plots of maximum missing rate versus number of 
individuals removed, individuals with more than 2% missing data in the female 
caregiver dataset and more than 3% missing data in the Bt20 participant dataset 
were removed. 
A sex check was carried out on the original files to check for discrepancies 
between the genotype data and the recorded sex in the phenotype data, 
possibly arising from mislabelling of DNA samples or incorrect reporting of sex 
during recruitment. The sex check is done by calculating the homozygosity rate 
across all SNPs in the X chromosome for each individual and comparing it to the 
expected rate (males: homozygosity rate >0.8; females: homozygosity rate<0.2) 
(Anderson et al., 2010). Individuals are identified as being problems if there are 
discrepancies between the genotype and phenotype data or if the sexes are 
inconclusive/unspecified according to the genotype data. Problem individuals 
not already removed in a previous step were removed from the latest QC file for 
each dataset.  
To avoid an introduction of bias into the analysis, any duplicate individuals or 
cryptically related individuals (individuals that are unknown second-degree 
relatives or higher) were removed from the dataset. These individuals were 
identified by calculating an identity by state (IBS) metric for each pair of 
individuals. This metric is based on the average proportion of alleles in common 
at the genotyped autosomal chromosome SNPs. Identity by decent (IBD) scores 
were then estimated from the IBS data. IBD = 1 for duplicates or monozygotic 
twins, IBD = 0.5 for first-degree relatives, IBD = 0.25 for second-degree relatives 
and IBD = 0.125 for third-degree relatives. The initial step involved LD pruning of 
the datasets so that only independent SNPs were included in the calculations. 
This was followed by generation of IBD scores (PI_HAT column in the .genome 
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file) and then removal of one of each of the pair of individuals with IBD score 
(PI_HAT) > 0.1875. This is a common value to use and is halfway between the 
expected IBD for third- and-second-degree relatives. The number of individuals 
removed due to cryptic relatedness is quite high. This may be due to the fact that 
all samples were taken from the same very integrated community and the 
chances of second- or third-degree relatives may be high. (Anderson et al., 2010) 
All duplicate individuals should have been identified in the previous step by an 
IBD=1 between individuals in a duplicate pair. This was, however, not the case 
for all duplicates and, as we were no longer sure of their identities, all suspected 
duplicates were removed at this point. 
Individuals with extreme mean heterozygosity were also removed, if not already 
removed in previous steps. All individuals are expected to have a certain 
proportion of heterozygous genotypes. Mean heterozygosity/observed 
heterozygosity rate can be calculated across all individuals as (number of non-
missing genotypes (N) – observed number of homozygous genotypes (O))/N) and 
individuals are removed in cases of extreme heterozygosity. Excessive mean 
heterozygosity could indicate DNA sample contamination while reduced mean 
heterozygosity could indicate inbreeding. To decide on a reasonable threshold at 
which to exclude individuals based on extreme heterozygosity, a graph of 
observed heterozygosity rate per individual (x-axis) versus proportion of missing 
SNPs per individual (y-axis) was plotted. A .het file was generated, using 
genotype files produced from the initial removal of SNPs with complete missing 
data, to give the observed number of homozygous genotypes (third column) and 
the number of non-missing genotypes (fifth column) per individual. The 
proportion of missing SNPs per individual was obtained following a calculation of 
missingness (the sixth column in the generated .imiss file is the proportion of 
missing SNPs per individual) and all individuals with a heterozygosity rate ± 3 
standard deviations from the mean were excluded (Anderson et al., 2010). 
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Population stratification, where genotype differences may be due to different 
population origins rather than actual disease risk differences (Cardon & Palmer, 
2003), is a source of bias that can be introduced into analysis. This was dealt with 
in two ways: removal of extreme population outliers during this QC step (using 
visual cut-offs from the principal component analysis (PCA) plots) and further 
control for population stratification during analysis, when deemed necessary 
through visualisation of quantile–quantile (Q-Q) plots, by including principal 
components (PCs) as covariates [See Chapter 4]. The initial step involved LD 
pruning of the datasets and PCA was then run using SMARTPCA (Patterson et al., 
2006), an EIGENSTRAT program. PCA plots were drawn in Genesis 
(http://www.bioinf.wits.ac.za/software/genesis) to first identify and remove 
outliers and then to visualise the genetic structure of the datsets in the context 
of other African populations following all QC steps [See 2.6.2 below]. 
2.4.2 Phenotype data quality control 
The female caregiver phenotype data also went through a QC process and 
corrections were made where inconsistencies were found between the original 
questionnaires and captured data. As the year 17/18 Bt20 participant data were 
captured using electronic questionnaires, no QC could be carried out on this 
data. 
2.5 Merging of datasets and update to Build 37 
The female caregiver and Bt20 participant datasets were merged for association 
analysis in PLINK and then pruned to remove any non-overlapping SNPs between 
the datasets. During the merging step, nine SNPs were found to have the same 
base pair positions as other SNPs in the dataset and were removed at this point.  
SNP names and coordinates were also updated, manually and using PLINK --
update-name and --update-map commands, from Build 36 (Metabochip SNPs 
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are mapped to Build 36) to Build 37, as is required by the imputation programs 
[See Chapter 5].  
2.6 Post-quality control data characteristics 
Following all QC steps, there were 971 individuals and 140649 SNPs remaining in 
the female caregiver dataset and 976 individuals and 127764 SNPs remaining in 
the Bt20 participant dataset, with 763 caregiver-participant pairs. The merged 
and pruned dataset contained 1947 individuals and 125906 SNPs. 
2.6.1 Descriptive statistics 
Descriptive statistics of the individuals remaining after QC in the individual 
datasets are shown in Table 2.1. 
2.6.2 Population structure 
PCA plots drawn using each of the datasets in combination with other African 
populations (Figures 2.2 and 2.3) showed good clustering of the Bt20 samples 
with southeastern Bantu-speakers (SEB) and other black Sowetans (BSO), who 
are also southeastern Bantu-speakers. Also evident is the very clear separation of 
Bt20 individuals and individuals from the Yoruba in Ibadan, Nigeria (YRI); the 
Luhya in Webuye, Kenya (LWK) and the Maasai in Kinyawa, Kenya (MKK), 
indicating differences in genetic structure across African populations.  
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Table 2.1 Descriptive statistics of the individuals remaining after QC in the individual datasets.  
 
 
Bt20 Participants (n=976) 
Female Caregivers (n=971) 
 
Females (n=456) Males (n=518) 
  
Mean (SD) Median Range Mean (SD) Median Range Mean (SD) Median Range 
Age (years) 17.9 (0.4) 17.9 17.3-18.9 17.9 (0.4) 17.9 17.3-18.9 41.9 (8.6) 41.0 18.0-84.0 
Weight (kg) 59.5 (12.9) 56.9 36.1-136.6 59.2 (9.8) 57.8 38.5-128.4 76.1 (17.0) 74.7 36.3-135.7 
Height (m) 1.6 (0.1) 1.6 1.4-1.8 1.7 (0.1) 1.7 1.5-1.9 1.6 (0.1) 1.6 1.2-1.8 
BMI (kg.m-2) 23.3 (4.8) 22.3 15.5-53.1 20.3 (3.1) 19.8 14.9-48.3 30.4 (6.6) 30.0 16.6-58.8 
SBP (mmHg) 115.7 (10.5) 115.5 87.0-172.0 120.5 (11.4) 119.8 81.5-170.0 117.4 (20.9) 112.5 77.0-206.5 
DBP (mmHg) 72.4 (9.1) 71.5 44.5-129.5 70.7 (8.3) 70.0 50.0-102.0 76.6 (12.5) 75.0 46.5-126.5 
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Figure 2.2 PCA plot of population structure in the female caregivers and other African populations. PC1 and PC2 are shown. 
Bt20_CG = female caregivers; YRI = Yoruba in Ibadan, Nigeria; LWK = Luhya in Webuye, Kenya; MKK = Maasai in Kinyawa, Kenya; 
SEB = southeastern Bantu-speakers; SWB = southwestern Bantu-speakers and BSO = black Sowetans. 
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Figure 2.3 PCA plot of population structure in the Bt20 participants and other African populations. PC1 and PC2 are shown. 
Bt20_yr1718 = Bt20 participants; YRI = Yoruba in Ibadan, Nigeria; LWK = Luhya in Webuye, Kenya; MKK = Maasai in Kinyawa, Kenya; 
SEB = southeastern Bantu-speakers; SWB = southwestern Bantu-speakers and BSO = black Sowetans. 
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Chapter 3: DESIGN OF A QUERYABLE CARDIOMETABOLIC 
DATABASE 
Advances in technology, high-throughput experiments and multi-disciplinary 
research have resulted in a huge growth in the amount and complexity of 
biological data being generated in recent years. There is an increasing need for 
the development of databases to efficiently store and manage the data and 
make it more accessible. Typically, publicly available datasets and the associated 
annotation data are accessed through internet-based browsers that offer a user-
friendly interface to a database, which makes complex queries simple to execute. 
Research project-specific data are, however, not commonly stored in this way.  
This chapter focuses on the development of MetaboBTT, a queryable 
cardiometabolic database, and accompanying user interface, which houses the 
Bt20 phenotype, Metabochip SNP annotation and association analysis data from 
a current project focused on identifying risk factors for cardiometabolic disease 
in South Africans. Although the current study involved a cross-sectional analysis, 
the database has been designed for longitudinal data (i.e. data from multiple 
data collection time points within the cohort can be incorporated and queried). A 
secondary output is a model/structure for research groups with similar data 
(phenotype, genotype, annotation and association analysis data) to use for 
implementation of their own databases. The aim is for the data to be more easily 
accessible and queryable for useful information by all members of a research 
group to ultimately accelerate biological knowledge discovery. 
3.1 Database construction 
The database was developed in MySQL (v 5.7). Tables were constructed using 
standard SQL code (Appendix D) and data was entered into the database tables 
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using a MySQL database connector (MySQLdb) in Python (v 2.7.12) (Appendix E). 
The database is a relational, multiuser (supports multiple users at the same 
time), centralised (data located at a single site) database. 
3.1.1 Database content 
Each individual recorded in the database has a unique Individual ID (with a suffix 
‘C’ or ‘CG’ for the Bt20 participants and female caregivers, respectively). This ID is 
the primary key for all tables containing phenotype data. 
As previously mentioned, the Bt20 cohort is a longitudinal cohort consisting of 
data collected at multiple time points since its inception. Phenotype data 
currently present in the database is that which is appropriate to the current 
study (i.e. year 17/18 data for the Bt20 participants and the year 13 data for the 
female caregivers). Tables have, however, been constructed for other data 
collection time points for the Bt20 participants (year 5, year 7, year 9/10, year 
11/12, year 13, year 14, year 15, year 16, year 19, year 20) and can be populated 
with the data when obtained.  Phenotype data only exists in the database for 
individuals with available genotype data. 
SNP annotation/Metabochip data exists for all 196725 SNPs on the Metabochip 
and includes Build 36 and 37 SNP information and locations of the SNPs within 
the genome. Information is also given about whether or not the SNP remained in 
the dataset for either or both of the datasets after QC. 
All association analysis data for the available phenotypes under investigation are 
recorded and includes corrected and uncorrected p-values and beta values/odds 
ratios (OR) and a list of covariates (up to three can be listed in the current design) 
that were corrected for in each analysis. The datasets available can be analysed 
as individual or merged datasets – results for all possible scenarios are recorded.  
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The phenotype, Metabochip and association analysis data are arranged in tables 
in the database as indicated in the relational model in Figure 3.1. The QC’ed 
genotype data exists as separate binary PLINK format files (.bed/.bim/.fam) for 
both the Bt20 participants and the female caregivers and can be accessed on 
request.  
3.1.2 Database design evaluation 
The database has been normalised to a certain extent as there are no repeating 
groups in individual tables, there exist separate tables for each set of related 
data and each set of data is identified by a primary key. There are some 
dependencies in the SNP tables (for example the Build 37 base pair position is 
dependent on the Build 37 SNP ID), meaning that the current database is in first 
normal form. The phenotype data was split into data which doesn’t change over 
time and data which does change over time, rather than all being included in one 
table. Separate tables then exist for the changeable phenotype data at each data 
collection time point. This allows for easy extension of the database to include 
additional time points, without possible corruption of already existing data. The 
phenotype data which exists in the tables is data which is currently relevant to 
the larger project. SQL allows for the addition of extra columns to the tables, 
making it easy for additional phenotypes to be included. The different 
association analysis scenarios are also split across multiple tables for easier initial 
input of the data into the tables and more efficient querying. The database is 
largely free of redundant data with the only information repeated across tables 
being the Individual ID (for the phenotype tables) and the Build 36 SNP IDs 
(SNPID36) (for the SNP tables).   
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Figure 3.1 The relational model for MetaboBTT. 
(Drawn in Lucidchart: https://www.lucidchart.com) 
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3.2 Web interface 
The data within the MySQL database can be accessed and queried via a web 
interface (which will be made available at 
http://www.bioinf.wits.ac.za/software/metabobtt to members of the research 
group with permitted access) constructed using CSS, HTML and PHP code (See 
Web_interface.pdf available at https://github.com/ LieslH/Liesl-Hendry-PhD-
Code). 
3.2.1 Access and security 
The interface is username and password protected, therefore allowing only 
those individuals allocated access to view and query the data. Individuals who 
request permission to access the database will be assigned a username and will 
then be able to register their own passwords via a link available on the login 
page. The passwords are stored as hashed passwords along with the usernames 
in a separate MySQL table within the database and users can be added or 
removed when necessary. Once logged in, the home page (Figure 3.2) allows for 
easy navigation to other pages. The interface also has a ‘session timeout’ feature 
which ensures that any user inactive for longer than eight minutes will be 
automatically logged out of the interface and will be required to login again to 
query the database further. Alert/error messages have also been included to 
alert users when an inappropriate selection or input is made or if users forget to 
select required options, therefore further preventing some misuse of the 
database. 
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 Figure 3.2 Home page of the MetaboBTT Database web interface.  
 
3.2.2 Function 
Users can access the database from the web interface to generate summary 
statistics (basic and complex counts and average/minimum/maximum) on the 
phenotype data, download relevant phenotype, Metabochip and association 
analysis data that match certain user-supplied criteria and get information on 
how to work with the genotype files in PLINK (Figure 3.3). 
Summary statistics 
Users are able to perform basic counts (count of number of individuals, males or 
females in a particular dataset) (Figures 3.4 and 3.5), complex counts (count of 
number of individuals, males or females in a particular dataset and data 
collection time point matching up to three criteria) (Figures 3.6 and 3.7) and 
calculate or retrieve the average, minimum or maximum of a particular 
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phenotype for all, male, female or specific individuals in a particular dataset and 
time point (Figures 3.8 and 3.9). The summary statistics are printed to the 
screen. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Summary statistics, data download and genotype data landing  
pages. 
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Figure 3.4 Layout of the basic count page. 
 
Figure 3.5 An example of the input and output of a basic count query. 
  
59 
 
 
 
 
 
 
 
 
 
Figure 3.6 Layout of the complex count page. 
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Figure 3.7 An example of the input and output of a complex count query. 
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Figure 3.8a Layout of the average/minimum/maximum page where the user can specify all/male/female individuals. 
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Figure 3.8b Layout of the average/minimum/maximum page where the user can specify specific individuals by uploading a file of 
Individual IDs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 An example of the input and output of an average/minimum/maximum query. 
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Data download 
Users are able to download: 
 Phenotype data for specific or all/male/female individuals from a specific 
dataset and data collection time point matching certain criteria (Figures 
3.10, 3.11 and 3.12). Separate pages exist for the female caregiver and 
Bt20 participant datasets.  
 SNP-related data filtering by SNPID (Build 36 or 37), base pair position 
(Build 36 or 37), gene, chromosome or location within the gene (Figures 
3.13 and 3.14). 
 Association analysis-related data for specific phenotypes in all or a 
specific subset of the dataset, filtering by SNPID (Build 36 or 37) or gene 
and/or p-value threshold (Figures 3.15 and 3.16). 
The data can be printed to the screen (by selecting ‘Print to screen’) or 
downloaded as a comma separated values (CSV) file (by selecting ‘Save to file 
(.csv)’). 
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Figure 3.10a Layout of the female caregiver phenotype data download page 
where the user can specify all individuals. The phenotype and operator options 
for the criteria are the same as in the summary statistics. 
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Figure 3.10b Layout of the female caregiver phenotype data download page 
where the user can specify specific individuals by uploading a file of Individual 
IDs.  
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Figure 3.11a Layout of the Bt20 participant phenotype data download page 
where the user can specify all/male/female individuals. The phenotype and 
operator options for the criteria are the same as in the summary statistics and 
the data collection time point options for the criteria are the same as in the 
larger table. 
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Figure 3.11b Layout of the Bt20 participant phenotype data download page 
where the user can specify specific individuals by uploading a file of Individual 
IDs.  
  
  
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 An example of the input and output of a phenotype data download 
query. The empty BMI columns are due to the fact that only yr17/18 data 
currently exists in the database.  
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Figure 3.13 Layout of the Metabochip data download page.  
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Figure 3.14a Example one of the input and output of a Metabochip data 
download query. 
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Figure 3.14b Example two of the input and output of a Metabochip data 
download query. 
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Figure 3.15 Layout of the association analysis data download page. 
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Figure 3.16 An example of the input and output of an association analysis data 
download query. 
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Genotype data 
Genotype data, although not directly downloadable from the web interface, is 
available in PLINK format on request. For convenience, useful information is 
provided on the genotype data page for manipulating the genotype files and 
generating basic genotype data summary statistics (missingness, HWE, MAF) in 
PLINK as follows:  
(a) Manipulating genotype files in PLINK: 
To extract/keep genotype data for specific individuals (saved as a list of Family 
ID/Individual ID pairs in a file called myIDs.txt): 
plink --bfile {INPUT GENOTYPE FILENAME} --keep myIDs.txt --make-
bed --out {OUTPUT GENOTYPE FILENAME} 
To exclude/remove genotype data for specific individuals (saved as a list of Family 
ID/Individual ID pairs in a file called myIDs.txt): 
plink --bfile {INPUT GENOTYPE FILENAME} --remove myIDs.txt --make-
bed --out {OUTPUT GENOTYPE FILENAME} 
To extract/keep genotype data for a specific SNP, multiple specific SNPs (saved as a list 
of SNP IDs in a file called mySNPs.txt) OR a specific chromosome: 
plink --bfile {INPUT GENOTYPE FILENAME} --snp {SNP ID} --make-bed 
--out {OUTPUT GENOTYPE FILENAME} 
 
plink --bfile {INPUT GENOTYPE FILENAME} --extract mySNPs.txt --
make-bed --out {OUTPUT GENOTYPE FILENAME} 
 
plink --bfile {INPUT GENOTYPE FILENAME} --chr {CHROMSOME NUMBER} -
-make-bed --out {OUTPUT GENOTYPE FILENAME} 
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To exclude/remove genotype data for specific SNPs (saved as a list of SNP IDs in a file 
called mySNPs.txt): 
plink --bfile {INPUT GENOTYPE FILENAME} --exclude mySNPs.txt --
make-bed --out {OUTPUT GENOTYPE FILENAME} 
(b) Generating basic summary statistics on the genotype data 
Missingness: 
plink --bfile {INPUT GENOTYPE FILENAME} --missing --out {OUTPUT 
FILENAME} 
Hardy-Weinberg Equilibrium: 
plink --bfile {INPUT GENOTYPE FILENAME} --hardy --out {OUTPUT 
FILENAME} 
Minor allele frequencies: 
plink --bfile {INPUT GENOTYPE FILENAME} --freq --out {OUTPUT 
FILENAME} 
Additional features 
Each page has a footer with links to useful websites (NCBI 
(https://www.ncbi.nlm.nih.gov/) and Ensembl (www.ensembl.org)) and the 
home and main landing pages. Pages that allow for the selection of various 
criteria/options have a reset button to easily clear all previously selected fields 
before selecting new options. Some queries allow for users to upload a file 
containing a list of Individuals, SNPs etc. The uploaded file should be a text file 
containing a list of Individual IDs/SNPIDs etc. each on a separate line. 
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A user manual/README has been set up to allow users to easily navigate 
themselves around the web interface (Appendix F). It contains information about 
the data stored in the database, including the unit of measurement of each 
variable.  
3.3  Expandability of the database 
The database has been designed in such a way that all fixed/unchangeable data 
(IDs, gender, ethnicity, relationship to child, caregiver’s ID) for a particular 
dataset are in separate tables to the phenotype data that changes (age, height, 
weight, etc.) at each data collection time point. Therefore, data from future time 
points can easily be added to the database, with a simple edit made to the user 
interface to include the additional time points. For example, if new data for the 
Bt20 participants from year X becomes available, a new phenotype table will be 
created using the ‘CREATE TABLE phenotype_yrN_bt20_participants’ SQL code 
in Appendix D. Each phenotype column name will be appended with ‘yrX’ to 
allow for easy queries. Data will then be added into the table using the Python 
code shown in Appendix E. A “Year X” data collection time point will be added as 
an option to the drop down menu of the complex count and 
average/minimum/maximum pages and the year selection checkboxes and 
criteria of the phenotype data download pages of the web interface. Appropriate 
changes to the actual queries will also be made.  
The Metabochip and Bt20 phenotype data also has the potential to be used 
further in genetic association analyses. As association analysis data involving 
other traits becomes available, this can also be added to the database with 
another simple edit made to the user interface to allow selection of data for 
these additional traits. 
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3.4 Use by other research groups 
The MetaboBTT database and user interface provide a useful model for setting 
up databases for the storage and querying of similar data from other genetic 
association studies. The MetaboBTT code has been generalised and some notes 
added to it to guide users to modify it to fit to their own phenotype, SNP 
annotation and association analysis data (See General_database_model.pdf 
available at https://github.com/ LieslH/Liesl-Hendry-PhD-Code).  
3.5 Discussion 
Here presented is the first version of MetaboBTT, a research group-specific 
relational database for the storage and querying of data relating to a specific 
project in the field of genetics investigating risk factors for cardiometabolic-
related diseases. Users are able to query the database for summary statistics 
relating to the phenotype data and download phenotype, SNP annotation and 
association analysis data matching certain user-supplied criteria. Also presented 
is the general code for the implementation of this database model in other 
research groups. 
The growth in and increasing complexity of data across many biological fields 
poses an ongoing challenge to store, manage and analyse the data efficiently. At 
the most basic level is data from projects within individual research groups. As is 
the case in many research groups, including our own, data are often stored in 
spreadsheets due to their simplicity and ease of use. Unless individuals know 
some basic command-line scripting or a programming language, the files require 
manual manipulation to sort through the data and obtain useful information 
from it. This can often be slow and error prone. In addition, datasets are reaching 
sizes that are too big to handle within spreadsheets, with manipulation of the 
data again being slow or in some cases not possible.  
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Although sometimes challenging to design and develop, databases, and in 
particular relational databases, are a lot more flexible and have several 
advantages over storing data in simple spreadsheets. With a database, all the 
data is stored in one central location making access to the data quick and easy. 
There is also increased consistency and reduced updating errors as there aren’t 
multiple copies of the data which could be edited or updated. If changes or 
updates to the data are required, this only needs to be done once.  In a relational 
database, data are split across multiple tables which are linked by a primary key 
or column of unique identifiers. This makes individual records easy to locate. In 
addition, complex queries can be made that extract data from more than one 
table at a time using a simple join function. Queries like this would usually be 
more complicated to perform manually. Relational databases also have increased 
security. As the data exists in multiple tables, users can have restricted access to 
any tables that contain sensitive data. This may be particularly useful if the Bt20 
data were to become publically available in the future. The current database 
could also become a publically available tool for anyone to access the phenotype 
and SNP annotation data, but the association analysis results could be hidden. 
Lastly, when manipulating data in spreadsheets, many intermediate 
spreadsheets are often generated which creates disorder and confusion as to 
which version of the data is correct. Databases eliminate this problem and help 
to ensure that there is minimal corruption of the data and that the integrity of 
the data is maintained.   
A study showed that two thirds of users accessing online biological databases 
have limited programming experience (Schultheiss, 2011) and therefore require 
a web interface to aid data access and retrieval (Helmy et al., 2016). The 
interface should ideally be easy to navigate by non-experts and should require 
minimal user actions to retrieve the desired information quickly (Helmy et al., 
2016). A simple, user-friendly web interface has therefore been designed to 
accompany this database to allow users in a biological setting with little or no 
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experience in MySQL and various programming languages to easily query and 
access the data contained within the database. This is possible with the click of a 
few buttons. The ease of use is further ensured by the inclusion of messages that 
alert users when an inappropriate selection or input is made or if users forget to 
select required options. The interface has also been tested by a few potential 
users or those with some knowledge of web design to ensure that it works and is 
easy to use.  
MetaboBTT, with its current functionality, is a useful tool to provide to all 
members of the research group involved in investigations into cardiometabolic 
diseases and their genetic or non-genetic risk factors. The calculation of 
summary statistics allows users to get a feel for the data contained within the 
database. The basic count option is particularly useful for first time users of the 
data to obtain information about the number of individuals and the composition 
of males and females within each dataset. The complex count and 
average/minimum/maximum options provide further information about the 
phenotypic and physiological characteristics of the individuals making up the 
datasets. The data download functionality allows users to download only the 
data that match very specific criteria and that is relevant to them for a particular 
investigation. In the case of the investigation into the genetics of 
BP/hypertension, the SBP and DBP data along with appropriate covariate data 
(age, sex and BMI) is easily downloaded for the Bt20 participants and their 
female caregivers for year 17/18 and year 13, respectively, and used in 
conjunction with the available genotype data.  In addition, association analysis 
results arising from the investigation were added to the database.  
An important feature of MetaboBTT is its ability to store data of a longitudinal 
nature (from past and future data collection time points). Users can obtain useful 
summary statistics and download data from multiple years, which is useful for 
conducting longitudinal studies and investigating changes over time. 
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The performance of the database is encouraging. The interface performs well in 
Firefox, Chrome and Internet Explorer web browsers. The query return time for 
most queries is within seconds, with some more complex queries (mostly those 
involving the association analysis data) taking slightly longer. The MySQL tables 
and data only take up about 355 megabytes, which, by database standards, is 
relatively small. Overall, the current database is therefore inexpensive on time 
and space. MySQL also has support for larger databases. The database currently 
runs on an InnoDB engine. For a default page size of 16 kilobytes (i.e. 16 
kilobytes of data are transferred between the disk and memory at any one time), 
the maximum size for a table is 64 terabytes. With this table size limit and a row 
size limit of about 65.5 kilobytes, over 1 billion rows can exist in a table. The 
database is, therefore, highly scalable for larger studies to include many more 
participants and SNPs, with possible limitations being the efficiency and speed of 
the queries and the available storage space and memory. 
 The database also has room for growth, not only through the addition of data 
from future data collection time points, but also through the addition of further 
association analysis results obtained using the Bt20 and Metabochip data. Having 
a comprehensive record of SNPs or genes that are associated with a particular 
phenotype(s) and having easy access to this information is useful to inform 
future replication or functional studies within the research group. In addition, 
the database is such that it can apply to any set of phenotype, SNP annotation 
and association analysis data. Although some table creation in MySQL, python 
data loading and manipulation of PHP/HTML/CSS scripts would be required, a 
general model with editing instructions has been set up to make it easy for 
researchers to adjust for their own data. The tools required to implement the 
database and interface are also freely available, making this a cost-free option 
for data storage and management. 
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As databases are used more readily and data becomes more accessible and well 
organised, researchers will be able to do a lot more with the data they have and 
will ultimately be able to accelerate biological knowledge discovery. This in turn 
will lead to great advancements in the scientific and medical fields in the coming 
years.  
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Chapter 4: INSIGHTS INTO THE GENETICS OF BLOOD 
PRESSURE IN BLACK SOUTH AFRICANS 
As described previously [See Chapter 1], CVDs are the leading causes of non-
communicable NCD deaths globally, with a major risk factor of CVDs being 
hypertension or raised BP. This makes studying their aetiology very important. 
Hypertension and BP are multifactorial in nature, with many genetic factors 
contributing to the disease phenotype or trait in addition to various non-genetic 
risk factors.  Numerous studies have already reported on genes and variants that 
have associations with hypertension, SBP and DBP. To date, however, most of 
the large scale studies that have been published were carried out in individuals 
of non-African ancestry. 
This chapter focuses on findings from the association analysis carried out in our 
black South African sample with the aim of providing some insight into the 
genetics of blood pressure in individuals of African ancestry. The work is in the 
form of a manuscript submitted to the Journal of Hypertension. Data were 
analysed mainly as a merged dataset (all participants and caregivers together). 
This was considered the best option to make use of the largest possible sample. 
Some methodology details not provided in detail in the manuscript are also 
presented.   
The individual contributions of each of the authors to the manuscript are as 
follows: 
 Liesl Hendry: QC, analysis and interpretation of the data, writing of the 
manuscript. 
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 Venesa Sahibdeen: Acquisition of genetic data, QC of the data, critically 
assessed the manuscript for intellectual content and approved final 
version to be published. 
 Ananyo Choudhury: Assistance with generation of Evoker plots, 
advice/help on the QC and power calculation, critically assessed the 
manuscript for intellectual content and approved final version to be 
published. 
 Shane Norris: Involvement in the larger Bt20 cohort study, critically 
assessed the manuscript for intellectual content and approved final 
version to be published. 
 Michèle Ramsay: Involvement in the larger AWI-Gen study, critically 
assessed the manuscript for intellectual content and approved final 
version to be published. 
 Zané Lombard: Conception and design of the study, critically assessed the 
manuscript for intellectual content and approved final version to be 
published. 
4.1 Post-analysis quality control 
A post-analysis QC process was carried out following initial association analysis to 
check the association signals and to confirm whether or not they were real. Q-Q 
plots were drawn and genomic inflation factors were calculated in R (v3.0.3) (R 
Development Core Team, 2009) (Appendix G). If there was any deviation of 
points from the normal line in the Q-Q plots or if the genomic inflation factors 
were significantly greater than one, association analysis was re-done with 
correction for principal components.  
This was followed by a prioritisation step. Any SNPs with p≤1x10-4 were 
examined further and compared to previously reported top hits (known hits) for 
DBP, SBP and hypertension. SNPs of interest were run through an annotation 
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pipeline provided by Dr Daniel Suveges from the Wellcome Trust Sanger 
Institute.  SNPs were disregarded due to poor separation or clustering examined 
in the cluster plots generated in Evoker (Morris et al., 2010). 
4.2 Manuscript  
(as it appeared in the Journal of Hypertension submission) 
Insights into the genetics of blood pressure in black South African individuals: 
the Birth to Twenty cohort 
Blood pressure genetics in black Africans 
Liesl M HENDRYa,b, Venesa SAHIBDEENb,c,  Ananyo CHOUDHURYb, Shane A 
NORRISd, Michele RAMSAYb,c & Zané LOMBARDa,b,c of the AWI-Gen study and as 
members of the H3Africa Consortium 
a School of Molecular & Cell Biology, Faculty of Science, University of the 
Witwatersrand, Johannesburg, South Africa  
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Abstract 
Objectives: Cardiovascular diseases (CVDs) are the leading cause of non-
communicable disease deaths globally, with hypertension being a major risk 
factor contributing to CVDs. Hypertension itself has numerous risk factors and is 
known to be approximately 30-50% heritable, but very few studies have been 
performed to investigate the role of genetics in African populations. This study 
aimed to identify single nucleotide polymorphisms and genes associated with 
systolic (SBP) and diastolic (DBP) blood pressure in a black South African 
population.  
Methods: Analysis was carried out in a merged sample of adult female caregivers 
(median age 41.0) and mixed sex participants (median age 17.9) (n=1947) from 
the Birth to Twenty cohort genotyped using the Metabochip. The dataset was 
further stratified to identify possible sex-and age-related associations.  
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Results: Association analysis identified regions of interest in the NOS1AP (DBP: 
rs112468105 – p=7.18x10-5 and SBP: rs4657181 – p=4.04x10-5), MYRF (SBP: 
rs11230796 – p=2.16x10-7, rs400075 – p=2.88x10-7) and POC1B (SBP: rs770373 – 
p=7.05x10-5, rs770374 – p=9.05x10-5) genes as well as some intergenic regions 
(DACH1|LOC440145 (DBP: rs17240498 – p=4.91x10-6 and SBP: rs17240498 – 
p=2.10x10-5) and INTS10|LPL (SBP: rs55830938 – p=1.30x10-5, rs73599609 – 
p=5.78x10-5, rs73667448 – p=6.86x10-5)). All of these were novel findings.  
Conclusions: The study provided insight into the genetics of blood pressure in 
black South Africans, with several novel blood pressure variants identified. 
Further functional and replication studies in larger samples are required to 
confirm the role of the genes identified in blood pressure regulation and whether 
or not the genetic links are African-specific. 
Keywords 
Genetics, blood pressure, black South Africans, Metabochip, Birth to Twenty 
Introduction 
Research on communicable or infectious diseases have been the focus until now, 
particularly in Africa where they are a main cause of morbidity and mortality. 
Non-communicable diseases (NCDs) are, however, gaining increasing interest 
and becoming as significant due to their increasing burden to the continent. In 
the latest global status report on NCDs, it was reported that in 2012 
approximately 38 million deaths (63% of total deaths) were due to NCDs [1] with 
this figure expected to increase to 52 million by 2030 [2]. Low-and middle-
income countries (LMIC) are the most affected, with about 28 million of the NCD 
deaths occurring in these countries and the NCD death rate being 625 and 673 
per 100 000 in low-income and lower-middle-income countries, respectively, 
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compared to 397 per 100 000 in high-income countries [3]. In addition, 82% of 
premature deaths (deaths before the age of 70) occur in LMIC. 
 Cardiovascular diseases (CVDs) are the leading cause of NCD deaths globally 
ahead of cancers, respiratory diseases and diabetes [3]. CVDs were responsible 
for approximately 17.5 million (46%) NCD deaths in 2012, with more than 80% 
occurring in LMIC, and this figure is expected to increase to about 22.2 million in 
2030, with approximately 85% occurring in LMIC [2,3]. 
 A major risk factor contributing to CVDs is hypertension or raised blood pressure 
(BP). In 2014 the global prevalence of raised BP was approximately 22% in adults 
aged 18 years and older, with the highest prevalence reported in Africa at 30% 
for all adults combined [3]. A recent review by Rayner and Spence, looking 
specifically at South Africans, highlighted the differences in patho-physiology of 
hypertension between black and white individuals and stated that black 
individuals generally warrant a different approach to causation, outcome and 
treatment of hypertension [4].   
Risk factors associated with BP and hypertension include obesity or increased 
body mass index (BMI), increased salt intake, age, sex, insulin resistance, physical 
inactivity, alcohol intake, psychosocial stress and consumption of high-fat foods 
[5–11]. BP and hypertension are multifactorial traits, with a significant genetic 
contribution (approximately 30-50% heritable [12]) in addition to the various 
non-genetic risk factors [13]. The genetic contribution itself is polygenic, with 
small contributions from risk alleles in multiple genes playing a role in the 
aetiology of the trait or disorder [14]. Numerous studies have already reported 
on genes and variants that have associations with hypertension, systolic blood 
pressure (SBP) and diastolic blood pressure (DBP). To date, however, most of the 
large scale studies have been in individuals of European Ancestry [15], with 
fewer conducted in individuals of Asian or African ancestry [16]. African-related 
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studies have also largely been carried out in African-Americans with studies 
conducted in native Africans being limited.  
The current study aims to contribute to what is known about the genetics of 
blood pressure, looking specifically at African individuals. The specific aim is to 
identify single nucleotide polymorphisms (SNPs) and genes associated with SBP 
and DBP in a black South African population. The study uses participants and 
their female caregivers from the Birth to Twenty (Bt20) cohort [17] using the 
Metabochip [18] as a genotyping tool.  
Methods  
Study Participants 
The study participants were taken from the Bt20 cohort, which is the most 
extensive longitudinal study on child and adolescent health and development in 
Africa. The cohort initially enrolled 3273 individuals born as single births during a 
7-week period in early 1990 to women living in Soweto [17]. The cohort consists 
of African (78%), White (6%), Coloured (12%) and Indian (4%) individuals, which 
is an approximate representation of the race groups in the South African 
population [17], although only African individuals were used in this particular 
study.  Data, including body composition and cardiometabolic data, have been 
collected at regular time points since inception of the cohort, with some 
individuals dropping out of the study along the way due to migration and loss of 
follow up [17].  
This study made use of DNA samples from a mixed sex subset of Bt20 
participants (n=1240), with phenotype data collected in year 17/18 of the study, 
and their female caregivers (n=1033), with phenotype data collected at year 13 
of the study. Of the 2273 samples in total, there were 975 caregiver-participant 
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pairs and of those with a known relationship between caregiver and participant, 
864 were mother-participant pairs. 
Informed consent was obtained for the collection of data and DNA samples. 
Ethical clearance was obtained from the University of the Witwatersrand Human 
Research Ethics Committee (Medical) for collection of DNA samples and 
phenotype data from this cohort (M010556). Further clearance was obtained for 
use of these samples to identify genetic risks associated with obesity (M120647) 
and blood pressure (M1411116) in a black South African population. DNA is 
currently stored in the Division of Human Genetics at the National Health 
Laboratory Service (NHLS), Braamfontein, South Africa.  
Phenotype measurements 
Blood pressure (BP) readings were taken using an Omron 6 automated machine 
(Kyoto, Japan). Measurements were taken with participants in a seated position. 
After five minutes of sitting in a resting position, three measurements were 
taken at intervals of two minutes. The first reading was discarded, in case of 
possible “white coat syndrome”, and an average of the second and third 
measurements was calculated and used in all analyses [19].  
Weight was measured to the nearest 0.1 kg using a digital scale with participants 
wearing light clothes and no shoes. Standing height was measured to the nearest 
0.1 cm using a wall-mounted stadiometer (Holtain, UK). Body mass index (BMI) 
was calculated as weight (kg) divided by height squared (m2) [19].  
Genotyping 
DNA, extracted using the salting out method [20], was normalized to 50ng.ul-1 
prior to genotyping. The DNA samples were genotyped in two separate batches 
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(participants and caregivers) at the UC Davis Genome Centre (California, USA) for 
almost 200,000 SNPs known to influence cardiometabolic traits using the 
Metabochip (Illumina, San Diego, CA, USA). A few duplicate samples from each 
batch were sent with the unique samples to assess genotyping consistency. 
Genotypes were called using GenomeStudio Software for Illumina (v2011.1) and 
a custom DNAtech cluster file and final output was provided as final reports in 
the forward strand orientation.  
Data Quality Control  
Pre-analysis quality control (QC) of the data was carried out separately for the 
two datasets using PLINK (v1.9) [21,22]. Additional tools used included 
SMARTPCA (to run the principal component analysis (PCA) for identification of 
population outliers) [23] and Genesis (to visualize the PCA) [24]. The final report 
files were converted into binary PLINK format files. An initial SNP and sample 
removal step involved removing SNPs with complete missing genotype data and 
poorly genotyped samples (more than 20% missing genotype data). Further SNP 
QC involved removal of SNPs with high missingness rate (> 2%), low minor allele 
frequency (MAF) (< 0.01) and those failing Hardy-Weinberg equilibrium (HWE) 
(p<1x10-5). Additional sample QC involved removal of samples with high 
missingness rate (> 2% for caregivers and > 3% for participants), those with 
discordant sex, related samples (PI_HAT > 0.1875), duplicates, samples with 
extreme heterozygosity (heterozygosity rate ± 3 standard deviations from the 
mean [25]) and population outliers. A few SNPs were also disregarded due to 
poor clustering examined in the cluster plots generated in Evoker [26].  
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Checks were also carried out on the phenotype data and corrections were made 
where inconsistencies were found between the original questionnaires and 
captured data. 
Association analysis 
Data were initially analysed as a merged dataset (all participants and caregivers 
together). Possible sex-related associations were further examined by stratifying 
the sample into female (female caregivers and female Bt20 participants merged) 
and male (male Bt20 participants) individuals, while age-related associations 
were examined by stratifying the sample into old (female caregivers) and young 
(Bt20 participants) individuals.  
Association analysis of the merged datasets was performed in GEMMA (v0.94.1) 
[27] using univariate linear mixed models and incorporating a centered 
relatedness matrix to account for the relatedness between individuals from the 
different datasets. Analysis of the individual datasets was done by linear 
regression under an additive model using PLINK (v1.9). All analyses included 
adjustments for age, sex (where appropriate) and BMI, as well as principal 
components if deemed necessary after examination of quantile-quauntile (Q-Q) 
plots, constructed in R (v3.0.3) [28]. 
The standard Bonferroni significance threshold for correction for multiple testing 
used in genome-wide association studies (p<5x10-8) was considered too strict in 
this study as this is a replication study and the Metabochip is a fine-mapping 
array with variants in high linkage disequilibrium (LD). The threshold to measure 
“array-wide” significance was thus calculated as 0.05/number of unlinked 
markers: p<6.7x10-7 (0.05/74475), p<6.1x10-7 (0.05/82239) and p<6.6x10-7 
(0.05/75834) for the merged, caregiver and Bt20 participant datasets, 
respectively. To address the possible introduction of Type II errors through the 
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application of this rigorous correction, we chose to also present results where a 
cut-off of p ≤ 1 x 10-4 was met. 
Association analysis results were visualized using Manhattan plots (for genome-
wide visualisation) drawn in R(v3.0.3) [28] and LocusZoom plots (for regional 
visualisation) [29]. 
Power calculation 
The power to detect associations was assessed using Quanto (v 1.2.4) [30]. 
Power was assessed for a range of beta and allele frequency (AF) values for 
reported associations obtained from the genome-wide association study (GWAS) 
catalogue [31] for both DBP and SBP. We were more than 80% powered to 
detect associations with an effect size of approximately 1.02 and higher for DBP 
and 1.53 and higher for SBP. In both cases the smaller effect sizes were only 
detectable at higher MAFs, with the power to detect associations at low MAFs 
increasing as the effect size increased.  
Results 
Pre-analysis QC of the data resulted in 976 participants (median age = 17.9) and 
971 female caregivers (median age = 41.0), with 127,764 and 140,649 SNPs, 
respectively remaining. Upon merging of the datasets, 1947 individuals and 
125,906 SNPs remained for analysis. Descriptive statistics of the individuals 
remaining after QC in the merged dataset are shown in Table 1. 
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Table 1 Descriptive statistics of the individuals remaining after QC in the 
merged dataset. 
    Mean (SD) Median Range 
Merged (n=1947) 
 
   
      Females: 73.3% Age (years) 30.1 (13.5) 30.0 17.3-84.0 
      Males: 26.6% Weight (kg) 68.0 (16.7) 64.4 36.1-136.6 
 
Height (m) 1.6 (0.1) 1.6 1.2-1.9 
 
BMI (kg.m-2) 26.2 (7.1) 24.6 14.9-58.8 
 
SBP (mmHg) 117.8 (16.8) 116.0 77.0-206.5 
 
DBP (mmHg) 74.1 (11.1) 72.5 44.5-129.5 
 
 
Analysis of the merged dataset across the genome can be visualised in the 
Manhattan plots in Figure 1. All SNPs associated with DBP or SBP at p ≤ 1 x 10-4 in 
the merged dataset are shown (see Table, Supplemental Digital Content 1, 
associations with DBP and SBP at p ≤ 1 x 10-4). Regions that contained two or 
more SNPs associated with one of the two traits under investigation or that were 
associated with both traits were examined further (Table 2). SNPs in introns in 
NOS1AP and intergenic to DACH1|LOC440145 associated with both DBP and SBP. 
SNPs intronic to MYRF and POC1B and intergenic to INTS10|LPL associated with 
SBP only. The only SNPs to reach “array-wide” significance are two intronic SNPs 
in MYRF (rs11230796-G and rs400075-T) which are associated with SBP. Regional 
plots centered around the lead SNPs of NOS1AP (DBP and SBP), MYRF (SBP), 
POC1B (SBP) and the intergenic region of INTS10|LPL are shown (see Figures, 
Supplemental Digital Content 2-6, LocusZoom plots).  
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Figure 1. Manhattan plots drawn from the association results (with correction 
for covariates and PCs where necessary) of the all merged dataset. Plots are 
shown for association with (a) DBP and (b) SBP. The upper horizontal line 
indicates the calculated “array-wide” significance cutoff (p=6.7x10-7) while the 
lower horizontal line shows the cutoff of p=1x10-4. Identified regions of interest 
for further investigation are indicated by arrows.  DACH1 – Dachshund Family 
Transcription Factor 1; INTS10 – integrator complex subunit 10;  LPL – lipoprotein 
lipase; MYRF – myelin regulatory factor; NOS1AP – nitric oxide synthase 1 
(neuronal) adaptor protein; POC1B – POC1 centriolar protein. 
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Table 2 Identified regions of interest associated with DBP or SBP in the merged dataset. 
CHROMOSOME GENE/REGION SNP ID a 
BASE PAIR 
POSITION a 
ALLELES A1 FREQUENCY c DBP SBP 
A1 b A2 Bt20 YRI CEU P-value d Beta e P-value d Beta e 
1 NOS1AP 
rs112468105 162195649 G C 0.011 0.023 0.000 7.18x10-5 6.69 - - 
rs4657181 162255385 T A 0.046 0.023 0.556 - - 4.04x10-5 -5.62 
13 DACH1 | LOC440145 rs17240498 72965307 C T 0.011 0.000 0.182 4.91x10-6 7.93 2.10x10-5 11.68 
11 MYRF 
rs11230796 61529267 G T 0.058 0.056 0.222 - - 2.16x10-7 6.12 
rs400075 61528814 T C 0.058 0.056 0.217 - - 2.88x10-7 6.02 
12 POC1B 
rs770373 89818289 T C 0.176 0.329 0.449 - - 7.05x10-5 -2.95 
rs770374 89818022 T G 0.231 0.366 0.561 - - 9.05x10-5 -2.62 
8 INTS10 | LPL 
rs55830938 19735188 G T 0.026 0.028 0.000 - - 1.30x10-5 7.49 
rs73599609 19756974 C G 0.050 0.051 0.000 - - 5.78x10-5 5.14 
rs73667448 19747475 C A 0.028 0.042 0.000 - - 6.86x10-5 6.72 
 
a All SNP IDs and base pair positions are reported using GRCh37 (Genome Reference Consortium human genome Build 37). 
b A1 corresponds to the minor allele in the dataset.  
c Frequencies of allele 1 are recorded for the merged dataset used in this study (Bt20) and for an African and European 1000 Genomes 
population -  the Yoruba in Ibadan, Nigeria (YRI) and the Utah Residents (CEPH) with Northern and Western Ancestry (CEU). 
d p-value adjusted for age, sex, BMI and principal  components. P-values that pass the “array-wide” significance threshold (p<6.7x10-7) are 
shown in bold. 
e Beta values are with respect to the minor allele in the sample. A positive beta indicates that the minor allele is associated with an 
increased blood pressure relative to the major allele, and vice versa 
DACH1 – Dachshund Family Transcription Factor 1; INTS10 – integrator complex subunit 10; LPL – lipoprotein lipase; MYRF – myelin 
regulatory factor; NOS1AP – nitric oxide synthase 1 (neuronal) adaptor protein; POC1B – POC1 centriolar protein
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Stratification of the sample into males and females and older and younger 
individuals revealed possible sex- and age-related associations (see Table, 
Supplemental Digital Content 7, sex- and age-related associations). Associations 
specific to females and older individuals included SNPs in NOS1AP (DBP and SBP). 
Associations of SNPs in MYRF (SBP) and intergenic to DACH1 and LOC440145 
(DBP and SBP) were specific to females only. SNPs in POC1B or intergenic to 
DUSP6 and POC1B were associated with SBP in both older and younger 
individuals, but the SNPs were different in each case. 
Discussion  
This study revealed several associations with DBP and SBP in black South 
Africans. The analysis pointed to regions of interest in the NOS1AP (DBP and 
SBP), MYRF (SBP) and POC1B (SBP) genes as well as two intergenic regions 
(DACH1|LOC440145 and INTS10|LPL). Two SNPs in the MYRF gene met the 
calculated “array-wide” significance threshold (p<6.7x10-7 for the merged 
dataset) for multiple testing. All SNPs identified were novel associations with BP.  
Of the non-intergenic regions identified, only POC1B (POC1 centriolar protein B) 
has previously shown any kind of link to blood pressure. In our study, two 
intronic SNP alleles (rs770373-T and rs770374-T) associated with decreased SBP. 
rs770373 and rs770374 are shown to be in high LD in both the YRI and CEU 
populations and could also be in high LD in the South African population used in 
this study. In a previous study testing the SNP main effects and SNP-age 
interactions, a SNP (rs4842666) intergenic to POC1B (encoding a POC1 protein 
with a role in basal body and cilia formation) and ATP2B1 (ATPase plasma 
membrane Ca2+ transporting 1) was found to be associated with SBP (7.91x10-13), 
DBP (2.13x10-10) and mean arterial pressure (MAP) (7.24x10-13). This study was 
conducted among individuals of age 40 to 49 years in a meta-analysis to 
determine age-specific genetic effects [32]. Polymorphisms in ATP2B1 are known 
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to be associated with BP/hypertension [33] so it may be that rs4842666 is in LD 
with other variants within ATP2B1, thus presenting as an association with BP.  
Apart from a link to BP, a missense mutation in POC1B is known to cause an 
autosomal recessive form of cone-rod dystrophy [34].  
In our study, SNPs in the NOS1AP (nitric oxide synthase 1 (neuronal) adaptor 
protein) gene were found to be associated with increased DBP (rs112468105-G) 
and decreased SBP (rs4657181-T). Polymorphisms in this gene have not 
previously been associated with blood pressure, but have been associated with 
other cardiovascular phenotypes in various populations, most notably QT 
interval length [35–44]. Other associations, with significance at a genome-wide 
level, have been found with sudden cardiac death [45] and change in body mass 
index over time [46]. Polymorphisms in NOS1AP have also shown a suggestive 
association with hip circumference [47] and word reading [48]. One SNP 
identified in this study (rs4657181) showed a previous association with 
schizophrenia in a South American population [49].  Interestingly, several genes 
in the chromosome 1q linkage region, in which NOS1AP falls, have previously 
been reported to be associated with hypertension [13] which motivates for this 
gene and regions on chromosome 1 to be investigated further for their role in 
blood pressure/hypertension. Of all the regions of interest identified, NOS1AP 
could have the most plausible functional link to blood pressure regulation or 
hypertension risk. The gene encodes an adaptor protein for neuronal nitric oxide 
synthase (nNOS), an enzyme involved in nitric oxide (NO) synthesis in the 
nervous tissue in the central and peripheral nervous systems. NO has several 
roles in the body, one of which is as a vasodilator and regulator of vascular tone 
and blood flow [50]. Most research until now has implicated NO synthesised in 
the blood vessels by endothelial NOS (eNOS) in regulation of vascular tone and 
blood flow, but more recent animal and human studies have suggested the 
involvement of the neuronal-derived NO in this process too [50]. NO has also 
been implicated in BP regulation and impaired NO bioactivity has shown to be 
  
99 
 
associated with hypertension, although the mechanism is unclear [51]. Research 
has also shown that NO synthesised in the central nervous system by nNOS is 
involved in the central regulation of blood pressure and inhibition of nNOS 
activity in the medulla and hypothalamus has been linked to systemic 
hypertension [52]. Studies have debated the possible association of mutations in 
eNOS with hypertension, with some studies showing an association and others 
not [51], but no studies have identified associations between mutations in the 
nNOS gene and hypertension. The exact role of the NOS1AP protein in the 
regulation of nNOS function in human disease is not clear, but a recent study 
showed that over-expression of NOS1AP increased nNOS activity [53].   
Despite associations of the two SNPs in MYRF (myelin regulatory factor) 
(rs11230796-G and rs400075-T) with increased SBP at “array-wide” significance 
(p<6.7x10-7 for the merged dataset), there is no clear functional link to blood 
pressure. MYRF encodes a transcription factor involved in myelination in the 
central nervous system. Polymorphisms in this gene have not shown any 
previous associations with BP or hypertension, but have been associated with 
fatty acid, phospholipid and blood metabolite levels [54–57] and colorectal 
cancer risk in East Asians [58], with most associations being at a genome-wide 
significance level.  
Of the intergenic regions of interest identified through analysis of the merged 
dataset, INTS10 (Integrator complex subunit10)|LPL (lipoprotein lipase) is the 
most interesting finding. The LPL gene encodes a lipase expressed in the heart, 
muscle and adipose tissue. Linkage studies have linked SBP to a region at or near 
the LPL gene in Taiwanese individuals [59] and in a more recent study an 
association was suggested between the LPL gene and hypertension following 
haplotype analysis [60]. The findings are, however, inconclusive and the same 
has not been seen in Caucasian individuals [61]. Associations have also been 
reported between SNPs in LPL and coronary artery disease (rs264-A) [62] and 
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triglycerides-BP (rs15285-A) [63]. Interestingly, the SNPs identified in this study 
in this region are monomorphic in European, East Asian and South Asian 
populations. 
An accurate investigation into the genetics of hypertension as a binary disease 
trait was not possible in this study due to the number of cases and controls being 
insufficient to observe any meaningful effect. A simple analysis was nevertheless 
carried out after classifying individuals into having high blood pressure (SBP 
≥140mmHg and/or DBP ≥90mmHg) versus normal or low blood pressure and 
these findings (see Table, Supplemental Digital Content 8, associations with 
high BP) along with possible age- and sex-related findings are shown (see Table, 
Supplemental Digital Content 9, age- and sex-related associations with high 
BP). One interesting observation is the association of three intronic SNPs 
(rs1557647-A, rs179434-A and rs179431-G) in KCNQ1 (channel, voltage gated 
KQT-like subfamily Q, member 1) with high blood pressure. KCNQ1 encodes a 
voltage-gated potassium channel which is required in the repolarisation phase of 
the cardiac action potential. A study conducted in African Americans identified a 
variant near KCNQ1 (rs4930130) with a suggestive association with DBP [64]. In 
another study in the Han Chinese, a suggestive association was found between 
rs10832417 and MAP responses to high-sodium intervention [65]. 
Polymorphisms in KCNQ1 have in the past been most commonly linked to type 2 
diabetes risk, in a range of populations including Europeans [66–68], African 
Americans [69], Asians [68,70–75], American Indians [76] and Hispanics [77–79], 
and QT interval [35,38–40,42,43]. Polymorphisms in this gene were also chosen 
to be part of a locus fine mapping region on the Metabochip based on previous 
association with the QT trait and type 2 diabetes.  Other associated phenotypes 
have included height [80–82] and BMI [83] (at genome-wide significance level) 
and plasma amyloid beta peptide concentrations [84], platelet aggregation [85] 
and lactic dehydrogenase levels [86] (suggestive associations).  
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The three SNPs intergenic to INTS10 and LPL that associated with SBP also 
associated with high blood pressure in the binary analysis, with one SNP 
(rs55830938-G) reaching “array-wide” significance. This association, however, 
could have been driven by the high SBP. 
The Population Architecture using Genomics and Epidemiology (PAGE) study, 
whose main goal is to assess the generalizability of GWAS-identified variants 
across different populations, assessed the fine mapping capability of the 
Metabochip in African-Americans [87] and found it to be successful. Although it 
is known that African-Americans are genetically different to our African 
population, the Metabochip served as a good starting point in the investigation 
of blood pressure genetics in black South Africans, despite the tool being 
developed from data on European populations. The Metabochip was developed 
in 2009 and several new BP/hypertension associated variants and regions have 
been identified since then, therefore possibly limiting the capacity to replicate in 
our population what has previously been found. In addition, as the Metabochip 
only contains variants known to be previously associated with cardiometabolic 
traits, the chances of identifying novel associations in Africans is reduced.   
This study has provided some insight into the genetics of blood pressure in black 
South Africans. Studies in larger samples could enable us to identify more 
associated variants that have modest to small effects. The functional significance 
of the associations identified is unclear, though some have plausible biological 
explanations for their role in regulating blood pressure. Functional and 
replication studies in larger African studies, as are proposed within the H3Africa 
Consortium [88] and more specifically the AWI-Gen study [89], will no doubt 
provide more insight into the genetics in African populations.  
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Supplemental Digital Content 
Supplemental Digital Content 1. All SNPs associated with DBP or SBP at p ≤ 1 x 10-4 in the merged dataset 
PHENOTYPE CHROMOSOME GENE/REGION LOCATION SNP ID 
a
 BASE PAIR POSITION 
a
 
ALLELES A1 FREQUENCY 
c
 
P-value 
d
 Beta 
e
 
A1 
b
 A2 Bt20 YRI CEU 
DBP 
13 DACH1 | LOC440145 INTERGENIC rs17240498 72965307 C T 0.011 0.000 0.182 4.91x10
-6
 7.93 
21 ADAMTS5 | C21orf94 INTERGENIC rs469709 28801007 A G 0.051 0.019 0.131 9.21x10
-6
 3.50 
10 LOC642666 | LOC727960 INTERGENIC rs12761063 82533425 T C 0.112 0.120 0.101 1.58x10
-5
 2.47 
2 PLEKHH2 | LOC728819 INTERGENIC rs13423605 43886460 C T 0.127 0.176 0.040 2.25x10
-5
 2.29 
12 SCARB1 INTRON rs10846744 125312425 G C 0.227 0.241 0.854 2.49x10
-5
 -1.79 
2 ARL6IP6 | LOC391453 INTERGENIC rs2114653 153648587 G A 0.163 0.144 0.364 4.28x10
-5
 -1.94 
19 EML2 | GIPR INTERGENIC rs4994276 46164172 T C 0.150 0.199 0.187 5.87x10
-5
 -1.96 
12 TRPV4 INTRON rs16939725 110250587 G A 0.137 0.139 0.015 7.08x10
-5
 -2.04 
1 NOS1AP INTRON rs112468105 162195649 G C 0.011 0.023 0.000 7.18x10
-5
 6.69 
12 DNAH10 COMPLEX rs6488908 124377814 G A 0.127 0.144 0.040 7.94x10
-5
 -2.02 
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Supplemental Digital Content 1 (continued) 
PHENOTYPE CHROMOSOME GENE/REGION LOCATION SNP ID 
a
 BASE PAIR POSITION 
a
 
ALLELES A1 FREQUENCY 
c
 
P-value 
d
 Beta 
e
 
A1 
b
 A2 Bt20 YRI CEU 
SBP 
11 MYRF INTRON rs11230796 61529267 G T 0.058 0.056 0.222 2.16x10
-7
 6.12 
11 MYRF INTRON rs400075 61528814 T C 0.058 0.056 0.217 2.88x10
-7
 6.02 
8 INTS10 | LPL INTERGENIC rs55830938 19735188 G T 0.026 0.028 0.000 1.30x10
-5
 7.49 
10 LOC100128511 | C10orf114 INTERGENIC rs6482175 21573536 C T 0.081 0.111 0.192 1.42x10
-5
 4.31 
13 DACH1 | LOC440145 INTERGENIC rs17240498 72965307 C T 0.011 0.000 0.182 2.10x10
-5
 11.68 
1 FMO4 | BAT2D1 INTERGENIC rs10798391 171389938 T G 0.022 0.014 0.187 2.19x10
-5
 8.16 
1 NOS1AP INTRON rs4657181 162255385 T A 0.046 0.023 0.556 4.04x10
-5
 -5.62 
15 CYP19A1 INTRON rs10459592 51536141 G T 0.196 0.273 0.581 5.75x10
-5
 2.81 
8 INTS10 | LPL INTERGENIC rs73599609 19756974 C G 0.050 0.051 0.000 5.78x10
-5
 5.14 
8 INTS10 | LPL INTERGENIC rs73667448 19747475 C A 0.028 0.042 0.000 6.86x10
-5
 6.72 
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Supplemental Digital Content 1 (continued) 
PHENOTYPE 
CHROMOSOME GENE/REGION LOCATION SNP ID 
a
 BASE PAIR POSITION 
a
 
ALLELES A1 FREQUENCY 
c
 
P-value 
d
 Beta 
e
 
A1 
b
 A2 Bt20 YRI CEU 
12 POC1B INTRON rs770373 89818289 T C 0.176 0.329 0.449 7.05x10
-5
 -2.95 
11 STK33 INTRON rs1596888 8455344 T G 0.432 0.481 0.722 7.51x10
-5
 2.20 
3 C3orf17 | BOC INTERGENIC rs1881941 112852476 A T 0.123 0.282 0.066 7.66x10
-5
 3.39 
22 FLJ46257 | FAM19A5 INTERGENIC rs6519991 48725535 A G 0.173 0.157 0.101 8.31x10
-5
 -2.89 
7 TAX1BP1 INTRON rs6944913 27826523 G A 0.019 0.005 0.242 8.63x10
-5
 8.09 
11 KCNQ1 INTRON rs1557647 2551363 A G 0.255 0.315 0.682 9.00x10
-5
 2.51 
12 POC1B INTRON rs770374 89818022 T G 0.231 0.366 0.561 9.05x10
-5
 -2.62 
 
a All SNP IDs and base pair positions are reported using GRCh37 (Genome Reference Consortium human genome Build 37). 
b A1 corresponds to the minor allele in the dataset.  
c Frequencies of allele 1 are recorded for the merged dataset used in this study (Bt20) and for an African and European 1000 Genomes 
population -  the Yoruba in Ibadan, Nigeria (YRI) and the Utah Residents (CEPH) with Northern and Western Ancestry (CEU). 
d p-value adjusted for age, sex, BMI and principal  components. P-values that pass the “array-wide” significance threshold (p<6.7x10-7) are 
shown in bold. 
e Beta values are with respect to the minor allele in the sample. A positive beta indicates that the minor allele is associated with an 
increased blood pressure relative to the major allele, and vice versa. 
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Supplemental Digital Content 2. LocusZoom plot for the association of 
rs112468105 (in NOS1AP) with DBP against a YRI LD background. rs112468105 
is represented by a purple diamond. SNPs around this index SNP are coloured 
according to the LD between each SNP and the index SNP. SNPs with missing LD 
information are shown in grey. rs112468105 is monomorphic in the CEU 
population.  
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Supplemental Digital Content 3. LocusZoom plot for the association of 
rs4657181 (in NOS1AP) with SBP against a CEU LD background. rs4657181 is 
represented by a purple diamond. SNPs around this index SNP are coloured 
according to the LD between each SNP and the index SNP. SNPs with missing LD 
information are shown in grey.  The plot shows evidence of high LD in this region 
in the CEU population. rs4657181 had completely missing LD information when 
drawn for the YRI population. 
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Supplemental Digital Content 4. LocusZoom plots for the association of rs11230796 (in MYRF) with SBP against (a) YRI and (b) CEU LD 
backgrounds. rs11230796 is represented by a purple diamond. SNPs around this index SNP are coloured according to the LD between 
each SNP and the index SNP. SNPs with missing LD information are shown in grey. MYRF is referred to by an alternative name (C11orf9) in 
this plot. The plot shows evidence of high LD in both the YRI and CEU populations between rs11230796 and the other SNP (rs400075) 
that has a strong association with SBP.   
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Supplemental Digital Content 5. LocusZoom plots for the association of rs770373 (in POC1B) with SBP against (a) YRI and (b) CEU LD 
backgrounds. rs770373 is represented by a purple diamond. SNPs around this index SNP are coloured according to the LD between each 
SNP and the index SNP. SNPs with missing LD information are shown in grey. POC1B is referred to by an alternative name (WDR51B) in 
this plot. The plot shows evidence of high LD in both the YRI and CEU populations between rs770373 and the other SNP (rs770374) that 
has a strong association with SBP.   
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Supplemental Digital Content 6. LocusZoom plot for the association of 
rs55830938 (intergenic to INTS10 and LPL) with SBP against a YRI LD 
background. rs55830938 is represented by a purple diamond. SNPs around this 
index SNP are coloured according to the LD between each SNP and the index 
SNP. SNPs with missing LD information are shown in grey. rs55830938 is 
monomorphic in the CEU population. 
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Supplemental Digital Content 7. Identified regions of interest associated with DBP and SBP stratified into a) sex- and b) age-specific 
associations. 
 
(a) 
CHROMOSOME GENE/REGION SNP ID a 
BASE PAIR POSITION 
a 
ALLELES DBP SBP 
 
A1 b A2 P-value c Beta d P-value c Beta d 
FEMALES (female 
caregivers and 
female Bt20 
participants merged) 
1 NOS1AP 
rs112468105 162195649 G C 4.30x10-5 8.91 9.27x10-6 15.39 
rs4657181 162255385 T A - - 8.08x10-5 -6.66 
11 MYRF 
rs11230796 61529267 G T - - 6.76x10-7 7.51 
rs400075 61528814 T C - - 1.45x10-6 7.22 
13 
DACH1 | 
LOC440145 rs17240498 72965307 C T 7.01x10-6 9.16 3.40x10-5 13.49 
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Supplemental Digital Content 7 (continued) 
 
a All SNP IDs and base pair positions are reported using GRCh37 (Genome Reference Consortium human genome Build 37). 
b A1 corresponds to the minor allele in the dataset.  
c p-value adjusted for age, sex, BMI and principal  components. P-values that pass the “array-wide” significance threshold (p<6.7x10-7) are 
shown in bold. 
d Beta values are with respect to the minor allele in the sample. A positive beta indicates that the minor allele is associated with an 
increased blood pressure relative to the major allele, and vice versa. 
(b) 
CHROMOSOME GENE/REGION SNP ID a 
BASE PAIR 
POSITION a 
ALLELES DBP SBP 
 
A1 b A2 P-value c Beta d P-value c Beta d 
OLDER INDIVIDUALS 
(female caregivers 
only) 
1 NOS1AP 
rs113559977 162202520 G A 5.21x10-5 10.66 1.37x10-5 18.74 
rs112468105 162195649 G C 8.20x10-5 10.15 2.41x10-5 17.80 
12 
POC1B 
rs770374 89818022 T G - - 2.83x10-5 -4.63 
rs770373 89818289 T C - - 3.06x10-5 -5.01 
DUSP6 | 
POC1B rs770370 89812993 G A - - 3.88x10-5 -4.92 
YOUNGER 
INDIVIDUALS (Bt20 
participants only) 
12 POC1B rs114077950 89879278 C T - - 3.29x10-6 7.97 
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Supplemental Digital Content 8. All SNPs associated with high blood pressure at p ≤ 1 x 10-4 in the merged dataset.  
CHROMOSOME GENE/REGION LOCATION SNP ID 
a
 BASE PAIR POSITION 
a
 
ALLELES A1 FREQUENCY 
c
 
P-value 
d
 OR 
e
 
A1 
b
 A2 Bt20 YRI CEU 
8 INTS10 | LPL INTERGENIC rs55830938 19735188 G T 0.026 0.028 0.000 5.20x10
-7
 1.17 
8 INTS10 | LPL INTERGENIC rs73599609 19756974 C G 0.050 0.051 0.000 3.46x10
-6
 1.12 
8 INTS10 | LPL INTERGENIC rs73667448 19747475 C A 0.028 0.042 0.000 4.13x10
-6
 1.15 
11 KCNQ1 INTRON rs1557647 2551363 A G 0.255 0.315 0.682 9.25x10
-6
 1.05 
16 LITAF INTRON rs1345441 11679823 G A 0.344 0.315 0.369 1.40x10
-5
 1.05 
22 FLJ46257 | FAM19A5 INTERGENIC rs13056403 48727674 A G 0.176 0.171 0.101 1.47x10
-5
 0.94 
1 FAM5C INTRON rs16832100 190116031 G A 0.075 0.074 0.071 2.29x10
-5
 0.92 
10 LOC642666 | LOC727960 INTERGENIC rs12761063 82533425 T C 0.112 0.120 0.101 2.53x10
-5
 1.07 
4 MAN2B2 CODING chr4:6594947 6594947 A G 0.011     3.39x10
-5
 1.23 
1 FMO4 | BAT2D1 INTERGENIC rs10798391 171389938 T G 0.022 0.014 0.187 4.05x10
-5
 1.16 
15 RAB8B INTRON rs12593078 63517347 A G 0.398 0.449 0.318 4.08x10
-5
 0.96 
22 FLJ46257 | FAM19A5 INTERGENIC rs6519991 48725535 A G 0.173 0.157 0.101 4.18x10
-5
 0.95 
11 KCNQ1 INTRON rs179431 2552148 G A 0.323 0.407 0.692 4.20x10
-5
 1.05 
11 FAT3 INTRON rs11019985 92266200 C T 0.402 0.458 0.071 4.27x10
-5
 0.96 
11 KCNQ1 INTRON rs179434 2553601 A C 0.208 0.384 0.692 4.43x10
-5
 1.05 
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Supplemental Digital Content 8 (continued)  
CHROMOSOME GENE/REGION LOCATION SNP ID 
a
 BASE PAIR POSITION 
a
 
ALLELES A1 FREQUENCY 
c
 
P-value 
d
 OR 
e
 
A1 
b
 A2 Bt20 YRI CEU 
8 NAT2 | PSD3 INTERGENIC rs17126618 18278776 C T 0.025 0.023 0.005 4.79x10
-5
 1.14 
11 PLEKHA7 | LOC729362 INTERGENIC rs177544 16925046 T C 0.030 0.028 0.157 4.89x10
-5
 1.13 
15 SGK269 | HMG20A INTERGENIC rs17385059 77637812 C T 0.107 0.060 0.293 5.72x10
-5
 1.07 
8 NAT1 | NAT2 INTERGENIC rs1565684 18246664 G A 0.357 0.273 0.465 5.75x10
-5
 1.04 
10 CDC123 INTRON rs117334547 12284397 T A 0.037 0.028 0.025 6.14x10
-5
 1.11 
10 CDC123 INTRON rs77611247 12285815 A G 0.037 0.028 0.040 6.14x10
-5
 1.11 
11 ARHGEF12 | GRIK4 INTERGENIC rs6589829 120530973 T C 0.145 0.176 0.601 6.99x10
-5
 0.95 
13 SLC7A1 UTR rs2490264 30084535 T G 0.094 0.139 0.015 7.11x10
-5
 1.07 
11 SLC22A18 INTRON rs60055747 2941104 A G 0.016 0.037 0.000 8.52x10
-5
 1.17 
15 RAB8B INTRON rs72747098 63525249 A G 0.464 0.380 0.682 9.02x10
-5
 1.04 
Possible regions of interest are shaded in grey. 
a All SNP IDs and base pair positions are reported using GRCh37 (Genome Reference Consortium human genome Build 37). 
b A1 corresponds to the minor allele in the dataset.  
c Frequencies of allele 1 are recorded for the merged dataset used in this study (Bt20) and for an African and European 1000 Genomes 
population -  the Yoruba in Ibadan, Nigeria (YRI) and the Utah Residents (CEPH) with Northern and Western Ancestry (CEU). 
d p-value adjusted for age, sex, BMI and principal  components. P-values that pass the “array-wide” significance threshold (p<6.7x10-7) are 
shown in bold. 
e Odds ratio (OR) values are with respect to the minor allele in the sample. An OR greater than one indicates that the minor allele is 
associated with an increased risk for high blood pressure relative to the major allele, and vice versa. 
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Supplemental Digital Content 9. Identified regions of interest associated with high blood pressure stratified into a) sex- and b) age-
specific associations. 
(a) 
CHROMOSOME GENE/REGION SNP ID a BASE PAIR POSITION a 
ALLELES 
P-value c OR d 
 
A1 b A2 
FEMALES (female 
caregivers and 
female Bt20 
participants 
merged) 
11 KCNQ1 
rs179434 2553601 A C 1.77x10-5 1.07 
rs1557647 2551363 A G 7.17x10-6 1.07 
rs179431 2552148 G A 1.83x10-5 1.06 
22 
FLJ46257 | 
FAM19A5 
rs13056403 48727674 A G 1.94x10-5 0.93 
MALES (male 
Bt20 participants 
only) 
8 INTS10 | LPL rs73667448 19747475 C A 2.97x10-5 12.48 
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Supplemental Digital Content 9 (continued) 
(b) 
CHROMOSOME GENE/REGION SNP ID a BASE PAIR POSITION a 
ALLELES 
P-value c OR d 
 
A1 b A2 
OLDER 
INDIVIDUALS 
(female 
caregivers only) 
15 RAB8B rs12593078 63517347 A G 8.49x10-5 0.59 
22 
FLJ46257 | 
FAM19A5 
rs13056403 48727674 A G 7.66x10-6 0.39 
YOUNGER 
INDIVIDUALS 
(Bt20 participants 
only) 
8 INTS10 | LPL rs73667448 19747475 C A 9.51x10-5 4.91 
 
a All SNP IDs and base pair positions are reported using GRCh37 (Genome Reference Consortium human genome Build 37). 
b A1 corresponds to the minor allele in the dataset.  
c p-value adjusted for age, sex, BMI and principal  components. P-values that pass the “array-wide” significance threshold (p<6.7x10-7) are 
shown in bold. 
d Odds ratio (OR) values are with respect to the minor allele in the sample. An OR greater than one indicates that the minor allele is 
associated with an increased risk for high blood pressure relative to the major allele, and vice versa. 
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Chapter 5: AN INVESTIGATION INTO GENOTYPE 
IMPUTATION OF METABOCHIP DATA IN BLACK SOUTH 
AFRICANS USING A MIXED REFERENCE PANEL 
Genotype imputation is the inference of genotype data at SNPs not initially 
genotyped using information from reference panel haplotypes. It is a useful 
extension of GWAS and other association studies to provide a more detailed 
view of an associated region, to provide a wider range of SNPs for analysis and 
follow-up or replication and to point to possible causal variants.  Imputation in 
African individuals can be challenging due to their genetic diversity and lower 
levels of LD [See Chapter 1].  
In this investigation, the aim was to explore the success of imputation in black 
South African individuals using Metabochip data as a starting dataset and a 
mixed population 1000 Genomes Project Phase 3 reference panel (The 1000 
Genomes Project Consortium, 2015). To do this, regions where association 
signals were observed in the merged dataset or individual datasets with either 
DBP (NOS1AP) or SBP (NOS1AP, POC1B, MYRF) were selected.  
5.1 Methodology 
5.1.1 Preparation of files for imputation 
Each imputation run focused only on the specific gene of interest, rather than 
the entire genome. The first step therefore involved extracting the genotype 
data of the chromosome in which the gene of interest sits from the merged, 
pruned, Build 37 file [See Chapter 2].   
The SNPs in the reference panel are all aligned to the sense strand whereas the 
SNPs on the Metabochip are of a mixed strand orientation (sense and antisense). 
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Therefore, in preparation for imputation, a strand-check was run using SHAPEIT 
(v2) (Delaneau et al., 2012) and a strand flip was carried out in PLINK for any 
SNPs in the genotype data that did not align with the reference panel data. Any 
SNPs that still presented with problems following a second strand check were 
excluded from the dataset. 
Imputation involved two main steps – a pre-phasing step and the actual 
imputation step.  
5.1.2 Pre-phasing 
Pre-phasing [See Chapter 1] was carried out using SHAPEIT using the merged 
(caregivers and participants) dataset. This step involved processing the study 
genotypes to produce the best-guess haplotypes and was carried out over the 
entire chromosome containing the gene of interest.  
5.1.3 Imputation 
Alleles from the 1000 Genomes Project Phase 3 mixed population reference 
panel (The 1000 Genomes Project Consortium, 2015) were then imputed into the 
estimated haplotypes in IMPUTE (v2.3.1) (Howie et al., 2009) over the specific 
genes of interest in the merged or individual dataset only. IMPUTE2 generates an 
info metric for each SNP which gives an indication of the certainty with which 
each SNP is imputed. An info metric of 1 indicates that the SNP has been 
imputed with high certainty. Any SNPs with an info metric < 0.4 were removed 
before further analysis (see below). 
5.1.4 Association analysis 
For the merged dataset, post-imputation association analysis was carried out in 
GEMMA (v 0.94.1) (to be able to account for relatedness between individuals) 
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using univariate linear mixed models with correction for covariates (age, BMI and 
sex and PCs, where applicable). The imputation output files were first converted 
to PLINK files using fcGENE (Roshyara & Scholz, 2014) and all SNPs with an info 
metric < 0.4 were excluded. Creation of the relatedness matrix involved input of 
the phenotype data into the PLINK .fam files and then calculation of the matrix in 
GEMMA for each of the phenotypes under investigation. 
For the individual datasets, post-imputation association analysis was carried out 
using SNPTEST (v2.5.1) (an appropriate tool to use in conjunction with IMPUTE2) 
using an additive model with correction for covariates (age, BMI and sex (where 
applicable)).     
The significance threshold for post-imputation analysis to measure array-wide 
significance was also calculated here as 0.05 divided by the number of unlinked 
markers. The significance thresholds for the different datasets and genes 
investigated are shown in Table 5.1.  
Table 5.1 Significance thresholds for post-imputation analysis. 
  Gene 
  NOS1AP MYRF POC1B 
Dataset 
Merged  
p<2.9x10-5 
(0.05/1724) 
p<3.0x10-4 
(0.05/167) 
p<9.3x10-5 
(0.05/538) 
Female 
Caregivers 
p<3.1x10-5 
(0.05/1616) 
- 
p<9.9x10-5 
(0.05/505) 
Bt20 Participants - - 
p<9.9x10-5 
(0.05/507) 
 
5.1.5 Result visualisation 
Post-imputation plots showing genotyped and imputed SNPs together for each 
gene were drawn in R. 
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5.2 Results 
5.2.1 Overall assessment of accuracy and yield 
To get an indication of the overall quality of the imputation, IMPUTE2 performs 
an internal cross-validation by masking and re-imputing genotyped SNPs one at a 
time and then comparing the imputed genotypes with the original genotypes to 
give an overall concordance value. NOS1AP (merged and female caregivers), 
MYRF (merged) and POC1B (merged, female caregivers and Bt20 participants) 
were all imputed with high confidence (98.1%, 96.9% and 99.4% concordance 
between genotyped and imputed SNPs for the three genes, respectively, before 
applying any filters).  
Table 5.2 outlines the number of SNPs before and after imputation in the region 
under investigation and the number of SNPs with an info metric ≥ 0.4 (well-
imputed SNPs) that were taken through to analysis. Figure 5.1 shows the 
proportion of SNPs with an info metric ≥ 0.4 in different MAF bins. The bins are 
separated into MAF=0, rare SNPs (0<MAF≤0.01), less common SNPs 
(0.01<MAF≤0.05) and common SNPs (MAF>0.05). In all but one scenario, the 
highest proportion of SNPs with info metric ≥ 0.4 are common SNPs.  
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Table 5.2 Number of SNPs pre- and post-imputation and with info metric ≥ 0.4 
for each imputation scenario considered. 
Gene Dataset 
Number of SNPs 
pre-imputation 
Number of SNPs 
post-imputation a 
Number of SNPs (%) 
with info metric ≥0.4 b 
NOS1AP 
Merged 
568 8633 
3078 (35.7) 
Female 
Caregivers 
2958 (34.3) 
MYRF Merged 53 966 246 (25.5) 
POC1B 
Merged 
222 2920 
987 (33.8) 
Female 
Caregivers 
954 (32.7) 
Bt20 Participants 965 (33.0) 
a
 This indicates the number of SNPs resulting from imputation, before the info metric filter was 
applied. 
b
 SNPs with an info metric ≥0.4 were taken through to association analysis. 
 
 
 
 
 
 
 
 
Figure 5.1 The proportion of well-imputed SNPs (info metric ≥ 0.4) in different 
MAF bins for each imputation scenario considered. 
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5.2.2 Merged dataset 
For the merged dataset, a more detailed view/enrichment of the region, where 
an association signal was observed before imputation, was only evident in 
NOS1AP for association with both DBP and SBP (Figure 5.2). Top associated SNPs 
are shown in Tables 5.3. For both DBP and SBP, the pre-imputation associated 
SNPs had a higher p-value (DBP: rs112468105 p=1.18x10-4; SBP: rs4657181 
p=1.01x10-4) than the top imputed SNPs and previously observed.      
 
 
 
 
 
 
 
 
Figure 5.2a Imputation in the merged dataset resulted in a more detailed 
view/enrichment of the region where an association signal was observed 
before imputation for NOS1AP (SBP and DBP). Imputed SNPs are in grey and 
genotyped SNPs are in black. The blue significance line is at p=1.0x10-4 and the 
red significance line is at p=2.9x10-5. 
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Figure 5.2b Imputation in the merged dataset didn’t result in a more detailed 
view/enrichment of the region where an association signal was observed 
before imputation for MYRF or POC1B. Imputed SNPs are in grey and genotyped 
SNPs are in black. The blue significance line is at p=1.0x10-4 and the red 
significance line is at p=3.0x10-4 for MYRF and p=9.3x10-5 for POC1B. 
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Table 5.3a Several imputed SNPs in the NOS1AP gene associated with DBP in 
the merged and female caregiver datasets. SNPs with p>1x10-4 are shown, with 
SNPs meeting the calculated significance threshold for multiple testing indicated 
in bold.  
SNP IDa 
Merged dataset Female caregiver dataset 
MAF P-valueb Beta MAF P-valueb Beta 
rs530351339 0.012 1.21x10-5 7.25 0.013 2.86x10-5 0.87 
rs115986274 0.012 1.21x10-5 7.25 0.013 2.91x10-5 0.87 
rs116537698 0.011 1.50x10-5 7.26 0.012 1.91x10-5 0.91 
rs75879850 0.010 2.07x10-5 7.51 0.011 1.41x10-5 0.96 
rs79382913 0.010 2.07x10-5 7.51 0.011 1.46x10-5 0.95 
rs114010317 0.011 5.37x10-5 7.03 0.012 6.43x10-5 0.84 
rs114372970 0.011 5.37x10-5 7.03 0.012 5.48x10-5 0.85 
rs113559977 0.011 5.37x10-5 7.03 0.011 5.43x10-5 0.85 
rs145140073 0.011 5.37x10-5 7.03 0.011 4.23x10-5 0.88 
rs77776939 - - - 0.009 1.93x10-8 4.06 
rs17459307 - - - 0.002 2.73x10-6 4.28 
rs112468105* - - - 0.012 8.50x10-5 0.81 
 
a All SNP IDs are reported using GRCh37 (Genome Reference Consortium human 
genome Build 37). 
b p-value adjusted for age, sex (where appropriate), BMI and PCs (where 
appropriate). 
*SNP associated before imputation. 
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Table 5.3b Several imputed SNPs in the NOS1AP gene associated with SBP in 
the merged and female caregiver datasets. SNPs with p>1x10-4 are shown, with 
SNPs meeting the calculated significance threshold for multiple testing indicated 
in bold.  
SNPa 
Merged dataset Female caregiver dataset 
MAF P-valueb Beta MAF P-valueb Beta 
rs530351339 0.012 2.33x10-5 11.20 0.013 4.03x10-6 0.94 
rs115986274 0.012 2.33x10-5 11.20 0.013 4.18x10-6 0.94 
rs75879850 0.010 3.17x10-5 11.70 0.011 2.19x10-6 1.03 
rs79382913 0.010 3.17x10-5 11.70 0.011 2.38x10-6 1.02 
rs116537698 0.011 5.75x10-5 10.80 0.012 2.38x10-6 0.99 
rs77776939 - - - 0.009 9.50x10-10 4.33 
rs144974259 - - - 0.006 2.18x10-7 3.40 
rs188310846 - - - 0.001 7.18x10-7 5.40 
rs17459307 - - - 0.002 5.88x10-6 4.29 
rs145140073 - - - 0.011 9.15x10-6 0.93 
rs113559977 - - - 0.011 1.45x10-5 0.90 
rs114372970 - - - 0.012 1.46x10-5 0.90 
rs114010317 - - - 0.012 1.78x10-5 0.88 
rs112468105* - - - 0.012 2.53x10-5 0.85 
 
a All SNP IDs are reported using GRCh37 (Genome Reference Consortium human 
genome Build 37). 
b p-value adjusted for age, sex (where appropriate), BMI and PCs (where 
appropriate). 
*SNP associated before imputation. 
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5.2.3 Individual datasets 
For the individual datasets, a more detailed view/enrichment of the region, 
where an association signal was observed before imputation, was again evident 
in NOS1AP for association with both DBP and SBP in the female caregivers and to 
a lesser extent in POC1B for association with SBP in the Bt20 participants (Figure 
5.3). 
 
 
 
 
 
 
 
 
 
Figure 5.3a Imputation in the individual datasets resulted in a more detailed 
view/enrichment of the region where an association signal was observed 
before imputation for NOS1AP (SBP and DBP) in the female caregivers. Imputed 
SNPs are in grey and genotyped SNPs are in black. The blue significance line is at 
p=1.0x10-4 and the red significance line is at p=3.1x10-5. 
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Figure 5.3b Imputation in the individual datasets resulted in a very slight 
enrichment of the region where an association signal was observed before 
imputation for POC1B (SBP) in the Bt20 participants and no enrichment for 
POC1B (SBP) in the female caregivers. Imputed SNPs are in grey and genotyped 
SNPs are in black. The blue significance line is at p=1.0x10-4 and the red 
significance line is at p=9.9x10-5. 
 
Top associated SNPs are shown in Table 5.3 (above) and Table 5.4. For NOS1AP 
for both DBP and SBP, the pre-imputation associated SNPs had a higher p-value 
(DBP: rs112468105 p=8.50x10-5; SBP: rs112468105  p= 2.53x10-5 and rs4657181 
p=2.24x10-3) than the top imputed SNPs and previously observed.  For POC1B, 
the pre-imputation associated SNP was more significantly associated with SBP 
than any of the top imputed SNPs.  
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Table 5.4. A few imputed SNPs in the POC1B gene associated with SBP in the 
Bt20 participant dataset. SNPs with p>1x10-4 are shown, with SNPs meeting the 
calculated significance threshold for multiple testing indicated in bold.  
SNP IDa 
Bt20 participant dataset 
MAF P-valueb Beta 
rs114077950* 0.022 3.55x10-6 0.71 
rs148043872 0.022 3.55x10-6 0.71 
rs544538503 0.003 7.28x10-6 -4.04 
rs146263687 0.007 1.16x10-5 1.26 
 
a All SNP IDs are reported using GRCh37 (Genome Reference Consortium human 
genome Build 37). 
b p-value adjusted for age, sex, BMI and PCs (where appropriate).  
*SNP associated before imputation. 
 
5.3 Discussion 
Imputation was carried out in few identified regions of interest using SHAPEIT 
(for pre-phasing) and IMPUTE2 (for imputation) and a 1000 Genomes mixed 
reference panel to investigate the success of imputation in our South African 
population that was genotyped using the Metabochip. Imputation was achieved 
with high confidence in all genes (>95% concordance between genotyped and 
imputed SNPs in each gene), but a more detailed view or improvement in the 
resolution of the region was only seen in NOS1AP (DBP and SBP in both the 
merged and female caregiver datasets) and POC1B (Bt20 participant dataset 
only).  In each of these cases, imputation resulted in more SNPs associated with 
SBP and/or DBP, with the imputed SNPs in NOS1AP being more significantly 
associated with SBP/DBP than any significantly associated genotyped SNPs.  
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Despite the high concordance seen in each gene, the percentage of SNPs with 
info metric < 0.4 was quite high meaning that a large number of SNPs were 
removed prior to association analysis. This has, however, been seen before in a 
study comparing imputation performance using the 1000 Genomes pilot CEU 
(~8.5 million SNPs), interim EUR (~11.5 million SNPs) and Phase 1 ALL (~37.4 
million SNPs) reference panels across different GWAS datasets. When using the 
1000G Phase 1 ALL reference panel, on average only about 28% of the SNPs had 
an info metric ≥ 0.4, compared to the pilot and interim reference panels with an 
average of 87% and 67% with an info metric ≥ 0.4, respectively, across the 
different GWAS datasets (Zheng et al., 2015a). Despite the much lower 
percentage, the actual number of well-imputed SNPs was still higher when using 
the Phase 1 reference panel due to there being many more SNPs in the reference 
panel to start with. With the later 1000 Genomes Phase 3 reference panel, there 
may also be a large proportion of SNPs with an info metric < 0.4, but the actual 
number of well-imputed SNPs should still be reasonably large due to the even 
higher number of variants in the reference panel (> 88 million variants).  
An assessment of the proportion of SNPs with info metric ≥ 0.4 in different MAF 
bins showed that in all but one scenario, the highest proportion of SNPs with info 
metric ≥ 0.4 are common SNPs. This is not surprising as common SNPs are 
generally more easily imputed than rare variants (Liu et al., 2012; Sung et al., 
2012a; Chanda et al., 2012; Band et al., 2013; Zheng et al., 2015a). Compared to 
NOS1AP and POC1B, imputation in MYRF appeared to give a different picture in 
terms of the proportion of SNPs with info metric ≥ 0.4 in different MAF bins, with 
the highest proportion being rare variants. In addition, MYRF appears to be the 
least successfully imputed of the three genes as it has the greatest proportion of 
SNPs with info metric < 0.4. As it is known that a lower SNP density in the study 
sample negatively influences imputation accuracy and performance (Zhang et al., 
2011; Wang et al., 2012; Howie et al., 2012), one might speculate that the 
number of SNPs present on the Metabochip for MYRF may be too small to allow 
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for successful imputation in this gene. The representation of SNPs for each of the 
genes, however, is relatively low on the Metabochip (less than 5% of the total 
variants present in each gene were available for imputation) and an increase in 
the SNP density in each case may improve imputation. The lack of an enhanced 
signal in MYRF may indicate that the gene is in fact not associated with SBP or 
the previously identified SNPs may be the actual causal variant(s).      
In this study, imputation was investigated in the merged and individual caregiver 
and participant sets for comparison. In each scenario, however, the pre-phasing 
step was performed using the merged dataset. Larger study sample sizes can 
increase haplotype estimation accuracy during phasing (Howie et al., 2009). In 
addition, merging of the two datasets meant that there were a large number of 
related individuals present in one dataset. Related individuals can have a positive 
influence on the haplotype estimations as they have longer stretches of shared 
haplotypes (Li et al., 2009). If haplotypes are well estimated, the subsequent 
imputation can be fast and highly accurate (Howie et al., 2012). The actual 
imputation in the different scenarios was comparable with a number of 
overlapping associated SNPs in the merged and individual datasets, as is seen in 
NOS1AP.  
Pre-imputation filtering of SNPs is believed to influence imputation accuracy, 
with little or no SNP filtering being favourable for imputing small to moderately 
sized datasets to keep the LD structure between SNPs intact (Roshyara et al., 
2014). In this study, the data went through a strict QC process to remove all SNPs 
and samples that failed certain criteria. This was, however, deemed necessary for 
all parts of the study, regardless of any effect it may have on LD structure 
between SNPs and imputation accuracy.   
Mixed/”cosmopolitan” reference panels have proven to be successful for 
imputation in several populations and are particularly useful in cases where no 
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clear reference panel matches exist (Roshyara et al., 2016). This was therefore 
the ideal choice in this study as no suitable publically available reference panels 
matching our South African population currently exists. Mixed reference panels 
are also thought to be able to improve imputation of rare variants (Howie et al., 
2009; Liu et al., 2014; Howie et al., 2011). This could be particularly useful when 
dealing with a phenotype such as BP where many small contributions from risk 
alleles in multiple genes across the genome play a role in its aetiology (Doris, 
2002). Many of these contributions may be from low frequency or rare variants 
which may only be identified following imputation.  In fact, all of the imputed 
SNPs in NOS1AP or POC1B that were associated with SBP or DBP fell into the rare 
or less common SNP categories.  
The choice of imputation tool is an important consideration. The chosen tool 
should, among other things, be fast, easy to install and handle, have meaningful 
default options and feed useful information back to the user (Ellinghaus et al., 
2009). In addition, it should be accurate in its imputation. IMPUTE (1 and 2) is a 
sensible choice as it shows generally favourable performance compared to other 
commonly used imputation tools [See Chapter 1].  
Some studies have reported on the merit of using a mixed or “cosmopolitan” 
1000 Genomes reference panel in conjunction with IMPUTE 2 (Hancock et al., 
2012; Liu et al., 2014). In addition, using IMPUTE2 combined with a diverse 
reference panel from HapMap was applicable to African populations (Band et al., 
2013). Given the advantage of 1000 Genomes reference panels over HapMap 
reference panels, our use of IMPUTE2 and a diverse 1000 Genomes Phase 3 
reference panel was an appropriate choice for imputation in our African 
population.  
Pre-phasing has become a popular option when performing imputation as it 
speeds up imputation and allows for phasing of a particular gene/region to only 
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be performed once with multiple subsequent imputation runs. Pre-phasing was 
therefore chosen to be included as a step in this study and was carried out in 
SHAPEIT, a tool that is highly compatible with IMPUTE2. One recent study, 
however, suggests using the SHAPEIT-IMPUTE2 framework cautiously. The study 
ran pre-phasing using SHAPEIT and subsequent imputation with IMPUTE2 and 
using a HapMap reference panel. They reported that the SHAPEIT-IMPUTE2 
framework can overestimate the certainty of genotype distributions and inflate 
the IMPUTE info metric. This leads to a low percentage of correctly imputed 
SNPs, thus decreasing imputation accuracy. This was reported to be particularly 
evident with smaller sample sizes. (Roshyara et al., 2016) 
A different tool was used for association analysis in the merged and individual 
datasets. SNPTEST is considered an appropriate choice when using IMPUTE2, as 
it works well with its output. In analysis of the merged dataset, however, 
GEMMA was used to be able to account for the relatedness between individuals 
through incorporation of a relatedness matrix. Given the overlapping results in 
the merged and individual datasets using the two different tools, GEMMA 
appears to handle imputed data and genotype uncertainty as well as SNPTEST 
and is therefore probably a suitable enough tool to use following conversion of 
the IMPUTE2 output files into a format useable by GEMMA.  
Imputation in Africans, in general, can be a challenge due to their high genetic 
diversity and lower levels of LD, which could lead to a reduced imputation 
accuracy (Howie et al., 2011; Huang et al., 2011). A bigger sample size is often 
needed to maintain the power in imputation based studies in Africans (Huang et 
al., 2011). The size of the sample used in this study is relatively small and 
increasing the sample size may improve imputation performance in the future.  
This current investigation into imputation in our Metabochip-genotyped black 
South African population using a mixed 1000 Genomes reference panel showed 
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some promising results, especially in the NOS1AP gene, despite the high number 
of SNPs removed after imputation. Imputation is a useful addition to association 
studies to increase the SNP set for association analysis, thus increasing the 
power of the study and possibly helping to identify novel or subtle associations. 
Imputation in any population is not perfect and can produce inaccuracies. All 
imputation-based results should therefore be replicated, preferably through 
actual genotyping of the imputed SNPs in a separate dataset (Browning, 2008). 
Until now, many of the imputation-based studies in individuals of African 
ancestry have been carried out in African Americans, who are admixed and 
therefore not a true representation of Africans. More imputation-based studies 
need to be carried out in African populations to inform the most appropriate 
reference panel and parameter settings and to determine whether or not more 
exact matching reference panels, as they become available, may in fact perform 
better than the mixed panel. 
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Chapter 6: GENERAL CONCLUSIONS 
Bioinformatics is an area of ever-increasing importance. It is an interdisciplinary 
field involving research into biological areas of interest using various computer- 
or programming-based tools or software (both pre-existing and self-developed) 
and often involves the handling of large, complex datasets. Many areas of 
Bioinformatics require that a researcher has insight into both the biological and 
computational aspects necessary to tackle a scientific problem. Marrying these 
two areas provides the potential for significant discoveries. All aspects of the 
research presented here falls into the broader field of Bioinformatics.  
A major part of this study involved the development of a queryable 
cardiometabolic database for the current longitudinal project-specific data. The 
underlying motivation for this is the ever-increasing volume and complexity of 
biological data and the need for this data to be effectively stored, managed and 
used for biological knowledge discovery. Something which could be useful is to 
store project-specific data similar to how publically available data is stored with 
access to the data via an internet-based user interface. The phenotype (from 
multiple data collection time points), SNP annotation and association analysis 
data from this study was moved from basic Excel spreadsheets to structured 
tables making up a relational MySQL database. A user-friendly web interface 
linking to the database was designed using PHP, HTML and CSS code. The 
interface has made the project-specific data more easily accessible and 
queryable for useful data and information from any computer with internet 
access. The previous method of storing the data in spreadsheets was limited by 
the size of data that could be stored, the requirement to manually manipulate 
the data to obtain useful information and the fact that the data was spread 
across multiple files. Having all the data stored in one central location as a 
relational database means better management of the data, less chance of data 
handling errors and easier extraction of data and information with more complex 
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queries possible. Well managed data allows for studies to be conducted 
smoothly and for the data to be utilised to its full potential for discovery within 
the biological field. Access to the database is restricted to specific users within 
the research group via a username/password login. This and the session timeout 
feature ensure that the data remains protected and won’t be accessed by 
anyone without permission to use the data. If necessary, access to some tables 
containing sensitive data can also be restricted. The stored association analysis 
results also provide a means by which future follow-up or replication studies can 
be better informed. A useful extension of the current database will be to include 
more participants from the Bt20 cohort, data from future data collection time 
points, additional phenotypes for the same individuals and the data or 
information resulting from genotype imputation.  New features for more 
complex queries and extraction of additional useful information can also be 
added. This can specifically include longitudinal queries for extraction of useful 
information about changes in or stability of phenotypes over time. 
The database and interface do not only serve a purpose in the current study or 
research area, but can serve as a tool for other research groups to implement 
their own similar databases to improve management and analysis of data in 
various biological settings. The developed database and interface, therefore, 
have room for growth and improvement. As a project that makes use of a 
database such as the one described here expands, the database itself can expand 
in terms of its functionality and available information. Careful consideration must 
be given to the needs of the researchers involved and what information is 
required by them to carry out their investigations. The current design is able to 
include the basic information required for a genetic association study involving a 
relatively small set of individuals. One possible future use of this database could 
be in the greater AWI-Gen study. The database will need to be expanded to 
include many more individuals from multiple project sites. The individuals will 
also be genotyped using a different technology with many more SNPs.   
  
146 
 
The biological focus of this study was cardiovascular or cardiometabolic diseases 
and more specifically BP/hypertension. The burden of CVDs and hypertension 
was detailed in Chapter 1, with the overall message being that of high and 
increasing prevalence, particularly in black or African individuals. The need to 
better understand the aetiology of CVDs and to introduce better management 
and treatment options to decrease the associated morbidity and mortality is 
therefore essential.  
Hypertension is estimated to be 30-50% heritable (Munroe et al., 2013). 
Therefore, a large part of understanding its aetiology is discovering the 
underlying genetic factors. Blood pressure and hypertension are polygenic in 
nature with multiple genes and variants with small effect sizes contributing to BP 
variation or hypertension risk. It has also been shown that epistatic effects might 
exist where one gene(s) interacts with another gene(s) to exert its effect (Cicila 
et al., 2009; Norton et al., 2010; Wei et al., 2015; Scurrah et al., 2017). As the 
variants and loci identified so far explain less than 2.5% of the phenotypic 
variance for SBP and DBP (Ehret et al., 2011), researchers are a long way from 
elucidating the entire genetic architecture of BP/hypertension.  
Most of the studies into the genetics of BP/hypertension have been performed in 
non-African or African-American individuals and more needs to still be 
discovered about the genetics of BP/hypertension in native Africans, who remain 
understudied. African populations are genetically more diverse than non-African 
populations and tend to have a greater SNP density and lower LD between SNPs 
(Remm & Metspalu, 2002; Tishkoff & Verrelli, 2003). Studies have also suggested 
that there is great genetic diversity between subgroups within the African 
population itself (Tishkoff et al., 2009). Therefore conducting genetic studies in 
Africans, and more specifically different groups within Africa itself, is necessary. 
The burden of hypertension in SSA is also of increasing concern (Ogah & Rayner, 
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2013) and as with the rest of Africa, little is known about its genetics in SSA 
individuals.  
The second part of the study, therefore, was to identify genetic markers for SBP 
and DBP in black South African individuals and to record the findings in the 
developed database. The available cardiometabolic-related genotype data was 
harmonised with the rich phenotype data in the database, which is not disease 
specific, to enable easier investigation into disease-related genetics. The 
investigation mainly looked at SBP and DBP, two common measurements of 
hypertension, with an additional investigation into high versus normal/low BP 
and possible sex- and age-differences. The current study was exploratory in 
nature and used a set of SNPs with a previous association with cardiometabolic-
related traits or diseases. This allowed us to relax the significance threshold 
slightly and potentially carry out a replication of previously identified 
variants/loci in our African population. An additive model was used for this 
analysis, although future analyses could explore using a genotypic, dominant or 
recessive model. None of the variants or genes on the Metabochip chosen based 
on previous associations with BP/hypertension in Europeans were replicated in 
this study. Instead, novel associations between variants in other cardiometabolic 
loci and SBP and/or DBP were found. The analysis pointed to regions of interest 
in the NOS1AP (DBP and SBP), MYRF (SBP) and POC1B (SBP) genes as well as two 
intergenic regions (DACH1|LOC440145 (DBP and SBP) and INTS10|LPL (SBP)). 
Two SNPs in the MYRF gene met the calculated “array-wide” significance 
threshold (p<6.7x10-7 for the merged dataset) for multiple testing. Of all the 
regions of interest identified, NOS1AP could have the most plausible functional 
link to blood pressure regulation or hypertension risk. A lack of replication of 
previously identified variants/loci in this study and the identification of different 
or novel variants/loci could be due to the lack of power to detect previous 
associations with the available sample size, the different patterns of LD and allele 
frequencies in different populations or differences in environmental exposures. It 
  
148 
 
could also simply reflect a lack of association in non-Africans of the variants/loci 
identified here and lack of association in Africans of the previously identified 
variants/loci (Fox et al., 2011; Ehret et al., 2016). It is important to carry out 
genetic studies in populations of different ancestry to discover new genetic 
mechanisms underlying a phenotype (Zhao et al., 2013).   
In general, it is often difficult to relate identified SNPs to actual causal genes. 
Many of the identified variants in our and other studies are in non-coding regions 
and finding the exact causal variant and mechanism is often a challenge 
(Padmanabhan et al., 2015). Therefore, a post-study or post-GWAS analysis is 
usually required to test the effects of identified variants/loci on BP regulation or 
hypertension risk. Prioritisation of potential causal variants could narrow the list 
down to possible functional variants which can be further analysed by 
integration analysis to identify affected pathways. Further in vitro and in vivo 
experiments can also help to identify possible disease mechanisms. (Wang et al., 
2011) 
Genotype imputation is a useful addition to genetic association studies to 
increase the SNP panel for association testing and to help identify SNPs or 
genes/loci that may otherwise be missed. Imputation accuracy varies among 
populations of different ethnicities and is affected by several factors including 
the size and composition of the reference panel used, study sample size and SNP 
density of the region to be imputed, LD and MAF of the SNPs to be imputed [See 
Chapter 1]. As Africans are generally more challenging to impute (Howie et al., 
2011) and no ideal matching reference panel for black South Africans exists, it 
was unclear from the onset whether or not imputation would be successful in 
our sample. The third aim of this research was therefore to investigate the 
effectiveness of genotype imputation in this black South African dataset and 
possibly provide a more detailed view of identified association signals. The 
investigation looked at regions of interest identified in the association analysis. 
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Imputation was achieved with high confidence in all genes, but a more detailed 
view or improvement in the resolution of the region was only seen in NOS1AP 
(DBP and SBP in both the merged and female caregiver datasets) and POC1B 
(Bt20 participant dataset only). The findings of the investigation offer 
encouraging prospects for using imputation in future studies using the same or 
other South African data, with a mixed population reference panel being a good 
reference panel choice.  
Future studies in the field of disease genetics need to move beyond simple 
association studies or GWAS where mainly common variants are identified. Rare 
variants are a possible source of much of the missing heritability of many traits 
and need to be investigated in more detail (Jones et al., 2012). Genotype 
imputation is useful in this situation. In addition, as the environment and 
combinations of genes may play a significant role in modifying BP and other 
traits, gene-environment and gene-gene studies are an important future area to 
explore (Kidambi et al., 2012). Some of the variance in BP regulation, and 
probably other traits, is also likely due to epigenetic factors. Future studies could 
include epigenetic approaches looking at micro-ribonucleic acids (miRNAs), 
histone modifications and methylation (Wang et al., 2011). Longitudinal studies 
may also be key in predicting hypertension risk (Zhao et al., 2013). In addition, 
one could explore risk score analyses and SNP-set level testing using, for 
example, SNP-set (Sequence) Kernel Association Test (SKAT) (Ionita-Laza et al., 
2013).       
A better understanding of the genetics and general aetiology of BP/hypertension 
is important. Identifying the exact genes and pathways involved in BP regulation 
may highlight new ways to reduce BP and CVD risk (Ganesh et al., 2013). In 
addition it will highlight possible new prevention strategies (Padmanabhan et al., 
2010) or targets for existing anti-hypertensive drugs or preclinical compounds 
(Tragante et al., 2014) and will allow for personalised prevention and treatment 
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(Zheng et al., 2015b). This is, however, a challenge in developing countries, such 
as those in Africa, where lack of funds, infrastructure or experience often 
prevent adequate diagnosis and treatment of hypertension (Opie & Seedat, 
2005). A public health intervention is vital to improve access to the care and 
treatment needed for each individual (Ogah & Rayner, 2013). Until this happens, 
there needs to be an increased awareness of the implications of hypertension 
and other CVD risk factors and low-cost alternatives need to be implemented, 
such as changes in lifestyle including a decrease in dietary salt and increase in 
potassium intake, an increase in exercise, and a decrease in obesity and smoking 
(Opie & Seedat, 2005).  
The main limitations of this study are linked to a small sample size available for 
the genetic association analysis, despite some positive novel associations being 
found. As the variants associated with BP/hypertension have small effect sizes, a 
significantly larger sample is needed to identify more associated variants, 
including those that are rare. With our available sample, we were only powered 
to detect variants with higher effect sizes, with smaller effect sizes only 
detectable at higher MAFs. We were also under-powered to carry out accurate 
sex- and age-stratified analyses as the sample consists of only younger males and 
more older females compared to younger females. An accurate investigation into 
the genetics of hypertension as a binary trait was also not possible. Although we 
could classify individuals into those with high BP and those with normal/low BP, 
the number of individuals with normal/low BP outnumbered the number of 
individuals with high blood pressure making the case-control study biased. 
Another limitation of the study is in the measurement of SBP and DBP. An 
automated machine was used to take the readings, which eliminates some of the 
problems arising from manual measurement of BP (Kaczorowski et al., 2012). The 
readings were, however, still taken at one particular sitting and the state that the 
patient was in and the conditions under which the readings were taken could still 
have influenced the quality and accuracy of the readings. It has also been 
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suggested that SBP and DBP are not the best measures to use to better 
understand the genetic architecture of BP and hypertension and that newer 
phenotype parameters that can accurately reflect underlying mechanisms or 
subphenotypes may be valuable to study. Pulse wave velocity and central BP are 
two examples that are potentially better markers of hypertension risk, but the 
progress in using these in large scale studies has been slow or limited 
(Padmanabhan et al., 2015).    
The use of the Metabochip in this study also has some limitations including the 
questionable efficacy of using a genotyping tool developed from data on 
European populations in African populations. A large number of SNPs were in 
fact removed during QC for being monomorphic in the black South Africans. The 
Metabochip is also a relatively “old” tool having been developed in 2009. Several 
new BP/hypertension associated variants and regions have been identified since 
then, therefore further limiting the capacity to replicate in our population what 
has previously been found. The Metabochip was, however, one of the most cost-
effective options at the time of commencement of the broader project and its 
contents are specific to cardiometabolic traits, making it a good starting point for 
the investigation in our black South African sample. The contents of the chip 
may, however, be a limitation in itself as the chances of identifying novel 
associations in Africans is reduced. Low coverage sequencing may be a possible 
alternative for future investigations, but this can also be costly. 
The Human Heredity and Health in Africa (H3Africa) initiative and its latest 
developments provide a promising and exciting future for genetic studies in 
Africa. An Illumina African-specific genotyping chip containing 2.5 million variants 
specific to African populations has been designed under the H3Africa initiative 
and is expected to be available for use later in 2017 (https://www.illumina.com). 
This chip is the first to specifically target African populations, with most existing 
tools, such as the Metabochip, being of European origin and therefore most 
  
152 
 
suitable for use in European populations. This advancement will hopefully 
improve genomic and epidemiological research in Africa and ultimately improve 
the health and well-being of people in Africa. This is in line with the main goal of 
H3Africa which has been to bring infrastructure and genetic studies to Africa and 
to help in developing capacity and networks among researchers in Africa 
(http://h3africa.org). Understanding the underlying genetics of disease in 
Africans is critical to better understand the high burden of many diseases in 
Africa, but can also provide clues to the mechanisms underlying diseases across 
the globe.  
A follow-on and replication of this current study can therefore include a more 
powered and accurate investigation into BP genetics in Africans using the new 
African chip and a larger sample from the H3Africa consortium. Replication 
studies are important in any genetic study to confirm identified associations. The 
chip may also be useful in future imputation studies and can be tested for its 
efficiency as a reference panel compared to the mixed population reference 
panel used in this study.  
In summary, the current research has allowed for the development of 
MetaboBTT, a useful database, with accompanying interface, for the storage and 
querying of project-specific data currently being used in an investigation into 
identifying risk factors for cardiometabolic disease in South Africans. The 
database is easy to use and provides efficient access to the stored data. Some of 
this data was used to investigate the genetics of BP/hypertension in these 
individuals. The analysis and genotype imputation, which proved to be fairly 
successful in this dataset, pointed to several regions of interest and provided 
some insight into the genetics of blood pressure and hypertension in black South 
Africans. Further studies in larger samples and using a more African-specific 
genotyping tool are, however, required to confirm the identified associations and 
whether or not the genetic links are African-specific, followed by functional 
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studies to determine the role of the genes identified in blood pressure 
regulation.  
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MRC/Wits Developmental Pathways for Health Research Unit  
Department of Paediatrics  
School of Clinical Medicine  
Faculty of Health Sciences 
University of the Witwatersrand, Johannesburg  
17
th
 July 2011 
 
The Chair 
Human Ethics Research Committee 
University of the Witwatersrand, Johannesburg 
 
Dear Professor Cleaton-Jones, 
 
  Re-consenting Birth to Twenty cohort participants around historical blood and 
DNA samples 
 
When Birth to Ten transitioned to Birth to Twenty and the Bt20 cohort and the Bone 
Health sub-cohort was formed, the HERC approved protocols that entailed the collection 
of blood and DNA samples for the analyses linked to non-communicable disease 
(obesity, bone health, diabetes, etc). The participants are now 21 years of age and we 
wish to re-consent them around the management and use of biological samples 
collected. 
 
Below are the information and consent sheets. We are asking the participants to consent 
to the following: 
 I acknowledge that all procedure/tests on the stored blood and DNA samples have 
been or will be approved by the Human Research Ethics Committee of the 
University of the Witwatersrand.
 I understand that every time a new study is done on my DNA, permission will 
be obtained from the ethics committee for the study to make sure that it is 
used appropriately.
 I am in agreement that my DNA may be stored and used for the purposes 
described.
 I am in agreement that the data generated from my DNA may be made available 
in a public domain without any identifiers.
 I agree that a small bit of my DNA may be sent out of the country if the 
research cannot easily be done in South Africa.
 I understand that I will not benefit directly from the research done on my DNA.
 I understand that I may withdraw from the study at any time.
 
We piloted the re-consent procedure with 10 biological parents of the Bt20 cohort. The 
re-consent procedure included: 
 Power-Point on genetics and core concepts presented by a masters-level 
research assistant in both English and Zulu.
 Question & Answer session.
 Information sheet distributed and discussed as a group.
 Question & Answer session.
 Individual consent in private with a trained research assistant.
 
The response from the pilot study was extremely positive. The participants understood 
and appreciated the presentation; they understood the information sheet and 100% 
consented to all of the points above. I seek permission from the HERC to approve the re-
consent documents and procedure. 
 
Shane Norris 
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INFORMATION SHEET 
Birth to Twenty participants 
Re-consenting around historical blood and DNA samples 
 
Historical blood samples 
You have been a part of the Birth to Twenty cohort since 1990, now over 20 years. We 
have collected data on the Birth to Twenty participants at 16 time points. At some of these 
time points you provided consent for us to collect blood samples from you to test for health 
indicators such as blood sugar (glucose), cholesterol, vitamin D, calcium, etc. These blood 
samples are stored at the University of the Witwatersrand with only a unique number 
identifier so your name is not attached to the sample. The information linking you name to 
the unique number identifier is locked away in the study offices with strict access control 
and is not made available to the people working on your blood sample. 
 
In the future we may run additional tests on the stored blood samples, but we will not do 
so without the approval of the Human Research Ethics Committee of the University of the 
Witwatersrand. 
 
Historical DNA samples 
From the blood samples we collected from you in 2003/2004 you consented to us 
extracting DNA (the inherited material in your cells) so that this DNA could be used for 
studies that look for genes/changes in DNA that are involved in causing diabetes, obesity 
and cardiovascular diseases, and for studies to understand how the DNA works (we call 
this epigenetic studies). DNA studies give us information about how your body works and 
also whether you are more likely to get certain conditions or diseases. It will also tell us 
about your ancestry (your family) and about the way that your body uses medications (we 
call this pharmacogenetics). 
 
Just as for the blood samples, all DNA samples are stored in a safe place at the University 
of the Witwatersrand and strict control access. If at some future date we realize there are 
other studies that we would like to carry out on your DNA samples, such tests would only 
be performed if permission is given to us by the Human Research Ethics Committee of the 
University of the Witwatersrand. Your identity will be anonymous as your sample will be 
identified by a number (as described above). 
 
Blood and DNA sample management 
The scientists who do the research will generate information (data) which will be placed in 
databases. Some of the information in the databases will be shared with other scientists, 
possibly around the world. These scientists will not have access to your name and 
therefore the data will not be linked back to you. It is possible that we may send small 
amounts of the DNA out of the country where tests will be done that we cannot easily do in 
South Africa, but that would give us valuable information for our studies. 
 
Benefits 
The discoveries that come from the studies on your DNA will not be of direct benefit to 
you and will not be communicated back to you. The discoveries may lead to information 
that will help us in the future to diagnoses disease, understand who is most likely to get ill 
and how different people behave when they are given medication. The DNA belongs to 
you and we are the keepers of the DNA. You may withdraw your sample at any time. 
 
Risks 
Since the DNA of every person is different, it is possible that if someone tested your 
blood and compared it to the data in the databases, they could conclude that the two 
samples come from the same person. However, this is unlikely given the procedures in 
place that protect your samples. 
 183 
 
CONSENT SHEET 
 
The information around the blood and DNA samples taken from me in the past is clear 
and that the purpose is for me to inform the study what they can or cannot do with these 
samples. 
 
I acknowledge that all procedure/tests on the stored blood and DNA samples have been 
or will be approved by the Human Research Ethics Committee of the University of the 
Witwatersrand. 
                                               YES            NO 
 
I am in agreement that my DNA may be stored and used for the purposes described above. 
 
                                                YES NO 
 
I am in agreement that the data generated from my DNA may be made available in a 
public domain without any identifiers. 
 
YES NO 
 
I agree that a small bit of my DNA may be sent out of the country if the research 
cannot easily be done in South Africa. 
 
YES NO 
 
I understand that every time a new study is done on my DNA, permission will be 
obtained from the ethics committee for the study to make sure that it is used only for the 
purposes stated above. 
YES NO 
 
I understand that I will not benefit directly from the research done on my DNA. 
 
YES NO 
 
I understand that I may withdraw from the study at any time. 
 
YES NO 
 
RESEARCH ASSISTANT: 
________________________________________________________________________ 
Printed Name     Signature/Mark or Thumbprint 
Date and Time 
 
 
PARTICIPANTS: 
_________________________________________________________________________ 
Printed Name     Signature/Mark or Thumbprint 
Date and Time 
 
 
WITNESS: (If applicable) 
_________________________________________________________________________ 
Printed Name     Signature/Mark or Thumbprint 
Date and Time 
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APPENDIX B – Script for conversion of GenomeStudio 
forward report files into transposed PLINK files 
#!/usr/local/bin/python 
import os 
 
# Arrays 
snpdata = {} 
csvfiles = [] 
tfamarray = [] 
tpedarray = {} 
tfamfilename = "batch1.tfam" 
tpedfilename = "batch1.tped" 
 
# Create a list of CSV files 
files=os.listdir("./") 
for eachfile in files: 
 if eachfile[-3:] == "csv": 
  csvfiles.append(eachfile) 
 
# Read in metabochip SNP annotations 
annotationfile = open("Metabochip_Gene_Annotation.txt",'r') 
annotations = annotationfile.readlines() 
for annotation in annotations: 
 annotation = annotation.strip().split("\t") 
 snpdata[annotation[0]] = 
[annotation[1],annotation[0],"0",annotation[2]] 
annotationfile.close() 
 
# Read in individual CSV files 
for eachfile in csvfiles: 
 datafile = open(eachfile, 'r') 
 FRdata = datafile.readlines() 
 samplerow = "" 
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 for i in range(10): 
  samplerow = FRdata.pop(0) 
 samplelist = samplerow.strip().strip(",").split(",") 
 print samplelist 
 tfamarray.extend(samplelist) 
 for row in FRdata: 
  row = row.strip().split(",") 
  snpid = row.pop(0) 
  for genotype in row: 
   try: 
    if genotype != "--": 
    
 tpedarray[snpid].append(genotype[0]) 
    
 tpedarray[snpid].append(genotype[1]) 
    else: 
     tpedarray[snpid].append("0")  
     tpedarray[snpid].append("0")  
   except: 
    if genotype != "--": 
     tpedarray[snpid] = 
[(genotype[0])] 
    
 tpedarray[snpid].append(genotype[1]) 
    else: 
     tpedarray[snpid] = ["0"] 
     tpedarray[snpid].append("0") 
     
         
 datafile.close() 
  
# Write out tfam file 
tfamfile = open(tfamfilename, 'w') 
for individual in tfamarray: 
 tfamfile.write("\t".join([individual,individual,"0","0
","0","0"])+"\n") 
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tfamfile.close() 
 
# Write out tped file 
tpedfile = open(tpedfilename, 'w') 
for snp in tpedarray.keys(): 
 snpcols = "\t".join(snpdata[snp]) 
 tpedfile.write(snpcols+"\t"+"\t".join(tpedarray[snp])+
"\n") 
tpedfile.close() 
 
print tfamarray 
  
 188 
 
APPENDIX C – PLINK, SMARTPCA GEMMA, SHAPEIT, 
IMPUTE2, SNPTEST and R commands for chapters 2, 4 and 5 
Chapter 2 - QC Steps 
 Conversion from transposed to binary PLINK files: 
plink --tfile File1 --make-bed --out File1 --allow-no-sex 
 
--tfile: Specifies the PLINK input file prefix (in this case it reads a transposed 
fileset). 
--make-bed: Directs PLINK to create a binary fileset. 
--out: Specifies the output file prefix. 
--allow-no-sex: Disables the automatic setting of the phenotype to missing if the 
individual has an ambiguous sex code. 
 
 Removal of SNPs with complete missing data: 
plink --bfile File1 --exclude NaNsnps.txt --make-bed --out 
File2 --allow-no-sex 
 
--bfile: Specifies the PLINK input file prefix (in this case it reads a binary  
fileset). 
--exclude: Directs PLINK to remove the SNPs listed in the specified .txt file. 
 
 Initial removal of poorly genotyped samples: 
plink --bfile  File2 --mind 0.20 --make-bed --out File3 --
allow-no-sex 
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--mind: Directs PLINK to remove individuals with more than 20% missing  
genotypes. 
 
 SNP QC (missingness, MAF, HWE): 
plink --bfile  File3  --geno 0.02 --maf 0.01--hwe 0.00001 --
make bed --out File4 --allow-no-sex 
 
--geno: Directs PLINK to remove SNPs with more than 2% missing data. 
--maf: Directs PLINK to remove SNPs with MAF less than 0.01. 
--hwe: Directs PLINK to remove SNPs with HWE p-value less than 1x10-5. 
 
 Removal of samples with high missingness rate: 
plink --bfile  File4 --mind 0.02 --make-bed --out File5 --
allow-no-sex  
[female caregivers] 
 
AND 
 
link --bfile  File4 --mind 0.03 --make-bed --out File5 --
allow-no-sex  
[Bt20 participants] 
 
 Sex check and removal of samples with discordant sex: 
plink --bfile File1 --check-sex --out File1 
 
--check-sex: Directs PLINK to perform a sex check and flag any problem 
individuals. 
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plink --bfile File5 --remove sexremoved.txt --make-bed --out 
File6 
 
--remove: Directs PLINK to remove the individuals listed in the specified .txt file. 
 
 Removal of related samples: 
LD pruning: 
 
plink --bfile File6 --indep-pairwise 50 5 0.2 --out LDpruned 
 
plink --bfile File6 --extract LDpruned.prune.in --make-bed -
-out File6_LDpruned 
 
--indep-pairwise: Directs PLINK to generate a pruned subset of SNPs that are in 
approximate linkage equilibrium with each other based on pairwise genotypic 
correlation. At each step it considers a window of 50 SNPs, shifts the window 5 
SNPs forward each time, and calculates the LD between each pair of SNPs in the 
window and removes one of a pair of SNPs if the LD is greater than 0.5.  
--extract: Directs PLINK to extract the SNPs which are not pruned out.  
 
Generation of IBD scores: 
 
plink --bfile File6_LDpruned --genome --min 0.05 
 
--genome: Directs PLINK to calculate IBD. 
--min: Directs PLINK to only output pairs where PI_HAT is greater than 0.05 to the 
.genome file. 
 
Removal of one of each of the pair of individuals: 
 
 191 
 
plink --bfile File6 --remove IBDremoved.txt --make-bed --out 
File7 
 
 Removal of duplicates: 
plink --bfile File7 --remove duplicates.txt --make-bed --out 
File8 
 
 Removal of samples based on extreme heterozygosity: 
Generation of .het file: 
 
plink --bfile File2 --het --out File2 
 
--het: Directs PLINK to generate an output file containing the observed and 
expected number of homozygotes and number of non-missing genotypes. 
 
Calculation of missingness: 
 
plink --bfile File2 --missing --out File2 
 
--missing: Directs PLINK to generate genotyping/missingness rate statistics. 
 
Exclusion of individuals with a heterozygosity rate ± 3 standard deviations from 
the mean:  
 
plink --bfile File8 --remove extremehet.txt --make-bed --out 
File9 
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 Principal component analysis (PCA) and removal of population outliers: 
LD pruning of the datasets: 
 
plink --bfile File9 --indep-pairwise 50 5 0.2 --out LDpruned 
 
plink --bfile File9 --extract LDpruned.prune.in --make-bed -
-out File9_LDpruned 
 
Running of PCA using SMARTPCA: 
 
smartpca.perl -i $1.bed -a $1.bim -b $1.fam -p $1.pca -e 
$1.eval -o $1.pca -q NO -l $1.log 
 
-i: Specifies input genotype file. 
-a: Specifies input SNP file 
-b: Specifies input individual file. 
-p: Specifies prefix of output plot files of top two PCs. 
-e: Specifies output file of all eigenvalues. 
-o: Specifies output file of PCs. 
-q: Specifies output log file. 
-l: Set to NO to indicate that there is not a single population and that the 
population field doesn’t contain real-valued phenotypes. 
 
Removal of population outlier: 
 
plink --bfile File9 --remove popoutliers.txt --make-bed -–
out File10 
 
* File10_1 = Final QC’ed female caregiver genotype files 
* File10_2 = Final QC’ed Bt20 participant genotype files 
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Chapter 2 - Merging of datasets and update to Build 37 
plink --bfile File10_1 --bmerge File10_2.bed File10_2.bim 
File10_2.fam --make-bed –-out merged_ALL --allow-no-sex 
 
plink --bfile merged_ALL --exclude Same_pos_SNPs.txt --
make-bed --out merged_ALL2 --allow-no-sex 
 
plink --bfile merged_ALL2 --geno 0.05 --make-bed --out 
merged_pruned_ALL --allow-no-sex 
 
--bmerge: Directs PLINK to merge binary PLINK files. 
 
Chapter 4 – Association analysis of merged dataset in GEMMA 
Creation of relatedness matrix: 
 
gemma -bfile merged_pruned_ALL_DBP -gk 1 –o 
Merged_ALL_DBP_RM    [DBP] 
 
gemma -bfile merged_pruned_ALL_SBP -gk 1 -o 
Merged_ALL_SBP_RM    [SBP] 
 
gemma -bfile merged_pruned_ALL_HT -gk 1 -o Merged_ALL_HT_RM  
[high versus normal/low BP] 
 
-bfile: Specifies the PLINK binary file prefix. 
-gk 1: Directs GEMMA to calculate the centered relatedness matrix. 
-o: Specifies the output file prefix. 
 
 
 
 
 194 
 
Association analysis (with correction for covariates): 
 
gemma \ 
-bfile merged_pruned _ALL_DBP \ 
-k Merged_ALL_DBP_RM.cXX.txt \ 
-c Merged_ALL_covariates.txt \ 
-lmm 4 \ 
-o Merged_ALL_DBP_ULMM_covar [DBP] 
 
gemma \ 
-bfile merged_pruned _ALL_SBP \ 
-k Merged_ALL_SBP_RM.cXX.txt \ 
-c Merged_ALL_covariates.txt \ 
-lmm 4 \ 
-o Merged_ALL_SBP_ULMM_covar [SBP] 
 
gemma \ 
-bfile merged_pruned _ALL_HT \ 
-k Merged_ALL_HT_RM.cXX.txt \ 
-c Merged_ALL_covariates.txt \ 
-lmm 4 \ 
-o Merged_ALL_HT_ULMM_covar  [high versus normal/low BP] 
 
-k: Specifies the relatedness matrix file name. 
-lmm4: Directs GEMMA to perform a Wald test, likelihood ratio test and score 
test. P-values generated from these three tests were almost identical and only 
the Wald test p-values were therefore recorded.  
-c: Specifies the covariate file name in the case of multivariate analysis. The 
covariate file is in the format: Column 1: intercept term (1’s), Columns 2 to n: 
covariates and headings are removed. 
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Chapter 4 – Association analysis of individual datasets in PLINK (with correction 
for covariates) 
plink \ 
--bfile File10 \ 
--pheno Caregiver_Phenotypes.txt \ 
--pheno-name DBP \ 
--linear \ 
--allow-no-sex \ 
--covar Caregiver_Phenotypes.txt \ 
--covar-name AGE,BMI \ 
--out CG_ALL_DBP_multi_linear [DBP] 
 
plink \ 
--bfile File10 \ 
--pheno Caregiver_Phenotypes.txt \ 
--pheno-name SBP \ 
--linear \ 
--allow-no-sex \ 
--covar Caregiver_Phenotypes.txt \ 
--covar-name AGE,BMI \ 
--out CG_ALL_SBP_multi_linear [SBP] 
 
plink \ 
--bfile File10 \ 
--pheno Caregiver_Phenotypes.txt \ 
--pheno-name HT \ 
--logistic \ 
--ci 0.95 \ 
--allow-no-sex \ 
--covar Caregiver_Phenotypes.txt \ 
--covar-name AGE,BMI \ 
--out CG_ALL_HT_multi_logistic [high versus normal/low BP] 
 
--bfile: Specifies the PLINK binary file prefix. 
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--pheno: Specifies the phenotype file name. 
--pheno-name: Specifies the phenotype to use in the analysis. 
--linear/logistic: Directs PLINK to perform linear/logistic regression analysis. 
--ci: Gives the specified confidence intervals for the estimated parameters. 
--allow-no-sex: Disables the automatic setting of the phenotype to missing if the 
individual has an ambiguous sex code. 
--out: Specifies the output file prefix. 
--covar: Specifies the covariate file name. 
--covar-name: Specifies the covariate(s) to use in the analysis. 
 
The PLINK commands above are for the female caregiver dataset. The same 
commands applied for analysis in each of the individual datasets, with inclusion 
of appropriate covariates in each case.  
 
Chapter 4 – Manhattan, Q-Q plots and calculation of genomic inflation factors 
(R) 
Manhattan plots: 
Plot = read.table("Merged_ALL_DBP_ULMM_covar.assoc.txt", 
header = T,as.is=T) 
 
manhattan(Plot, chr = "chr", bp = "ps", p = "p_wald", snp = 
"rs", col = c("gray10", "gray60"), chrlabs = NULL, main = 
"Merged_ALL_DBP_multi",suggestiveline = -log10(1e-04), 
genomewideline = -log10(6.7e-07),ylim=c(0,8), highlight = 
NULL, logp = TRUE) 
[Merged, DBP] 
Q-Q plots: 
Plot = read.table("Merged_ALL_DBP_ULMM_covar.assoc.txt", 
header = T,as.is=T) 
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qq(Plot$p_wald, main="Merged (all): DBP (with correction for 
covariates)")   
[Merged, DBP] 
Genomic inflation factor calculation: 
median(qchisq(Plot1a[,9],df=1,lower.tail=F),na.rm=T)/0.456 
Chapter 5 – Preparation of files for imputation (PLINK and SHAPEIT) 
Extraction of chromosome containing gene of interest: 
 
plink --bfile merged_pruned_ALL_37 --chr 1 --make-bed --out 
merged_pruned_ALL_37_chr1 --allow-no-sex 
 
Strand check, flip and removal of problem SNPs: 
 
shapeit \ 
-check \ 
-B merged_pruned_ALL_37_chr1 \ 
-M genetic_map_chr1_combined_b37.txt \ 
--input-ref 1000GP_Phase3_chr1.hap 1000GP_Phase3_chr1.legend 
1000GP_Phase3.sample \ 
--output-log merged_pruned_37_ALL_chr1.alignments 
 
-B: Specifies the input filename prefix of unphased genotypes in PLINK binary file 
format. 
-M: Specifies the input genetic map file. 
--input-ref: Specifies the input reference panel of haplotypes in the IMPUTE2 file 
format (.hap contains the reference haplotypes, .legend contains the SNP map, 
.sample contains information about the individuals). 
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--output-log: Specifies the log file where the screen output is copied and gives the 
prefix of all the files generated by SHAPEIT when checking input data. 
 
plink –bfile merged_pruned_ALL_37_chr1 –flip 
Chr1_strand_issue_SNPs.txt --make-bed –out 
merged_pruned_ALL_37_chr1_2 
 
plink --bfile merged_pruned_ALL_37_chr1_2 --exclude 
Strand_issue_SNPs_to_exclude.txt --make-bed --out 
merged_pruned_ALL_37_chr1_3 --allow-no-sex 
 
Chapter 5 – Pre-phasing (SHAPEIT) 
shapeit \ 
-B merged_pruned_ALL_37_chr1_3 \ 
-M genetic_map_chr1_combined_b37.txt \ 
--duohmm \ 
-W 5 \ 
--output-max merged_pruned_ALL_37_chr1_3.phased.haps 
merged_pruned_ALL_37_chr1_3.phased.sample 
 
--duohmm and -W: Take into account the relatedness of the individuals in the 
sample to improve phasing. 
--output-max: The most likely pair of haplotypes for each individual in IMPUTE2 
format is added to the .haps file and all extra information present in the input 
files is added to the .sample file. 
 
Chapter 5 – Imputation (IMPUTE2) 
For the merged dataset: 
 
impute2 \ 
-use_prephased_g \ 
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-known_haps_g merged_pruned_ALL_37_chr1_3.phased.haps \ 
-m genetic_map_chr1_combined_b37.txt \ 
-h 1000GP_Phase3_chr1.hap \ 
-l 1000GP_Phase3_chr1.legend \ 
-int 162039564 162340265 \ 
-Ne 20000 \ 
-buffer 500 \ 
-o NOS1AP_MERGED.gen 
 
For the individual datasets: 
 
impute2 \ 
-use_prephased_g \ 
-known_haps_g merged_pruned_ALL_37_chr1_3.phased.haps \ 
-m genetic_map_chr1_combined_b37.txt \ 
-h 1000GP_Phase3_chr1.hap \ 
-l 1000GP_Phase3_chr1.legend \ 
-sample_g merged.sample \ 
-exclude_samples_g Children_IDs.txt \ 
-int 162039564 162340265 \ 
-Ne 20000 \ 
-buffer 500 \ 
-o NOS1AP_CG.gen 
 
-use_prephased_g: Tells IMPUTE2 to perform imputation with pre-phased 
haplotypes (generated in the pre-phasing step). 
-known_haps_g: Specifies the file containing the known pre-phased haplotypes 
(generated in the pre-phasing step). 
-m: Specifies fine-scale recombination map for the region to be analysed. 
-h: Specifies file of known haplotypes.  
-l: Specifies legend file with information about the SNPs in the ‘-h’ file. 
-sample_g: File of sample IDs for the individuals in the haplotypes input files 
(SPECIFIC TO INDIVIDUAL DATASET IMPUTATION). 
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-exclude_samples_g: Indicates which samples to exclude from the pre-phased 
files during imputation (e.g. if we just want to impute genotypes in the female 
caregiver dataset, the exclude file would contain all IDs of the Bt20 participants 
to exclude) (SPECIFIC TO INDIVIDUAL DATASET IMPUTATION). 
-int: Specifies the region/genomic interval to be imputed. 
-Ne: Specifies the "effective size" of the population from which the dataset was 
sampled. 20000 recommended for most modern imputation analyses. 
-buffer: Specifies the length of the buffer region (in kilobases) to include on each 
side of the analysis interval specified by the ‘-int’ option. 
-o: Specifies the name of the main output file. 
 
Chapter 5 – Association analysis of merged imputed dataset (GEMMA) 
Conversion of imputation output files to PLINK files: 
 
fcgene --gens NOS1AP_MERGED.gen –-info 
NOS1AP_MERGED.gen_info --info-thresh 0.4 --oformat plink --
out NOS1AP_MERGED 
 
Creation of relatedness matrix: 
 
gemma -bfile NOS1AP_MERGED_SBP -gk 1 -o NOS1AP_MERGED_SBP_RM 
         [SBP, NOS1AP] 
 
Association analysis: 
 
gemma -bfile NOS1AP_MERGED_SBP –k 
NOS1AP_MERGED_SBP_RM.cXX.txt -c Covariates.txt -lmm 4 -o 
NOS1AP_MERGED_SBP_ULMM_multi 
[SBP, NOS1AP] 
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Chapter 5 – Association analysis of individual imputed datasets (SNPTEST) 
snptest_v2.5.1 \ 
-data NOS1AP_CG.gen CG.sample \ 
-frequentist 1 \ 
-method score \ 
-pheno pheno1 \ 
-cov_names cov_1  cov_4 \ 
-o NOS1AP_CG_SBP _multi.txt        
           [SBP, NOS1AP] 
 
-data:  Specifies the input genotype (.gen) and the sample files. The sample file 
stores the IDs and associated phenotype and covariate information for each 
individual. 
-frequentist: Specifies which model of association to test. 1 represents an additive 
model. 
-method: Controls the way genotype uncertainty is taken into account. ‘score’ 
uses a missing data likelihood score test. 
 -pheno: Specifies which phenotype in the sample file to test. 
-cov_names: Specifies which covariate(s) in the sample file to test. 
-o: Specifies the name of the output file. 
 
Chapter 5 – Result visualisation (R) 
NOS1AP_SBP = 
read.table("NOS1AP_MERGED_SBP_ULMM_multi.assoc.txt", header 
= T,as.is=T) 
 
plot(NOS1AP_SBP$ps, -log10(NOS1AP_SBP 
$p_wald)*(NOS1AP_SBP[,1] == "---"), ylim = c(0, 8), main = 
"NOS1AP Typed + Imputed SNPs: SBP (Merged, with correction 
for covariates)", col = 8*(NOS1AP_SBP[,1] == "---"), pch = 
16*(NOS1AP_SBP[,1] == "---"), ylab = "-log10 p-value", xlab= 
"BP Position") 
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par(new=T)  
 
plot(NOS1AP_SBP$ps, -
log10(NOS1AP_SBP$p_wald)*(NOS1AP_SBP[,1] == "1"), ylim = 
c(0, 8), main = "NOS1AP Typed + Imputed SNPs: SBP (Merged, 
with correction for covariates)", col = 1*(NOS1AP_SBP[,1] == 
"1"), pch = 16*(NOS1AP_SBP[,1] == "1"), ylab = "-log10 p-
value", xlab= "BP Position") 
 
par(new=T) 
 
abline(h = -log10(2.9e-05), untf = FALSE, col=2) 
abline(h = -log10(1e-04), untf = FALSE, col=4) 
 
par(new=F) 
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APPENDIX D – MySQL code for creation of database tables 
CREATE DATABASE metabobtt; 
 
USE metabobtt; 
 
#Phenotype data tables: 
CREATE TABLE female_caregivers_basic ( 
IndividualID  VARCHAR(5) NOT NULL PRIMARY KEY, 
Gender   VARCHAR(1), 
Ethnicity   INTEGER(1), 
RelationshipToChild VARCHAR(1) ) ; 
 
CREATE TABLE bt20_participants_basic ( 
 IndividualID  VARCHAR(4) NOT NULL PRIMARY KEY, 
Gender   VARCHAR(1), 
Ethnicity   INTEGER(1), 
CaregiversID  VARCHAR(5)); 
 
CREATE TABLE phenotype_yr13_female_caregivers ( 
 IndividualID  VARCHAR (5)NOT NULL PRIMARY KEY, 
 Age_yr13   VARCHAR(6), 
Height_yr13  VARCHAR (5), 
Weight_yr13  VARCHAR (5), 
BMI_yr13   VARCHAR (6), 
HipCircumference_yr13 VARCHAR (5), 
WaistCircumference_yr13 VARCHAR (5), 
WaistToHipRatio_yr13 VARCHAR (5), 
AverageSBP_yr13  VARCHAR (5), 
AverageDBP_yr13  VARCHAR (5), 
SubtotalBodyFat_yr13 VARCHAR (7), 
SubtotalLeanMass_yr13 VARCHAR (7), 
PercentageBodyFat_yr13 VARCHAR (4)); 
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CREATE TABLE phenotype_yrN_bt20_participants ( 
 IndividualID  VARCHAR(4) NOT NULL PRIMARY KEY, 
 Age_yrN   VARCHAR(6), 
Height_yrN   VARCHAR (5), 
Weight_yrN   VARCHAR (5), 
BMI_yrN   VARCHAR (6), 
HipCircumference_yrN VARCHAR (5), 
WaistCircumference_yrN VARCHAR (5), 
WaistToHipRatio_yrN VARCHAR (5), 
AverageSBP_yrN  VARCHAR (5), 
AverageDBP_yrN  VARCHAR (5), 
SubtotalBodyFat_yrN VARCHAR (7), 
SubtotalLeanMass_yrN VARCHAR (7), 
PercentageBodyFat_yrN VARCHAR (4)); 
 
(Separate table were created for each data collection time point. N=5, 7, 9/10, 
11/12, 13, 14, 15, 16, 17/18, 19, 20) 
 
#Metabochip data tables: 
CREATE TABLE metabochip_snp_information_1 ( 
 SNPID36   VARCHAR(17)NOT NULL PRIMARY KEY, 
 SNPID37   VARCHAR(17)NOT NULL UNIQUE, 
 Chromosome   VARCHAR(2), 
 BasePairPosition36 VARCHAR(9), 
 BasePairPosition37 VARCHAR(9), 
NearestGene  VARCHAR(143), 
LocationWithinGene VARCHAR(20)); 
 
CREATE TABLE metabochip_snp_information_extra( 
 SNPID36  VARCHAR(17)  NOT NULL  PRIMARY KEY, 
 Allele1   CHAR(1), 
Allele2  CHAR(1)); 
 
CREATE TABLE metabochip_snp_information_extra2 ( 
 SNPID36  VARCHAR(17)  NOT NULL  PRIMARY KEY, 
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AfterQC  VARCHAR(6));  
 
CREATE TABLE metabochip_snp_information_2 AS (SELECT 
metabochip_snp_information_1.*, 
metabochip_snp_information_extra.Allele1, 
metabochip_snp_information_extra.Allele2 FROM 
metabochip_snp_information_1 LEFT JOIN 
metabochip_snp_information_extra ON 
metabochip_snp_information_1.SNPID36= 
metabochip_snp_information_extra.SNPID36); 
 
CREATE TABLE metabochip_snp_information AS (SELECT 
metabochip_snp_information_2.*, 
metabochip_snp_information_extra2.AfterQC FROM 
metabochip_snp_information_2 LEFT JOIN 
metabochip_snp_information_extra2 ON 
metabochip_snp_information_2.SNPID36= 
metabochip_snp_information_extra2.SNPID36); 
 
ALTER TABLE metabochip_snp_information ADD PRIMARY 
KEY(SNPID36); 
 
#Association analysis data tables: 
CREATE TABLE metabochip_snp_associations_batch1_all ( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
 Phenotype  CHAR (3), 
P_valueUncorrected VARCHAR(20), 
Beta_ORUncorrected  VARCHAR(20), 
P_valueCorrected  VARCHAR(20), 
Beta_ORCorrected  VARCHAR(20), 
Covariate1  CHAR (3), 
Covariate2  CHAR (3), 
Covariate3  CHAR (3)); 
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ALTER TABLE metabochip_snp_associations_batch1_all ADD 
PRIMARY KEY(SNPID36,Dataset,Phenotype); 
 
CREATE TABLE metabochip_snp_associations_batch2_all( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
 Phenotype  CHAR (3), 
P_valueUncorrected VARCHAR(20), 
Beta_ORUncorrected  VARCHAR(20), 
P_valueCorrected  VARCHAR(20), 
Beta_ORCorrected  VARCHAR(20), 
Covariate1  CHAR (3), 
Covariate2  CHAR (3), 
Covariate3  CHAR (3)); 
 
ALTER TABLE metabochip_snp_associations_batch2_all ADD 
PRIMARY KEY(SNPID36,Dataset,Phenotype); 
 
CREATE TABLE metabochip_snp_associations_batch2_females( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
 Phenotype  CHAR (3), 
P_valueUncorrected VARCHAR(20), 
Beta_ORUncorrected  VARCHAR(20), 
P_valueCorrected  VARCHAR(20), 
Beta_ORCorrected  VARCHAR(20), 
Covariate1  CHAR (3), 
Covariate2  CHAR (3), 
Covariate3  CHAR (3)); 
 
ALTER TABLE metabochip_snp_associations_batch2_females ADD 
PRIMARY KEY(SNPID36,Dataset,Phenotype); 
 
CREATE TABLE metabochip_snp_associations_batch2_males( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
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 Phenotype  CHAR (3), 
P_valueUncorrected VARCHAR(20), 
Beta_ORUncorrected  VARCHAR(20), 
P_valueCorrected  VARCHAR(20), 
Beta_ORCorrected  VARCHAR(20), 
Covariate1  CHAR (3), 
Covariate2  CHAR (3), 
Covariate3  CHAR (3)); 
 
ALTER TABLE metabochip_snp_associations_batch2_males ADD 
PRIMARY KEY(SNPID36,Dataset,Phenotype); 
 
CREATE TABLE metabochip_snp_associations_pre2_all( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
 Phenotype  CHAR (3), 
P_valueUncorrected VARCHAR(20), 
Beta_ORUncorrected  VARCHAR(20), 
PRIMARY KEY(SNPID36,Dataset,Phenotype)); 
 
CREATE TABLE metabochip_snp_associations_pre3_all ( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
 Phenotype  CHAR (3), 
P_valueCorrected  VARCHAR(20), 
Beta_ORCorrected  VARCHAR(20), 
Covariate1  CHAR (3), 
Covariate2  CHAR (3), 
Covariate3  CHAR (3), 
PRIMARY KEY(SNPID36,Dataset,Phenotype)); 
 
CREATE TABLE metabochip_snp_associations_merged_all AS 
(SELECT metabochip_snp_associations_pre3_all.SNPID36, 
metabochip_snp_associations_pre3_all.Dataset, 
metabochip_snp_associations_pre3_all.Phenotype, 
metabochip_snp_associations_pre2_all.P_valueUncorrected, 
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metabochip_snp_associations_pre2_all.Beta_ORUncorrected, 
metabochip_snp_associations_pre3_all.P_valueCorrected, 
metabochip_snp_associations_pre3_all.Beta_ORCorrected, 
metabochip_snp_associations_pre3_all.Covariate1, 
metabochip_snp_associations_pre3_all.Covariate2, 
metabochip_snp_associations_pre3_all.Covariate3 FROM 
metabochip_snp_associations_pre2_all RIGHT JOIN 
metabochip_snp_associations_pre3_all ON 
metabochip_snp_associations_pre2_all.SNPID36 = 
metabochip_snp_associations_pre3_all.SNPID36 AND 
metabochip_snp_associations_pre2_all.Dataset = 
metabochip_snp_associations_pre3_all.Dataset AND 
metabochip_snp_associations_pre2_all.Phenotype = 
metabochip_snp_associations_pre3_all.Phenotype); 
 
ALTER TABLE metabochip_snp_associations_merged_all ADD 
PRIMARY KEY(SNPID36,Dataset,Phenotype); 
 
CREATE TABLE metabochip_snp_associations_pre2_females ( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
 Phenotype  CHAR (3), 
P_valueUncorrected VARCHAR(20), 
Beta_ORUncorrected  VARCHAR(20), 
PRIMARY KEY(SNPID36,Dataset,Phenotype)); 
 
CREATE TABLE metabochip_snp_associations_pre3_females ( 
 SNPID36  VARCHAR (17)  NOT NULL , 
 Dataset  VARCHAR (14), 
 Phenotype  CHAR (3), 
P_valueCorrected  VARCHAR(20), 
Beta_ORCorrected  VARCHAR(20), 
Covariate1  CHAR (3), 
Covariate2  CHAR (3), 
Covariate3  CHAR (3), 
PRIMARY KEY(SNPID36,Dataset,Phenotype)); 
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CREATE TABLE metabochip_snp_associations_merged_females AS 
(SELECT metabochip_snp_associations_pre2_females.*, 
metabochip_snp_associations_pre3_females.P_valueCorrected, 
metabochip_snp_associations_pre3_females.Beta_ORCorrected, 
metabochip_snp_associations_pre3_females.Covariate1, 
metabochip_snp_associations_pre3_females.Covariate2, 
metabochip_snp_associations_pre3_females.Covariate3 FROM 
metabochip_snp_associations_pre2_females LEFT JOIN 
metabochip_snp_associations_pre3_females ON 
metabochip_snp_associations_pre2_females.SNPID36 = 
metabochip_snp_associations_pre3_females.SNPID36 AND 
metabochip_snp_associations_pre2_females.Dataset = 
metabochip_snp_associations_pre3_females.Dataset AND 
metabochip_snp_associations_pre2_females.Phenotype = 
metabochip_snp_associations_pre3_females.Phenotype); 
 
ALTER TABLE metabochip_snp_associations_merged_females ADD 
PRIMARY KEY(SNPID36,Dataset,Phenotype); 
 
#Username and password table: 
CREATE TABLE user ( 
 username VARCHAR (40) NOT NULL PRIMARY KEY, 
 password VARCHAR (40));  
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APPENDIX E – Python code for input of data into MySQL 
tables 
# female_caregivers_basic 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('female_caregivers_basic.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
female_caregivers_basic(IndividualID, Gender, Ethnicity, 
RelationshipToChild) VALUES (%s, %s, %s, %s), row) 
 
db.commit() 
 
cursor.close() 
 
#bt20_participants_basic 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
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db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('bt20_participants_basic.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
bt20_participants_basic(IndividualID, Gender, Ethnicity, 
CaregiversID) VALUES (%s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
 
#phenotype_yr13_female_caregivers 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('phenotype_yr13_female_caregivers.c
sv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
phenotype_yr13_female_caregivers(IndividualID, Age, Height, 
Weight, BMI, HipCircumference, WaistCircumference, 
WaistToHipRatio, AverageSBP, AverageDBP, SubtotalBodyFat, 
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SubtotalLeanMass, PercentageBodyFat) VALUES (%s, %s, %s, %s, 
%s, %s, %s, %s, %s, %s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
 
#phenotype_yr1718_bt20_participants 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('phenotype_yr1718_bt20_participants
.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
phenotype_yr1718_bt20_participants(IndividualID, Age, 
Height, Weight, BMI, HipCircumference, WaistCircumference, 
WaistToHipRatio, AverageSBP, AverageDBP, SubtotalBodyFat, 
SubtotalLeanMass, PercentageBodyFat) VALUES (%s, %s, %s, %s, 
%s, %s, %s, %s, %s, %s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
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#metabochip_snp_information_1 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('metabochip_snp_information_1.csv')
) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_information_1(SNPID36, SNPID37, Chromosome, 
BasePairPosition36, BasePairPosition37, NearestGene, 
LocationWithinGene) VALUES (%s, %s, %s, %s, %s, %s, %s)", 
row) 
 
db.commit() 
 
cursor.close() 
 
#metabochip_snp_information_extra 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
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cursor = db.cursor() 
 
csv_data=csv.reader(file('metabochip_snp_informationEXTRA.cs
v')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_information_extra(SNPID36, Allele1, Allele2) 
VALUES (%s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
 
#metabochip_snp_information_extra2 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('metabochip_snp_informationEXTRA2.c
sv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_information_extra(SNPID36, AfterQC) VALUES 
(%s, %s)", row) 
 
db.commit() 
 
cursor.close() 
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#metabochip_snp_associations_batch1_all 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('Assoc-Batch1_ALL.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_batch1_all(SNPID36, Dataset, 
Phenotype, P_valueUncorrected, Beta_ORUncorrected, 
P_valueCorrected, Beta_ORCorrected, Covariate1, Covariate2) 
VALUES (%s, %s, %s, %s, %s, %s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
 
#metabochip_snp_associations_batch2_all 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
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csv_data=csv.reader(file('Assoc-Batch2_ALL.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_batch2_all(SNPID36, Dataset, 
Phenotype, P_valueUncorrected, Beta_ORUncorrected, 
P_valueCorrected, Beta_ORCorrected, Covariate1, Covariate2, 
Covariate3) VALUES (%s, %s, %s, %s, %s, %s, %s, %s, %s, 
%s)", row) 
 
db.commit() 
 
cursor.close() 
 
#metabochip_snp_associations_batch2_females 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('Assoc-Batch2_FEMALES.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_batch2_females(SNPID36, Dataset, 
Phenotype, P_valueUncorrected, Beta_ORUncorrected, 
P_valueCorrected, Beta_ORCorrected, Covariate1, Covariate2) 
VALUES (%s, %s, %s, %s, %s, %s, %s, %s, %s)", row ) 
 
db.commit() 
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cursor.close() 
 
#metabochip_snp_associations_batch2_males 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('Assoc-Batch2_MALES.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_batch2_males(SNPID36, Dataset, 
Phenotype, P_valueUncorrected, Beta_ORUncorrected, 
P_valueCorrected, Beta_ORCorrected, Covariate1, Covariate2) 
VALUES (%s, %s, %s, %s, %s, %s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
 
#metabochip_snp_associations_pre2_all 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
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db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('Assoc-Merged_ALL_uni.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_pre2_all(SNPID36, Dataset, 
Phenotype, P_valueUncorrected, Beta_ORUncorrected) VALUES 
(%s, %s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
 
#metabochip_snp_associations_pre3_all 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('Assoc-Merged_ALL_multi.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_pre3_all(SNPID36, Dataset, 
Phenotype, P_valueCorrected, Beta_ORCorrected, Covariate1, 
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Covariate2, Covariate3) VALUES (%s, %s, %s, %s, %s, %s, %s, 
%s)", row) 
 
db.commit() 
 
cursor.close() 
#metabochip_snp_associations_pre2_females 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
 
db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('Assoc-Merged_FEMALES_uni.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_pre2_females(SNPID36, Dataset, 
Phenotype, P_valueUncorrected, Beta_ORUncorrected) VALUES 
(%s, %s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
 
#metabochip_snp_associations_pre3_females 
#!/usr/bin/python 
 
import csv 
import MySQLdb 
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db = 
MySQLdb.connect("localhost","<USERNAME>","<PASSWORD>","metab
obtt") 
 
cursor = db.cursor() 
 
csv_data=csv.reader(file('Assoc-Merged_FEMALES_multi.csv')) 
for row in csv_data: 
 cursor.execute("INSERT INTO 
metabochip_snp_associations_pre3_females(SNPID36, Dataset, 
Phenotype, P_valueCorrected, Beta_ORCorrected, Covariate1, 
Covariate2) VALUES (%s, %s, %s, %s, %s, %s, %s)", row) 
 
db.commit() 
 
cursor.close() 
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APPENDIX F – MetaboBTT README 
MetaboBTT Database 
 
What is the MetaboBTT Database? 
 
It is a MySQL database that stores project-specific data related to a current study 
in the field of genetics. The database is easily accessible and queryable by all 
members of the research group via a user-friendly web interface. 
 
Where can the database be accessed? 
 
The database can be accessed via a web interface available at 
http://www.bioinf.wits.ac.za/software/metabobtt and must be accessed with a 
username and password. 
 
What data does the database contain? 
 
The MetaboBTT Database houses phenotype, SNP annotation and association 
analysis data from an ongoing project focused on identifying risk factors for 
cardiometabolic disease in South Africans. The data is from participants and their 
female caregivers from the Birth to Twenty (Bt20) cohort and DNA samples were 
genotyped using the Metabochip. 
 
Each individual recorded in the database has a unique Individual ID (with a suffix 
‘C’ or ‘CG’ for the Bt20 participants and female caregivers, respectively). 
 
The Bt20 cohort is a longitudinal cohort consisting of data collected at multiple 
time points since its inception. PHENOTYPE DATA currently present in the 
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database is from the year 17/18 data collection time point for the Bt20 
participants and the year 13 data collection time point for the female caregivers. 
Tables have been constructed for other data collection time points for the Bt20 
participants (year 5, year 7, year 9/10, year 11/12, year 13, year 14, year 15, year 
16, year 19, year 20) and can be populated with the data when available. 
Phenotype data only exists in the database for individuals with available 
genotype data and includes: 
 
 Gender (1 = males, 2 = females) 
 Ethnicity (2 = Africans) 
 Relationship to Child (1 = Mother , 2 = Aunt, 3 = Grandmother, 4 = Sister, 5 = 
Other) [only relevant to the female caregivers]  
 Caregiver’s ID [only relevant to the Bt20 participants] 
 Age (in years) 
 Height (in metres) 
 Weight (in kilograms) 
 Body Mass Index (BMI) (in kg/m2) 
 Hip Circumference (in metres) 
 Waist Circumference (in metres) 
 Waist to Hip Ratio 
 Average Systolic Blood Pressure (SBP) (in millimetres of mercury) [average of the 
2nd and 3rd of three readings taken] 
 Average Diastolic Blood Pressure (DBP) (in millimetres of mercury) [average of 
the 2nd and 3rd of three readings taken] 
 Subtotal Body Fat (in grams) 
 Subtotal Lean Mass (in grams) 
 Percentage Body Fat (%) 
SNP ANNOTATION/METABOCHIP DATA exists for all 196725 SNPs on the 
Metabochip and includes: 
 
 Build 36 SNPID 
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 Build 37 SNPID 
 Chromosome 
 Build 36 Base Pair Position 
 Build 37 Base Pair Position 
 Nearest Gene [refers to the gene(s) in which the SNP lies or is intergenic to] 
 Location Within Gene (CODING, COMPLEX, INTERGENIC, INTRON or UTR) 
 Allele 1 
 Allele 2 
 After QC (BOTH = remained in both the Bt20 participant and female caregiver 
datasets after QC, BATCH1 = remained in only the female caregiver dataset after 
QC, BATCH2 = remained in only the Bt20 participant dataset after QC)    
All ASSOCIATION ANALYSIS DATA for the available phenotypes under 
investigation are recorded and includes: 
 
 Build 36 SNPID 
 Dataset* (BATCH1_ALL, BATCH2_ALL, BATCH2_FEMALES, BATCH2_MALES, 
MERGED_ALL, MERGED_FEMALES) 
 Phenotype 
 Uncorrected P-value 
 Uncorrected Beta/OR 
 Corrected P-value [corrected for the covariates listed] 
 Corrected Beta/OR [corrected for the covariates listed] 
 Covariate 1 
 Covariate 2 
 Covariate 3 
*The datasets available can be analysed as individual or merged datasets – 
results for all possible scenarios are recorded. 
 
BATCH1_ALL = yr13 female caregivers  
BATCH2_ALL = all yr 17/18 Bt20 participants 
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BATCH2_FEMALES = female yr 17/18 Bt20 participants 
BATCH2_MALES = male yr 17/18 Bt20 participants 
MERGED_ALL = yr13 female caregivers and Bt20 participants merged 
MERGED_FEMALES = yr13 female caregivers and female yr17/18 Bt20 
participants merged 
 
The GENOTYPE DATA has undergone an extensive quality control (QC) process. 
The data exists as cleaned/QC’ed binary PLINK format files (.bed/.bim/.fam) for 
both the Bt20 participants and the female caregivers and these can be accessed 
on request.  
 
What can users do? 
 
Users can access the database from the user interface to generate summary statistics 
(basic and complex counts and average/minimum/maximum) on the phenotype data, 
download relevant phenotype, Metabochip and association analysis data that match 
certain user-supplied criteria and get information on how to work with the genotype 
files in PLINK. 
 
1) File uploads 
 
When specifying a list of individuals/SNPs etc., the uploaded file must be a text 
file containing a list of Individual IDs/SNPIDs etc. each on a separate line. 
 
2) Specifying criteria 
 
When phenotype criteria can be specified, up to three criteria can be added (in 
the form <PHENOTYPE> <OPERATOR> <VALUE>). 
e.g. Height (m) >= 1.6  
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3) Output 
 
Summary statistics will always be printed to the screen. Phenotype, Metabochip 
and association analysis data download outputs can be printed to the screen 
(‘Print to screen’) or downloaded as a CSV file (‘Save to File’).  
 
Additional features 
 
 A reset button is present on each page to clear all previously selected 
fields. 
 Each page has a footer with links to useful websites (NCBI and Ensembl) 
and the home and parent pages. 
Contact 
 
To request access to the database or for any queries pertaining to the database 
or data contained in the database can be directed to Liesl Hendry (Sydney 
Brenner Institute for Molecular Bioscience/University of the Witwatersrand) at 
lieslmaryhendry@gmail.com.  
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APPENDIX G – Post-analysis QC: Q-Q plots and genomic 
inflation factors 
MAIN ANALYSIS: 
All merged dataset: 
Phenotype Before correction for PCs After correction for PCs 
SBP λ = 0.9982 λ = 0.9997 
DBP λ = 0.9988 NA 
High versus normal/low λ = 0.9977 λ = 1.0117 
 
SBP (corrected for first 10 PCs):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DBP (no correction for PCs): 
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High versus normal/low BP (correction for first 20 PCs):  
 
 
 
 
 
 
 
 
 
 
SEX-SPECIFIC ANALYSIS: 
Merged female dataset: 
Phenotype Before correction for PCs After correction for PCs 
SBP λ = 1.0120 NA 
DBP λ = 1.0073 NA 
High versus normal/low λ = 0.9930 λ = 1.0117 
 
SBP (no correction for PCs): 
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DBP (no correction for PCs): 
 
 
 
 
 
 
High versus normal/low BP (correction for first 10 PCs):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bt20 participant dataset (males only): 
Phenotype Before correction for PCs After correction for PCs 
SBP λ = 1.9769 NA 
DBP λ = 1.0009 λ = 1.0009 
High versus normal/low λ = 0.9261 λ = 0.9718 
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SBP (no correction for PCs): 
 
 
 
 
 
 
 
 
 
 
DBP (correction for first 10 PCs): 
 
 
 
 
 
 
 
 
 
 
High versus normal/low BP (correction for first 10 PCs):  
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AGE-SPECIFIC ANALYSIS: 
Female caregiver dataset: 
Phenotype Before correction for PCs After correction for PCs 
SBP λ = 1.0249 NA 
DBP λ = 1.0297 NA 
High versus normal/low λ = 1.0469 NA 
 
SBP (no correction for PCs): 
 
 
 
 
 
 
 
 
 
 
 
 
DBP (no correction for PCs): 
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High versus normal/low BP (no correction for PCs):  
 
 
 
 
 
 
Bt20 participant dataset: 
Phenotype Before correction for PCs After correction for PCs 
SBP λ = 0.9591 NA 
DBP λ = 0.9623 NA 
High versus normal/low λ = 0.9345 NA 
 
 
SBP (no correction for PCs): 
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DBP (no correction for PCs): 
 
 
 
 
 
 
 
 
 
 
 
High versus normal/low BP (no correction for PCs):  
 
